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Abstract
Antigen presentation is broadly implicated in disease and represents an important
target for prophylactic and therapeutic treatments. A better understanding of the
components of this system is fundamental to our understanding of disease path-
ways and to treatment design. This thesis focuses on modelling the processing of
peptides by enzymes in the cytosol and in the endoplasmic reticulum (ER) in the
context of major histocompatibility complex class I (MHC) antigen presentation,
and expounds upon current knowledge of the mechanistic details and specificity of
both the proteasome and the endoplasmic reticulum aminopeptidase-1 (ERAP1).
We use nonlinear ordinary differential equations to model the biochemical reaction
pathways of amino-terminal peptide trimming by ERAP1 and distinguish parameter
dependencies of two prevailing theories for the mechanism of ERAP1 trimming us-
ing algebraic and numerical analysis. Importantly, we show that ERAP1 has a role
in peptide optimisation when MHC acts as a template, but not when it trims free
peptide using an internal molecular ruler. We present testable hypotheses that may
elucidate the dominant trimming mechanism used by ERAP1 in vivo, which has
been the subject of debate for more than 25 years. We show that all ERAP1 trim-
ming mechanism hypotheses are able to predict the qualitative distribution of cell
surface presentation of SIINFEKL derived from amino-terminally extended precur-
sors. Notably, we find that the molecular ruler trimming mechanism is more robust
than the MHC-as-template mechanism. Finally, we use neural networks to predict
carboxyl-terminal cleavage by the proteasome, and demonstrate that we are able
to distinguish between cleavage and non-cleavage sites on an unseen set of known
peptide epitopes. Overall, this thesis contributes a more thorough quantitative and
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mechanistic understanding of the generation of peptides presented on MHC class I
molecules.
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Chapter 1
Introduction
The cell mediated immune system is directly involved in the pathogenesis of a va-
riety of diseases, including viral and bacterial infections, cancer, and autoimmune
diseases. A comprehensive understanding of what specifically elicits an effective
cell mediated response, as well as what elicits an autoimmune response remains
elusive.
All somatic nucleated cells of jawed vertebrates constitutively display short
fragments of proteins, called peptides, on major histocompatibility class I (MHC
I) molecules on their surface. When viral or bacterial proteins are expressed in an
infected cell, or when proteins are mutated in a cancerous cell, peptides from these
new proteins are added to the cell surface peptidome. The presence of antigenic
peptides flags the cell as diseased to circulating CD8+ cytotoxic T lymphocytes
(CTLs) which express T cell receptors (TCRs) for the recognition and binding of
cognate antigens, as well as the CD8 glycoprotein, which binds to a conserved
region of the MHC I molecule. Upon binding, the CTL becomes activated and
starts a process of clonal expansion [180], followed by destruction of the infected
cells via lysis and the release of cytokines [83]. Autoimmune responses occur when
the TCR fails to distinguish constitutive or ‘self’ peptides, from antigenic, ‘non-
self’ peptides, causing the destruction of healthy cells [13].
The repertoire of peptides displayed at the cell surface is determined by several
stages of intracellular peptide processing, known collectively as the antigen process-
ing and presentation pathway. The pathway starts in the cytosol with the cleavage
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of proteins by the proteasome. The proteasome tends to generate peptides with the
correct carboxyl (C) terminus for binding to MHC I, and with an amino (N) terminal
extension [122]. The cleaved peptides are transported into the endoplasmic reticu-
lum (ER) by the transporter associated with transport (TAP) [3]. Here, the endoplas-
mic reticulum aminopeptidase I (ERAP1) trims the N-termini of the peptides [185]
whilst MHC I, with the help of several chaperone molecules, concomitantly sam-
ples the available peptides for stability. Stable peptide:MHC complexes (p:MHC)
egress through the golgi to the cell surface for display to CTLs.
Mathematical models, such as chemical kinetic pathway models and machine
learning algorithms, offer many insights to immunological problems. These mod-
elling techniques can be used to make quantitative predictions of cellular outcomes
that are too complex or large to measure experimentally. Further, many cellular
processes cannot be directly observed, which limits our understanding of their un-
derlying mechanisms. Mathematical modelling can be used to test hypotheses about
the mechanisms of such processes. The work presented in this thesis uses chemical
kinetic models and artifical neural networks to further our knowledge of epitope
generation by the proteasome and N-terminal peptide trimming by ERAP1.
1.1 The immune system
The vertebrate immune system can be broadly divided into two subsets: innate
immunity and adaptive immunity. Innate immunity consists of fast or immediate
antigen-independent and antigen-non-specific defences that have no immunological
memory, whilst adaptive immunity is slower to reach its maximum response, is
antigen-dependent and antigen-specific, and has immunological memory [84].
1.1.1 Innate immunity
The innate immune system consists of anatomical, humoral, and cellular barriers
to infection. Anatomical barriers include: physical barriers such as the skin, mu-
cous, tears, and saliva, as well as peristalsis and cilia which move pathogens in the
lungs and gastrointestinal tract; chemical barriers such as defensins in the lungs and
gastrointestinal tract which bind and form pores in pathogen cell walls, depleting
1.1. The immune system 19
the pathogen of essential nutrients and ions which leads to the eventual destruc-
tion of the pathogen by cell wall rupture (a process known as lysis), lysozyme and
phospholipase enzymes in the saliva, tears and nasal fluids, which lyse bacterial
cells by hydrolising bonds of their cell walls, and surfactant proteins in the lungs
which bind to the surface of pathogens targeting them for destruction by a subset of
immune cells called phagocytes (a process known as opsonisation); and biological
factors such as the constitutive bacteria of the skin and gastrointestinal tract which
prevent colonisation by pathogenic bacteria both by releasing toxic substances and
by competing for nutrients and attachment [160].
Humoral innate immunity entails the actions of secretory proteins found in the
blood or secreted at the site of an infection by immune cells. A key component, the
complement protein cascade, triggers multiples responses to infection, including
opsonisation, chemical attraction (chemotaxis) of innate immune cells, inflamma-
tion, pathogen lysis, and induction of programmed cell death (apoptosis) of infected
cells. Other humoral proteins include the lysosyme enzyme, lactoferrin, which se-
questers free iron, an essential substrate for bacterial growth, and cytokines such
as interferons (INFs), interleukins (ILs), and tumor necrosis factors (TNFs) which
inhibit viral replication, activate innate immune cells, induce fever and stimulate
the adaptive immune response, and chemotactic cytokines, or chemokines which
recruit and activate both innate and adaptive immune cells [160].
The white blood cells (WBCs), also known as leukocytes, of the innate im-
mune system comprise granulocytes, which contain toxic granules in their cyto-
plasm, and non-specific cytotoxic killer cells, which induce apoptosis and lysis of
infected cells. The most abundant granulocyte, the neutrophil, is one of the first
leukocytes to arrive at the site of infection [85], attacking pathogens and infected
cells: by ingestion into compartments called phagolysosomes that are rich in toxic
granules or peroxides (phagocytosis); by secreting toxic granules (degranulation);
or by ensnaring them in neutrophil extracellular traps. Neutrophil granules com-
prise lysozyme, defensins, lactoferrin and other pathogen killing enzymes and pro-
teins [2]. The primary function of the other granulocytes: basophils, eosinophils,
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and mast cells is degranulation, although eosinophils and mast cells can also per-
form phagocytosis [82]. Natural killer cells tend to arrive next at the site of infection
and release granules containing perforin and granzyme; perforin forms pores in the
cell membrane through which granzyme enters causing either oxidative damage or
apoptosis or inhibiting viral replication and activation [166]. Natural killer cells may
be induced by opsonising antibodies on the surface of infected cells, by cytokines,
or by irregular p:MHC expression detected by inhibitory receptors such as killer-
cell immunoglobulin-like receptors (KIRs) [16]. Finally, monocytes tend to arrive
later, and can differentiate into macrophages or dentric cells (DCs) in tissue [85].
These three leukocytes engage in phagocytosis, cytokine production, and profes-
sional antigen presentation on MHC class II molecules, which provides an impor-
tant link to the adaptive immune system [67]. Macrophages and DCs also express
patern recognition receptors (PRRs) which recognise molecular motifs shared by
broad classes of pathogens, called pathogen associated molecular patterns (PAMPs),
and motifs expressed by damaged cells, called damage-associated molecular pat-
terns (DAMPs) [128].
1.1.2 Adaptive immunity
Adaptive immunity comprises hummoral responses to extracellular pathogens in-
stigated by B lymphocytes and cell-mediated immune responses to intracellular
pathogens driven by T lymphocytes. B lymphocytes express unique B cell receptors
(BCRs) and T lymphocytes express unique T cell receptors (TCRs), which recog-
nise unique antigens. It is estimated that humans have a repertoire of between 2x106
and 2.5x108 different TCRs [108] and a similar number of BCRs [41]. This diver-
sity is generated by genetic recombination of DNA during lymphocyte development
[84].
B cells phagocytose their cognate antigen and present antigen-derived pep-
tides on MHC class II molecules to circulating helper T lymphocytes. Cytokines
released by the helper T cell stimulate the B cell to differentiate into a plasma cell
which generates and secretes antigen specific antibodies [35]. These antibodies bind
pathogens for three purposes: pathogen opsonisation which facilitates phagocyto-
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sis; neutralisation, whereby pathogen attachment to host cells is blocked by the
presence of the antibodies; and activation of the complement cascade [46].
T lymphocytes are comprised of three subsets: CD4+ T lymphocytes; CD8+
T lymphocytes, also known as cytotoxic T lymphocytes (CTLs); and gd T cells.
Naive CD4+ T cells may differentiate into one of several classes of T helper (Th)
effector cells upon encountering antigen: Th1, Th2 or Th17, or into T regulatory
cells (Tregs). Helper T cells express unique T cell receptors (TCRs) at their sur-
face which bind to specific antigenic peptides displayed on MHC class II molecules
on the surface of professional APCs. The CD4 protein, known as an accessory
molecule, also binds to the MHC class II molecule, to enhance the stability of the
TCR:p:MHC complex and to ensure that Th cells only interact with APCs. CD4+
T cells are incapable of killing infected cells or pathogens themselves. Instead, Th
cells release cytokines which activate other immune cells, such as CD8+ T cells,
whilst Tregs modulate Th cell activity [33]. The particular cytokine environment of
intracellular infections tends to induce Th1 cells which release cytokines that stimu-
late macrophages, NKs, and CTLs, whilst the cytokine environment of extracellular
pathogens induces Th2 cells which release B cell and eosinophil -stimulating cy-
tokines [89]. Th17 cells release the IL-17 cytokine which has been linked to many
autoimmune diseases [162].
CD8+ T cells express unique TCRs that recognise specific antigenic peptides
displayed on MHC class I molecules on the surface of any nucleated host cell. The
accessory molecule, CD8, which is equivalent to CD4 expressed by Th cells, binds
to MHC class I molecules to enhance the stability of the interaction between the
CTL and host cell and to ensure the CTL only binds to non-professional APCs.
This interaction activates the CTL to become an effector cell and it begins a process
of clonal expansion to increase the population of CTLs with this antigen-specificity
[180]. CTLs kill infected cells by one of two methods. Fas receptors and TNF
receptors expressed on the surface of nucleated cells contain death domains in their
cytoplasmic portions. CTLs, which express Fas and TNF ligands at their surface,
bind these receptors to induce apoptosis of infected cells [174]. Alternatively, CTLs
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release granules containing perforin and granzyme, in the same manner as the NK
cells of the innate immune system [173].
All T lymphocytes subsets express the co-stimulatory CD28 protein at their
surface which must bind to CD80 or CD81 on the host cell in order for T cell activa-
tion to occur. If this co-stimulation does not occur, the T cell will not mount an im-
mune response [1, 60, 171]. Towards the end of an infection, the inhibitory CTLA-4
protein binds to CD80 or CD81, which down-regulates the response [171]. Once the
infection is cleared the majority of T cells die and are removed by phagocytes. How-
ever, some T cells remain as memory T cells, which differentiate more quickly into
effector T cells in subsequent encounters with the same pathogen, thereby increas-
ing the rate and magnitude of the T cell response [84].
1.1.3 The lymphatic system
The lymphatic system is a complex network of primary lymphoid organs, compris-
ing the thymus and red bone marrow, and secondary lymphoid organs, including
lymph nodes, the tonsils, the spleen, appendix, Peyer’s patches of the small intes-
tine, and mucosa associated lymphoid tissue of the gastrointestinal tract, thyroid,
breasts, lungs, salivary glands, eyes and skin. The primary and secondary lymphoid
organs are connected by lymphatic vessels and the circulatory system [133].
The majority of lymphocytes are produced in the red bone marrow; B lympho-
cytes remain for maturation whilst T lymphocytes migrate to the thymus to mature.
During maturation, lymphocytes undergo a process of negative selection which en-
sures that only functional and self-tolerant lymphocytes leave. Self-reactive B lym-
phocytes may be induced to edit their cell surface receptors so that they no longer
present self-peptides. Alternatively, self-reactive B and T lymphocytes undergo
apoptosis. T lymphocytes also undergo a process of positive selection during which
they are tested for binding to MHC molecules in the thymus. If they are unable to
bind thymic epithelial cell surface MHC molecules then they also undergo apopto-
sis. If they bind MHC I then expression of CD4 is downregulated and they become
CD8+ T cells, whilst if they bind MHC II, the CD8 protein is downregulated and
they become CD4+ T cells. The size of the thymus decreases with age, and atrophies
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after puberty. Naive lymphocytes that pass all quality control enter the blood and
migrate to secondary lymphoid organs, where they search for their cognate antigen
[86].
Meanwhile, the fluid between tissue cells, known as interstitial fluid, is trans-
ported unidirectionally as lymph through the lymphatic system. Lymph is filtered
for dead or damaged cells and pathogens in the secondary lymphoid organs and is
then returned to the blood through the subclavian vein in the neck. Professional
APCs, in particular DCs, also transport antigens to secondary lymphoid organs.
When a lymphocyte detects antigen, a process of activation and proliferation oc-
curs, causing the lymph node to swell. After several days, effector lymphocytes
begin to leave the lymphoid tissue and migrate to the site of infection [133].
1.2 Antigen presentation
This thesis will focus on the MHC class I antigen processing and presentation sys-
tem, and directly associated mechanisms. The abbreviation, MHC, will hereby de-
note MHC class I molecules, and HLA will refer to HLA I molecules.
The MHC gene, also known as the human leukocyte antigen (HLA) gene in
humans, is highly polymorphic, meaning that there is a lot of variation within the
population. The gene encodes MHC proteins consisting of two polypeptide chains:
a long, polymorphic a-chain, also called the heavy chain (HC) and a short b -chain
called b2-microglobulin (b2m) which is not polymorphic. The peptide binding
groove, formed by two parallel a helix walls and a floor lined with eight b strands,
is the region with the highest variability [138]. The groove restricts peptide length,
typically to 8-10 amino acids, with the N and C termini of the peptide buried deep
in pockets known as the A and F pockets, respectively. Occasionally, longer pep-
tides of up to 13 residues are presented on MHC by bulging out in the middle [66,
111, 168]. However, shorter peptides tend to be favoured because many HLA alleles
have additional pockets within the binding groove which accommodate conserved
anchor residues within the peptide, thereby providing greater stability to the p:MHC
complex. Sufficient p:MHC stability improves T cell recognition [70], reduces the
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likelihood of exogenous peptides binding to MHC, and when compared to empty
MHC increases the stability of the HC:b2m heterodimer by more than 10 fold [48].
The peptide presentation pathway entails the assembly and export of p:MHC
complexes via multiple interactions with the multisubunit peptide loading complex
(PLC) and auxiliary proteins. Firstly, newly synthesised heavy chains associate
with binding immunoglobulin protein (BiP) and the chaperone calnexin. BiP and
calnexin facilitate HC folding, and retain any misfolded or incorrectly assembled
subunits in the ER. Calnexin dissociates upon binding of b2m to HC, and is re-
placed by the chaperone calreticulin and the thiol-disulfide oxidoreductase, endo-
plasmic reticulum resident protein 57, ERp57, which assist further folding stages
of MHC. Calreticulin and ERp57 remain bound as the HC:b2m heterodimer enters
the PLC [23]. The PLC comprises the MHC specific transporter associated with
antigen (TAP), the chaperone tapasin, and the enzyme protein disulfide isomerase
(PDI), in addition to the HC, b2m, calreticulin, and ERp57. TAP transports class
I peptides from the cytosol to the ER and is required for the formation of the PLC
[14]. MHC molecules exhibit an open, peptide receptive conformation when empty,
and a closed peptide stabilising conformation when bound to peptide ligand, as
well as various conformational intermediates [5]. PDI and tapasin stabilise an open
conformation of the peptide groove, thereby establishing peptide receptivity [134].
Tapasin also links and stabilises the association between TAP and MHC [6], en-
hances the rate of peptide sampling, and retains suboptimal p:MHC complexes in
the ER.
MHCmay sample multiple sub-optimal peptides before forming a heterotrimer
of sufficient stability to dissociate from the PLC and continue through the secre-
tory pathway. By stabilising the open conformation of the peptide binding groove,
tapasin increases the rate of dissociation of low affinity peptides as well as the
threshold level of stability required for the formation of an optimal p:MHC complex
[56]. Tapasin, in contrast to other PLC chaperones such as ERp57 and calreticulin,
alters the hierarchy of the MHC peptidome with respect to the peptide dissociation
rate, and enhances the quality of MHC peptide cargo over time [38, 49]. In addition,
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a tapasin-related protein, TAPBPR, acts in concert or in the absence of tapasin to
stabilise an open peptide receptive conformation of the MHC binding groove, but it
is not part of the PLC [73].
A cell can express up to six different HLA alleles [75]. As each HLA molecule
has different peptide specificity, this possibly enables a broader coverage of the
peptidome than what might be achievable by fewer HLA molecules. Furthermore,
it enables for more variation in the inheritedMHC specificities of parents’ offspring.
The antigen processing machinery must produce a repetoire of peptides that is both
broad and specific to facilitate the presentation of a varied and stable cell surface
peptidome. The potential peptide repetoire must be broad to encompass all CD8
TCR specificities, but must be specific to ensure stability between the peptide and
polymorphic MHC binding groove. Some peptide antigens, known as immunodom-
inant antigens, are particularly good at mounting immune responses across multiple
different HLA alleles [58].
1.3 Antigen processing
The antigen processing pathway initiates with the proteolytic processing of proteins
by the proteasome into short peptide fragments. The proteasome cleaves peptides
of 2-30 amino acids in length [101, 170] and generates the correct C- but not N-
terminus for presentation on MHC, with high fidelity [97, 131]. The peptides are
then translocated from the cytoplasm to the ER by TAP [3]. Since TAP is part of the
PLC, the peptides may bind MHC via the presentation pathway described in Section
1.2. However, due to the binding preference of TAP for peptides of between 8-16
amino acids [101, 170], many peptides will be sub-optimal for MHC presentation
and require further trimming. ERAP1 trims N-terminally extended precursor pep-
tides in the ER, typically to 8-9 residues, the correct size for binding to most HLA
alleles [27]. Peptides that fail to bind MHC are exported back out of the ER by the
translocator Sec61p [100], for processing into their constituent amino acids by cy-
tosolic proteases. The aim of this thesis is to further current knowledge concerning
the specificity, mechanism, and dynamics of peptide processing by the proteasome
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and by ERAP1.
1.3.1 The proteasome
The proteasome is a multi-subunit barrel-shaped protease that is expressed consti-
tutively in the nucleus and cytosol of nucleated cells. The 20S constitutive protea-
some, when not bound to regulatory caps, is responsible for the ATP- and ubiquitin-
independent degradation of oxidised proteins. It comprises seven alpha and seven
beta domains, each present in two copies. Three of the beta domains: b1, b2, and
b5, house the three catalytically active sites. The first, b1, has caspase-like activity
(cleavage after acidic residues), whilst b2 has trypsin-like activity (cleavage after
basic residues), and b5 has chymotrypsin-like activity (cleavage after hydrophobic
residues) [9].
The 20S constitutive proteasome binds to 19S regulatory particles at one or
both ends, forming the 26S proteasome (19S-20S) and the 30S proteasome (19S-
20S-19S) respectively [163]. The 26S and 30S proteasomes are responsible for the
rapid removal of short lived proteins, which is required for the maintenance of cel-
lular homeostasis, as well as for the removal of potentially toxic proteins [169].
The regulatory caps unfold polyubiquitinated proteins and translocate the protein
and peptide products in to and out of the proteasome. The majority of the peptide
products are then further processed into their constitutive amino acids by cytosolic
aminopeptidases and endopeptidases [143, 145].
The immunoproteasome is responsible for the generation of the majority of
antigenic peptides displayed at the cell surface by MHC I [96]. Immunoprotea-
somes are formed in the cytosol following cell exposure to the cytokine, interferon-
gamma (IFN-g) released by CTLs during an immune response. The three active
subunits of the 20S core particle are replaced by three immunosubunits: b1i (low-
molecular-mass polypeptide 2, LMP2), b2i (multicatalytic endopeptidase complex-
like-1, MECL-1), and b5i (LMP7), and new regulatory particles known as 11S or
PA28 are upregulated [159]. The subunit b1i, in contrast to b1 exhibits background
levels of caspase-like activity [102], but increased levels of chymotrypsin-like ac-
tivity enhancing the production of epitopes with small, nonpolar C-termini [7]. The
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purpose of the b2i substitution is poorly understood, but b2i deficient mice are pro-
tected from experimentally induced colitis [8]. The effect of exchanging b5i is not
well characterised, but it is thought to enhance the catalytic kinetics and to influence
the size and polarity of some of the interior residues of the peptide [7]. The overall
result is that the immunoproteasome generates more peptides with hydrophobic or
basic C terminals [121] and fewer with acidic C terminals than its constitutive coun-
terpart [61, 165]. Nevertheless, the constitutive proteasome is capable of generating
qualitatively similar peptide products [121].
The 20S immunoproteasome binds both 19S and 11s regulators. 11S regula-
tors enlarge the opening to the proteolytic core through which the protein substrate
and peptide products enter and exit. This disovery led to the hypothesis that the sub-
stitution of 11S regulators increases the average length of peptides cleaved by the
immunoproteasome [178], however the opposite effect has been observed in vitro
[140]. Nevertheless, 11S alters the proteasomal products, increasing the generation
of some MHC I epitopes and destroying others. The 11S regulator also binds to the
20S constitutive proteasome [178]. The diversity of proteasome complexes facili-
tates a diversity of potential MHC I epitopes.
It is thought that there is a negligible difference in degradation efficiency
between the immunoproteasome and constitutive proteasome [126]. Nevertheless,
several known factors ensure efficient presentation by MHC I of immunoprotea-
some generated peptides, in the context of the high cytosolic enzyme degradation
rates that destroy 99% of proteasomal products. Firstly, TAP and the immuno-
proteasome, unlike the constitutive proteasome, localise at the interface between
the cytoplasm and the ER [17] giving immunoproteasome derived peptides a better
chance of avoiding degradation by cytosolic proteases. In addition, TAP, ERAP1
and MHC I are upregulated by IFN-g during an immune response [188].
Importantly, the immunoproteasome degrades a greater proportion of abnormal
proteins known as defective ribosomal products, DRiPs [150]. DRiPs are a result of
errors in protein translation and occur more frequently during times of high protein
synthesis, such as during viral replication. DRiPs are degraded much more quickly
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than normal proteins: viral DRiPs have half lives of 5-10 minutes [183] compared
with normal viral proteins which have half lives of 1-2 days [87]. Thus DRiPs sig-
nificantly increase the rate and efficiency of antigen processing which enables early
presentation of antigenic peptides during infection [26].
1.3.2 ERAP1
Aminopeptidases are enzymes that trim the N-terminus of peptides. The only
aminopeptidases found in the ER of human cells are ERAP1 and ERAP2, and the
only aminopeptidase in the ER of mouse cells is ERAP1. Since TAP regularly
transports N-terminally extended peptides into the ER, ERAP has a critical role in
generating peptides of suitable lengths for presentation on MHC. ERAP1 deficiency
in mice increases the average length of peptides displayed on MHC and leads to the
generation of CD8+ T cells with specificities for N-terminally extended peptides
[11]. Other studies of ERAP1 deficiency in mice have shown that ERAP1 also has
a more general peptide editing role. ERAP1 knockout alters the repetoire of pep-
tides displayed by MHC [69, 181], decreases the stability [68, 69] and cell surface
expression of p:MHC [181], and results in altered T cell responses that can be both
nonimmunogenic [69, 181] as well as highly immunogenic [68]. ERAP1 deficient
mice do present a set of immunodominant epitopes, but an entirely different set to
that of wild type mice [139].
The molecular mechanism by which ERAP1 fulfils its peptide editing role in
vivo has been the subject of debate for 25 years but remains unknown [90, 47, 54].
Unlike other aminopeptidases which trim peptides down to their constituent amino
acids, ERAP1 somehow generates peptides of the correct length (8-9 aa) for bind-
ing to MHC. Early hypotheses supposed that ERAP1 trims peptides already bound
to MHC, using the peptide binding groove as a template for trimming [177]. How-
ever, it was later shown that ERAP1’s regulatory domain functions as an internal
molecular ruler, providing a mechanism for the length restricted trimming of free
peptide substrates [27]. Indeed, when incubated with free peptide substrates in vitro,
ERAP1 typically generates nonameric products [27]. In 2011, the crystal structures
of ERAP1 in open and closed states were solved [98, 129]. These revealed that
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ERAP1’s catalytic site sits at the back of a very deep cavity, the deepest seen to
date for an aminopeptidase. Together with estimates of the minimun distance be-
tween the N-terminus of an MHC bound peptide and the zinc center of ERAP1, it
was proposed that ERAP1 is only able to trim up to the sixth protruding amino acid
of an extended peptide in complex with MHC [129]. Nevertheless, another group
who crystallised ERAP1 in an open conformation suggested that ERAP1 is able to
change shape, which may allow it to fit around MHC [98].
More recently, it has been shown that ERAP1 also trims peptides bound to
MHC in vitro, such as peptides tethered to MHC at their C terminus [142]. This
year, it was shown that ERAP1/ERAP2 trimers increase the stability of the p:MHC
complex and trim MHC bound peptides to the correct length, but at a slower rate
than they trim free peptide [29]. The presence of MHC I changes the repertoire
of peptides generated by ERAP1 in vivo [91]. The extent to which MHC plays an
active role, as a template for trimming, and a passive role, by removing high affinity
peptides from ERAP1’s pool of substrate in vivo remains an open question.
1.4 Disease
Antigen presentation is critical for the control of viral infections, intracellular bac-
terial infections, and cancer. It is also implicated in the pathogenesis of autoimmune
diseases. In this thesis, we consider the two key proteases involved in the generation
of peptide antigens: the proteasome, which generates the C terminus and ERAP1,
which generates the N terminus. Understanding these processes is critical to under-
standing the availability of different peptides for MHC presentation under different
conditions. This work feeds into an ultimate goal of being able to predict the cell
surface peptidome for different genetics and under different cellular conditions and
disease states. This would facilitate personalised medicine enabling improvements
to the treatment of infections, cancer, and autoimmune diseases. The improper
functioning of the proteasome and of ERAP1 is already implicated in a variety of
diseases, as discussed in the following sections.
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1.4.1 The proteasome and disease
In Chapter 4, we use machine learning to find out more about proteasome specificity
and build a tool for the prediction of proteasomal cleavage sites. An accurate predic-
tion algorithm of protein cleavage would inform subunit and peptide based vaccine
design as well as immunotherapy. The proteolytic machinery of a diseased cell does
not always function correctly. Downregulation of the immunosubunits b1i and b2i
of the immunoproteasome prevents the normal processing of tumor associated anti-
gens and facilitates immune evasion by many tumor cells [158]. Many viruses de-
pend on and hijack the proteolytic machinery for their own purposes. The extent to
which this alters antigen presentation is not entirely understood. Some viruses have
specific immune evasion techniques which limit the presentation of CTL epitopes.
The Hepatitis B virus (HBV) middle envelope protein uses a ubiquitin independent
proteolytic pathway that results in its complete degradation, and the destruction
of MHC I epitopes [112]. Ubiquitination of this protein is sufficient to dramati-
cally increase antigen presentation [112]. An accurate predictor of the proteasomal
products of properly functioning proteasomes would provide vital information to
immunotherapy research. One immunotherapy vaccine, Melan-A/MART-1 vaccine
was largely unsuccessful in Melanoma patients because the immunoproteasome is
unable to generate one of the two MHC I-conserved epitopes [88]. An accurate pre-
diction algorithm of cleavage by the immunoproteasome would have forewarned
researchers and prevented the waste of time and resources that went in to develop-
ing a defective vaccine.
1.4.2 ERAP1 and disease
In Chapters 2 and 3 we use chemical reaction network models to investigate the
dominant mechanism of trimming used by ERAP1 in vivo. Determining whether
ERAP1 predominantly trims free peptide substrate or peptides bound to MHC
would increase our understanding of N terminal trimming specificity. To what ex-
tent does MHC I confer sequence by filtering the peptides available for ERAP1
trimming? If ERAP1 trims peptides that are bound to MHC, then it is likely that
MHC plays a greater role in determining the internal sequence of peptides that are
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presented at the cell surface. However, if ERAP1 predominantly trims free peptides
then ERAP1 is determines which peptide sequences will be trimmed and avail-
able for presentation at the cell surface. MHC may also play a role when ERAP1
trims free peptides, as it may save peptides of the correct length for presentation on
MHC from further degradation by ERAP1, or it may remove peptides from the pool
of ERAP1 substrate before they are trimmed to their optimal lengths. Therefore,
knowledge of the dominant trimming mechanism used by ERAP1 in vivo would
improve our understanding of the generation of mature peptides for presentation
on MHC. Importantly ERAP1 has been linked to autoimmune diseases; in the fol-
lowing section we provide a case study of the disease most correlated to ERAP1,
Ankylosing Spondylitis.
1.4.3 ERAP1 in the pathogenesis of Ankylosing Spondylitis
The genetic association between the MHC I HLA-B27 haplotype and Ankylosing
Spondylitis (AS) is amongst the strongest known for any autoimmune disease. More
than 85% of individuals with AS carry at least one HLA-B27 allele (compared with
less than < 10% of healthy people) [24, 34] but only 1-5% of HLA-B27+ individuals
develop AS. Genome wide association studies (GWAS) have revealed that ERAP1
has the second strongest association with AS [144] but only amongst HLA-B27+
individuals [51].
The mechanism by which HLA-B27 causes disease is unknown but the three
prevailing hypotheses: arthitogenic peptide, free HLA heavy chain, and HLA mis-
folding, all may include a role for ERAP1.
The arthritogenetic peptide hypothesis supposes that HLA-B27 restricted
CD8+ T cells which have been primed by an antigenic peptide, cross-react with
molecularly similar self-peptides. Several self-peptides have been identified in AS
that stimulate HLA-B27 restricted CD8+ T cells [4, 55], and that are associated
with the destruction of uninfected cells in patients with AS [74]. However, HLA-
B27 transgenic rats develop AS in the absence of CD8+ T cells [164]. A T cell
targeted drug, Abatacept, which limits T cell responses by binding to the CD80 and
CD86 proteins expressed on activated APCs, was found to be ineffective for AS
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treatment [154].
A mature p:MHC complex comprises a polymorphic HLA heavy chain, a
monomorphic light chain, b2-microglobulin, b2M, and a peptide. The second theory
posits that heavy chain dissociates from peptide(s) and b2M at the cell surface and
associates with other free heavy chain (FHC) proteins to form homodimers. These
cell surface heavy chain homodimers are ligands for killer-cell immunoglobulin-
like receptors (KIRs), expressed on natural killer (NK) cells and on some lympho-
cytes [99]. The interleukin-23 (IL-23) receptor, which is predominantly expressed
by KIR+ CD4+ T cells in AS patients [15], has been genetically linked to AS [115].
IL-23 is essential for the induction of a proinflammatory subset of CD4+ T cells, T
helper 17 (Th17) cells, so-called because they release the interleukin-17 (IL-17) cy-
tokine [104]. IL-17 is found at increased levels in the blood [107] and synovial fluid
of AS patients [153]. ERAP1 inhibition and silencing, and AS-protective ERAP1
variants are associated with decreased HLA-B27 FHC expression by APCs, sup-
pressed Th17 cell populations, and lower Il-17A secretion [31]. However, ERAP1
silencing increases the expression of HLA-B27 homodimers [167]. IL-23 knockout
mice are immune to experimental autoimmune encephalomyelitits (EAE), which is
a rodent model of human multiple sclerosis [36], collagen-induced arthritis (CIA)
[125], and inflammatory bowel disease (IBD) [81, 182].
HLA-B27 folding is significantly slower and requires a much higher peptide
supply than other HLA alleles [118]. The final hypothesis proposes that the slow
folding or misfolding of HLA-B27 in the ER signals a stress response, via either
the unfolded protein response (UPR) or the ER-overload response. Under normal
cellular conditions, these pathways are responsible for the elimination of improp-
erly folded proteins. However, persistent stimulation of these pathways can up-
regulate inflammatory cytokines, including interleukin-23 [40]. The UPR-marker,
immunoglobulin heavy chain binding protein, BiP, is expressed at high levels in the
synovial fluid [42], but not in peripheral blood mononuclear cells or ileal biopsies
of AS patients [93].
ERAP1 could have a role in all three hypotheses by altering the repertoire of
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ER peptides, and thus also altering the folding rate and stability of p:MHC com-
plexes. Intracellular expression of free heavy chain is increased in ERAP1 sup-
pressed cells that express AS associated HLA-B27 subtypes, B*27:04 and B*27:02,
but not in cells expressing the non-AS associated subtypes, B*27:06 or B*27:09
[71].
GWAS have identified single nucleotide polymorphisms in ERAP1 that are as-
sociated with AS, five of which have been verified across diverse ethnic groups [92].
ERAP1 is highly polymorphic across individuals and exists as distinct allotypes that
consist of multiple combinations of SNPs [141, 142]. In a study that sequenced the
pairs of ERAP1 allotypes of 34 AS patients and 38 controls, no pairs were shared
by both groups, and the ERAP1 pairs from cases were unable to restore the cell sur-
face expression levels of ERAP1 deficient cells to control levels. The AS-associated
allotype pairs consisted either of two hypoactive allotypes, or a normal and hyper-
active allotype, whilst control allotypes were typically both normal, or normal and
hypoactive. This indicates that AS pathogenesis may be caused by either too high
or too low levels of ERAP1 trimming activity, resulting in fewer and suboptimal
peptides, whereas protection is conferred so long as at least one allotype ensures
efficient trimming and there is no overtrimming [141].
1.5 Modelling techniques
Many natural phenomena in physics, chemistry, and biology can be accurately de-
scribed by differential equations. Differential equations measure the rate of change
of a dependent variable with respect to one or more independent variables. Ordi-
nary differential equations (ODEs) have just one independent variable, such as time,
whilst partial differential equations (PDEs) have multiple independent variables.
The most appropriate mathematical model for a given problem is often the
simplest. Simple models can be easily analysed and interpreted, which may help
to break down how a process works. Complexity may be added if it improves
the accuracy or predictive capacity of the model, or if the current model already
performs well allowing for the addition of new mechanisms and hypotheses to be
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tested.
1.5.1 Ordinary differential equation models
This thesis makes extensive use of ODEs to simulate molecular processes over time.
The number of molecules of a species, for example MHC molecules, M, can be
written as a function of time, t, as shown in equation (1.1a). The derivative of the
species with respect to time is an ODE (equation (1.1b)) that determines how the
number of MHC molecules changes over time
M = f (t) (1.1a)
dM
dt
= f ′(t) (1.1b)
It is instructive to look in detail at how we might set up these equations to model
the number of MHC molecules in the ER over time. First, consider the gener-
ation and destruction of MHC. MHC proteins are synthesised and assembled in
the ER. Misfolded or mistranslated MHC, as well as MHC that fail to form stable
p:MHC complexes undergo endoplasmic-reticulum-associated protein degradation
(ERAD), during which they are exported to the cytosol and targeted to the ubiquitin-
proteasome degradation pathway. MHC synthesis is dependent on the rate of protein
translation and folding and is independent of the number of MHCmolecules already
in the ER, so it can be described by a constant rate of generation, g. On the other
hand MHC degradation is governed by the law of mass action which states that the
rate of a chemical reaction is directly proportional to the quantity of the reactants.
Degradation of free MHC is proportional to the number of free MHC molecules in
the system because there are more defective MHC in a bigger pool of MHC. Thus
MHC will be depleted by dM molecules per unit of time
dM
dt
= g−dM (1.2)
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This ODE is linear inM, becauseM is multiplied by a constant rate of degradation,
d, rather than by other variables. All linear ODEs can be solved, which means we
can determine the in silico number of MHC molecules at any timepoint by integra-
tion of equation (1.2)
M(t) = g
d
+e−dt +M(0) (1.3)
The population of MHC decays exponentially over time from its initial population
(M(0)) plus the net rate of population change ￿ gd ￿.
MHC also interacts with other species, or variables, in the system. These
processes are all governed by the law of mass action, which has two components.
Firstly, the reaction kinetics are proportional to the quantities or concentrations of
the species involved. Second, at equilibrium, the rate of the forward reaction is
equal to the rate of the reverse reaction. MHC molecules are removed from the pool
of free MHC, M, when they come into contact and bind a peptide, P, with bind-
ing rate, b, forming a p:MHC complex, MP. When the complex, MP, dissociates,
with unbinding rate, u, MHC is returned to the pool of free MHC, M. This can be
represented by the following chemical reaction pathway
M+P b￿⇀
u
MP (1.4)
At equilibrium, the rate of the forward reaction (b[M][P]) is equal to the rate of
the reverse reaction (u[MP]), which facilitates the definition of a new constant, the
dissociation rate, kd . The dissociation rate is often easier to measure experimentally
than the binding and unbinding rates
b[M][P] = u[MP] (1.5)[M][P][MP] = bu = kd (1.6)
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The differential equation (1.2) can be updated to include these reactions
dM
dt
= g−d[M]−b[P][M]+u[MP] (1.7)
Equation (1.7) is a nonlinear ODE because it contains a product of the dependent
variable and an independent variable (the term b[P][M]). The new independent
variables, P and MP, have their own differential equations, d[P]dt and d[MP]dt . To-
gether, the differential equations governing all species, form a chemical reaction
network (CRN) of coupled ODEs. Each equation can be developed to include more
interactions as appropriate. In chapters 2 and 3 we use chemical reaction networks
to model peptide trimming by ERAP1 within the context of peptide optimisation
and presentation on MHC.
Very few nonlinear ODEs can be solved. We used the MATLAB ODE suite
to generate numerical approximations to the solutions of the coupled ODEs [151].
The ODE solver takes initial values for the species concentrations as input as well
as a time over which the simulation is to run. At each time step, the solver uses
an algorithm on the results of the previous steps. It outputs the set of time steps
and corresponding outputs for the species. MATLAB has solvers for both stiff and
non-stiff problems. Stiffness occurs when a model contains mechanisms that occur
on different time-scales. This is the case for our models, so we use the stiff solvers.
Specifically, we chose ode23tb because it has the same functionality as the other
solvers, but is additionally efficient for problems with crude error tolerances. The
ode23tb solver uses implicit Runge-Kutta methods to approximate the solutions
of the ODEs. Explicit methods are suitable for non-stiff equations, whilst implicit
methods are suitable for stiff equations [161]. The ode23tb solver uses a trape-
zoidal rule step as its first stage and a backward differentiation formula as its second
stage. We implemented the code in MATLAB R2016b. Examples of the code that
may be used to reproduce the results for System H1 are given in the Appendix Sec-
tion A.5.6. The largest ODE system in this thesis contains 13 differential equations
but the potential size of each system is boundless. Peptides are given a species,
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i, corresponding to the core epitope, and a length, j. The systems are designed
to allow the simulation of any peptide sequence. In Chapter 2, in addition to the
MATLAB ODE solvers, we used equilibrium analyses to identify key features and
determine theoretical parameter dependencies of each system.
However, application of these and many models is currently limited by the
availability of data. The rates governing peptide interactions with ERAP1, MHC,
and tapasin:MHC are not known for all peptide sequences. It is useful to instead
consider representative peptide species, for example three representative subsets of
peptides with low, medium, and high affinities for MHC [38]. The Dalchau model
uses a Markov chain Monte Carlo (MCMC) algorithm to fit unknown parameter
rates to dynamic data. MCMC is a useful tool to modellers when data is limited,
but the combination of parameter values it determines is one of many possible com-
binations that provide a fit of the model to the data. We used experimentally mea-
sured parameter values where available, and the MCMC derived parameter values
of the Dalchau model otherwise.To determine the parameter values defining trim-
ming by ERAP1, we fitted a Michaelis Menten system of ODEs to time series data
of ERAP1 trimming, using the Matlab algorithm fmincon.
It is important to assess the reliability of the model predictions with respect
to the parameters, given the inherent uncertainty in their values. To do this, we
performed a sensitivity analysis using SUNDIALS: a SUite of Nonlinear and DIf-
ferential/ALgebraic Equation Solvers [77].
Biochemistry is becoming more quantitative, and the predictive capabilities of
chemical reaction networks of differential equations will improve over time. Even-
tually CRNs are likely to become a reliable widely used tool for the generation of
parameter rates. At present, given the lack of detailed data, the aims of the CRNs
used in this thesis are to show how a process may work, and to provide testable
hypotheses that may stimulate new experimental studies.
The Dalchau model
My secondary supervisor, Neil Dalchau (Microsoft Research, UK), and his col-
leagues developed an ODE model of antigen presentation on MHC I [38]. The
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model consists of peptide, MHC I, tapasin and their interactions both in the peptide
loading complex and during transit to the cell surface. The model is independent of
peptide length but the peptides are assigned a low, medium, or high MHC dissoci-
ation rate. A key finding was that tapasin enhances the p:MHCI dissociation rate,
u, so that in the presence of tapasin, surface presentation of p:MHCI becomes more
sensitive to the unbinding rate, approximately u2, thereby ‘optimising’ the MHC
peptide cargo. That is, tapasin further enhances the stability of the peptides with
low dissociation rates relative to those with high dissociation rates, and therefore
increases the proportion of peptides with low dissociation rates that are presented
at the cell surface. The model was calibrated to human cell line data [179] but
was also able to reproduce observations in mice [80]. We developed this model to
incorporate peptide length and trimming by ERAP1.
1.5.2 Artificial neural networks
It is also useful to consider what data is currently available within the antigen pro-
cessing and presentation (APP) pathway, and to consider which modelling tech-
niques may make the best use of it. The largest dataset in the APP pathway com-
prises epitopes that are known to be displayed by HLA alleles [172]. The size and
intrinsic patterns contained within this dataset lends it to machine learning tech-
niques, such as artifical neural networks (ANNs; NNs). ANNs, inspired by biolog-
ical brains, can be used to detect nonlinear patterns within data. They have been
widely used in the APP pathway, to predict the specificity of the proteasome [94,
130, 175] and TAP [43, 18, 187], peptide binding to MHC [22, 113, 119], as well
as a combination of all three processes [105].
When we started our ANN project, it had been nearly 10 years since an ANN
for the prediction of proteasomal cleavage motifs had been published [94, 130].
Over this time a wealth of new epitope data became available [149, 172], beckoning
the possibility of improvements to the predictive capability of proteasomal cleavage
ANNs. Another ANN for proteasomal cleavage has since been published [175].
Artifical neural networks map input data via one or more layers of neurons
to output data. We used ANNs consisting of one hidden layer of neurons and one
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output layer of neurons because the universal approximator theorem states that a
single hidden layer is sufficient for the approximation of most non-linear continuous
functions [78]. The neural network architecture for classification of a single input
training example is shown in Figure 1.1. Each element, pr, of an input datum,
p, is connected via a weight, w1r,s. to every neuron, N1s , in the hidden layer. The
summation of the weighted inputs, p ⋅w1r,s, plus a scalar bias term, b, is the argument
to the neuron’s transfer function (equation (1.8a)). The output, y1s , of the transfer
function, f 1, is fed into an activation function, f 2, which determines the overall
output of the network
y1s = f 1(pr ⋅Ws) (1.8a)
y2 = f 2(y1s ⋅Ws) (1.8b)
The purpose of the ANNs of Chapter 4 is to predict whether a particular amino
acid within a polypeptide sequence is a cleavage site or not. Thus the output of
the network should be a real number between 0 and 1, where 0 represents a non-
cleavage site and 1 represents a cleavage site. The transfer fucntion is a tan-sigmoid
function, which outputs a value between -1 and 1, and the activation function is a
log-sigmoid function which outputs a value between the desired range, 0 to 1.
The ANN is trained by adapting the weights and bias values over successive
iterations to minimise some measure of error between the output values and the
target values. The backpropogation algorithm is used to find the combination of
weight and bias values that minimise the error function.
Artifical neural networks can provide accurate predictions of the outcomes of
processes that cannot be represented by explicit functions. There is a wealth of HLA
epitope data [149, 172], but there is not a wealth of data or information concerning
the mechanism and specificity of the proteasome. It is therefore appropriate to see
what information about the proteasome can be gleaned from ANNs. However, the
primary draw back of ANNs is that they are metaphorical ’black boxes’, and the
only information that can be ascertained pertaining to their classification decisions
is contained in the weight and bias values. They do not provide a mechanistic view
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Figure 1.1: Neural network architecture for classification of a single input datum. The
model takes a binary input datum P of length R. The hidden layer consists of
S neurons, N11 ,N
1
2 ...N
1
S , where the superscript 1 denotes the first layer. Each
datum is connected to each neuron in the hidden layer by a weight, wr,s. Each
neuron takes the dot product of its weights and the input data plus a bias term
as the argument to its transfer function, f 1, where the superscript 1 denotes the
first function. The output of all hidden layer neurons is connected to a single
neuron in the output layer, N2 where superscript 2 denotes the second layer. The
neuron takes the dot product of its weights and the input data plus a bias term
as the argument to its output function f 2 where the superscript 2 denotes the
second function. The output of this neuron is the output of the neural network
for the example training datum provided.
of the processes being studied.
Artificial neural networks and chemical reaction networks are two key com-
plementary modelling techniques for the study of biochemical molecular processes.
1.6 Hypotheses and main aims
This thesis seeks to further current understanding of the specificities and mech-
anisms of the key proteases in the antigen processing pathway: ERAP1 and the
proteasome. In Chapter 2, we use Michaelis Menten models of ERAP1 trimming
pathways to determine the conditions for each of the two prevailing trimming mech-
anism hypotheses to be dominant in vivo. In Chapter 3, we use in vitro data to
parameterise the ERAP1 models and compare their output to in vivo observations.
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The availability of data limits the accuracy of quantitative predictions. In Chapter 4,
we make use of one of the largest datasets available in immunology: MHC epitope
data. We train neural networks on this data to accurately predict C terminal cleav-
age specificities of the proteasome. We show that dynamical mechanistic models
and machine learning models are valuable mathematical tools that can be utilised to
provide insight into biological systems.

Chapter 2
Theoretical models of trimming by
ERAP1
Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an ER resident enzyme that
trims N-terminally extended precursor peptides to peptides of 8 or 9 residues, the
canonical length that is presented at the cell surface on major histocompatability
class I (MHC) molecules [27, 146]. ERAP1, as the primary editor of peptide length,
has an important role to play in shaping the length profile of MHC peptidomes. In
a study comparing the peptides presented on HLA-B27 in the prescence and ab-
sence of ERAP1, it was found that ERAP1− cells presented a lower proportion of
nonamers and a greater proportion of 11-13 mers [30] than their ERAP1+ counter-
parts. More generally, according to a dataset consisting of the binding affinities of
48000 different peptides for 48 different MHC, it seems that decamers make at least
as good candidates for binding to MHC as nonamers do (Figure 2.1d). However,
decamers are poorly presented relative to nonamers in vivo (Figure 2.1c). This is
likely to be a result of the efficient trimming of decamers by ERAP1, as well as the
relatively inefficient trimming of nonamers by ERAP1 (Figures 2.1a and 2.1b).
Over the past 25 years, numerous biochemical and crystallographic studies
have sought to determine the precise mechanism by which ERAP1 generates mature
antigenic peptides, usually of 8-9 amino acid residues in length, instead of trimming
peptides to their constitutive amino acids like other aminopeptidases [27]. It is now
known that ERAP1 is able to trim both free peptides to the correct lengths via an
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Figure 2.1: ERAP1 length dependency corresponds to the length profile of MHC pep-
tidomes. (a) Hydrolytic activity of ERAP1 towards the N terminus of 43
different peptides between 3 and 20 amino acids in length. Figure reprinted
from [27]. (b) Hydrolytic activity of ERAP1 towards the N terminus of
RY(Xn)NKTL where X reprents the amino acid (A, D, E, F, G, H, I, K, L,
M, P, Q, R, S, T, or V) and n represents the repetitions of X (4, 6, 8, 10, 12, 14,
19, or 24). Figure reprinted from [27] (c) The length distribution of peptides
presented on 10 different HLA class I alleles. Data for figure from [45],[64],
[116]. (d) The percentage of peptides of different lengths that bind to MHC
class I, calculated from p:MHC IC50 data for 48,828 different peptides and 48
different MHC class I molecules. Data for figure from [136]
‘internal molecular ruler’, and MHC bound peptides to the correct lengths, using the
MHC molecule as a template. However, the dominant trimming mechanism used
by ERAP1 in vivo remains unknown.
In this chapter, I have used theoretical and simulation analysis to determine
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the conditions required for a variety of hypothesized ERAP1 mechanisms to be
efficient. Throughout, this is quantified by the absolute and relative concentrations
of nonameric cell surface p:MHC complexes. By taking this strategy, we arrive at
testable predictions that could elucidate the dominant trimming mechanism utilised
by ERAP1 in vivo. The hypotheses compared in this chapter are:
H1. Free peptide is the preferred substrate of ERAP1.
H1a. Molecular ruler. ERAP1 has an ‘internal molecular ruler’. Short pep-
tides are not trimmed.
H1b. Indiscriminate trimming. ERAP1 trims indiscriminately; MHC confers
a protective role to high affinity peptides.
H2. MHC as a template. MHC-bound peptide is the preferred substrate of
ERAP1. The MHC binding groove functions as a template for trimming.
Within these models I have considered two mechanisms of trimming by ERAP1:
the bind-trim-releasemechanism and the ratchetmechanism. The bind-trim-release
mechanism assigns ERAP1 single amino acid catalytic activities, so that the short-
ened product is released from the enzyme upon removal of a single amino acid.
Rebinding must occur before additional trims are possible. The ratchet model as-
sumes that ERAP1 does not automatically release the shorterned product follow-
ing catalysis, which allows for the removal of multiple amino acids from a single
peptide:ERAP1 binding event. For both hypotheses, H1 and H2, the free species
ERAP1, E, MHC, M, tapasin, T , and full length peptide, Pext , are supplied to the
ER, as shown in Figure 2.2.
Within Hypothesis 1, the extended peptide can either bind to MHC, to
tapasin:MHC or to ERAP1. The left hand side of Figure 2.3 shows the possible
reactions that may take place if the extended peptide does not bind ERAP1. The
extended peptide may dissociate from MHC at any point or may egress in complex
with MHC to the cell surface. The complex is unlikely to remain bound for suffi-
cient time to stimulate a CD8+ T cell response due to its low stability. Alternatively,
the extended peptide may bind to ERAP1 for trimming. The peptide is likely to
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undergo successive rounds of trimming, until the process is no longer efficient due
to ERAP1’s internal molecular ruler. The trimmed peptide product of length j may
then bind to MHC and egress to the cell surface.
Within Hypothesis 2, peptides cannot directly bind ERAP1. Peptides bind
to free MHC and to MHC complexes. As in Hypothesis 1, extended peptides in
complex with MHC may egress to the cell surface, but these complexes have weak
stability due to the length of their peptide cargo. Alternatively, ERAP1 may bind
the p:MHC complex and initiate peptide trimming. The peptide is likely to undergo
successive rounds of trimming by ERAP1, until no further residues are protruding
from the MHC binding groove. The product of ERAP1 trimming within Hypothesis
2, is a p:MHC complex, which may then egress to the cell surface.
Figure 2.2: Generation of model species. Shapes represent a molecular species. Boxes
represent reactions, with the top rates indicating forward reactions and the bot-
tom rates indicating backwards reactions.
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Figure 2.3: Reaction scheme for Hypothesis 1. Shapes represent a molecular species.
Boxes represent reactions, with the top rates indicating forward reactions and
the bottom rates indicating backwards reactions. Species involved in a reaction
are connected by lines, and the product of a reaction is indicated by an arrow.
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Figure 2.4: Reaction scheme for Hypothesis 2. Shapes represent a molecular species.
Boxes represent reactions, with the top rates indicating forward reactions and
the bottom rates indicating backwards reactions. Species involved in a reaction
are connected by lines, and the product of a reaction is indicated by an arrow.
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2.1 Theoretical analysis
The models are inspired by the Dalchau model of peptide optimisation [38], which
describes the selection of peptides by MHC molecules within the ER, based on the
p:MHC dissociation rate. The models are presented as chemical reaction networks
(CRNs), as well as systems of ordinary differential equations (ODEs) that assume
mass action kinetics. All models share a basic subset of reactions (equations (2.1)
and Figure 2.2), that occur independently of trimming by ERAP1, including the
synthesis and degradation of all species: peptide, Pji , MHC, M, and ERAP1, E, as
well as peptide binding to and unbinding from MHC, and egression of the p:MHC
complex to the cell surface. The starting point of the model is the ER, so all species
are given a rate of ’generation’ in the ER, and a zero starting concentration, ￿. The
generation rate does not imply that the species are actually generated within the
ER; for peptides the generation rate most closely corresponds to the rate of TAP
translocation of peptides from the cytosol to the ER.
￿ gm￿⇀￿
dm
M (2.1a)
￿ gE￿￿⇀￿
dE
E (2.1b)
￿ g ji￿￿⇀￿
dp
P ji (2.1c)
M+Pji b￿⇀￿
u ji
MPji
e￿→MePji u ji￿→Me dMe￿￿→￿ (2.1d)
Peptides are identified by a subscript, i, which defines a unique sequence, and
a length superscript, j, which indicates the full length of the amino acid sequence.
For example, if we designate ASIINFEKL as the nonameric peptide P91 , then P
8
1
has amino acid sequence SIINFEKL. As the sequence of the peptide influences the
p:MHC off-rate, and the supply rate of the peptide to the ER, these parameters are
sequence specific in this notation, i.e. u ji and g
j
i , respectively.
Peptide translocation by transporter associated with antigen processing (TAP)
is the main route of peptide entry into the ER. Studies suggest that TAP preferen-
tially translocates peptides between 7-16 amino acids in length [124, 170]. In order
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to focus on peptide length editing by ERAP1, we assumed that only full length
peptide ( j = N = 14) is supplied to the ER, and all other lengths of peptide must be
generated from trimming by ERAP1 (g ji = 0, ∀ j ≠N).
2.1.1 Hypothesis 1: Free peptide is the assumed substrate of
ERAP1
In our first model, from now on referred to as System H1, free peptide is the assumed
substrate of ERAP1. We used Michaelis Menten (MM) kinetics to model peptide
trimming by ERAP1 because ERAP1 follows MM kinetics in vitro [52, 129, 186]:
E +Pj+1i bE￿￿￿￿⇀￿uE EPj+1i ki, j+1cat￿￿￿￿→ Pji +E (2.2)
Here, ERAP1, E, binds to peptide, Pj+1i , with binding rate, bE , forming a com-
plex EPj+1i . The complex will then either dissociate with unbinding rate, uE , or
ERAP1 will trim a single amino acid from the peptide according to the sequence-
and length-specific catalytic rate, ki, j+1cat , releasing the shortened product, peptide,
Pji , and the single amino acid. The ERAP1 molecule is then free to bind new sub-
strate and the process may repeat for the shortened peptide, Pji .
ERAP1 preferentially trims peptides of between 9-16 amino acids in length
[27]. The rate of N-terminal trimming is significantly slower for peptides of less than
nine residues and is negligible for peptides of less than five residues (Figure 2.1a)
[27]. The simplest way to encode this length dependency is with a step function,
that is equal to 0 when j < 8 and 1 when j > 9. We applied the step function only
to the catalytic parameter, ki, jcat , because it is known that ERAP1 binds, but does not
trim short peptides [129]. This requires the unbinding rate, uE to be high so that
ERAP1 does not become trapped, bound to short peptides that it cannot trim.
To quanitify the impact of the internal molecular ruler on the length distri-
bution of ERAP1 products, it is useful to compare the hypothesis, H1a, with the
indiscriminate trimming hypothesis, H1b. The same reactions can be used to de-
scribe H1a and H1b, but the length dependent step-function does not apply to the
catalytic parameters of H1b.
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The chemical reactions (2.1a)-(2.1d) and (2.2) can be translated into ordinary
differential equations (ODEs) by assuming mass action kinetics
[M]′ = gM +￿
j,i
u ji [MPji ]−(dM +bP￿
j,i
[Pji ])[M] (2.3a)
[E]′ = gE +￿
j,i
[EPji ](uE +ki, jcat)−(dE +bE￿
j,i
[Pji ])[E] (2.3b)
[EPji ]′ = bE[E][Pji ]−(uE +ki, jcat)[EPji ] (2.3c)[Pji ]′ = g ji +u ji [MPji ]+uE[EPji ]+ki, j+1cat [EPj+1i ]−(dP+bP[M]+bE[E])[Pji ]
(2.3d)
[MPji ]′ = bP[M][Pji ]−(u ji +e)[MPji ] (2.3e)[MePji ]′ = e[MPji ]−u ji [MePji ] (2.3f)[Me]′ =￿
j,i
u ji [MePi]−dMeMe (2.3g)
where ′ denotes differentiation with respect to time, t.
Alongside the conventional bind-trim-release trimming mechanism of equation
(2.2), we also considered a ratchet trimming mechanism. The ratchet model repre-
sents a departure from the classical Michaelis Menten model because the product is
not released upon catalysis, and as such requires a new reaction scheme
E +Pj+1i bE￿￿￿￿⇀￿uE EPj+1i ki, j+1cat￿￿￿￿→ EPji (2.4)
The system of ODEs for the ratchet mechanism is the same as for the bind-trim-
release mechanism (equations (2.3)) except the product of ERAP1 trimming is
enzyme-bound peptide, not free peptide. Accordingly, equations (2.3c) and (2.3d)
are replaced by the following equations:
[EPji ]′ = bE[E][Pji ]+ki, j+1cat [EPj+1i ]−(uE +ki, jcat)[EPji ] (2.5a)[Pji ]′ = g ji +u ji [MPji ]+uE[EPji ]−(dP+bP[M]+bE[E])[Pji ] (2.5b)
We used a quasi-steady state approximation (QSSA), as detailed in Section A.2.1,
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to reduce the dimension of the system. This enabled the removal of two ODE equa-
tions: free enzyme, E, and the trimming complex, EPji (equations (2.3b) and (2.3c)
or (2.5a)). The equation for free enzyme, E, (2.3b) is replaced by an expression for
the steady state concentration of free enzyme, [E]∗, in terms of the total enzyme in
the system, ET which is conserved:
[E]∗ = ET￿1+∑ j,i [Pji ]KM ￿ (2.6)
where Ki, jM = uE+ki, jcatbE
Equations (2.3c) of the bind-trim-release scheme, and (2.5a) of the ratchet
scheme have the following steady state approximations, respectively
[EPji ]∗ = [ET ][Pji ]
KM￿1+∑ j,i [Pji ]KM ￿ (2.7a)
[EPji ]∗ = [ET ][Pji ]
KM￿1+∑ j,i [Pji ]KM ￿ +
k j+1cat [EPj+1i ]∗
uE +k jcat (2.7b)
We also obtained a non-dimensional version of the simplified system, so that
the parameter rates are unitless and consequently are directly comparable. Non-
dimensionalisation also has the benefit of reducing the total number of parameters,
but at the cost of increasing the complexity of the right hand sides of the ODEs,
(2.3a)-(2.3g), which become less intuitive when the quantities and rates are re-
scaled. By the Buckingham Pi theorem, non-dimensionalisation reduces the number
of parameters by the number of independent dimensions [20], which for these sys-
tems is two: mass and time. Rescaling time, t, by the egression rate, eg, produces a
dimensionless measure of time, t
t = teg (2.8a)
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A parameter combination with dimension mass is required to obtain a dimensionless
measure of the species’ concentrations. We use the quotient of the peptide binding
rate and the egression rate: bPeg . For example, the dimensionless MHC species, m,
defined in terms of the dimensional species,M, is
[m] = bP[M]
eg
(2.8b)
The process of non-dimensionalisation applied to this model, and the resulting di-
mensionless system are detailed in Section A.3.1.
2.1.2 Hypothesis 2: MHC-bound peptide is the assumed sub-
strate of ERAP1
In our second model, from now on referred to as System H2, the MHC binding
groove functions as a template for peptide trimming by ERAP1. ERAP1 may bind
to free MHC and this complex may then bind peptide. Or ERAP1 may bind to
a p:MHC or tapasin:p:MHC complex. Upon removal of a single amino acid, the
p:MHC complex is released and ERAP1 is free to form a new trimming complex.
This is summarised by the following chemical reaction pathway:
E +M bE￿￿￿￿⇀￿
uE
EM (2.9a)
E +MPj+1i bE￿￿￿￿⇀￿uE EMPj+1i u j+1i￿￿￿￿⇀￿bP EM+Pj+1i￿￿￿￿￿￿ki, j+1cat
E +MPji (2.9b)
where the reused notation, ki, jcat , now denotes the catalytic activity of an MHC-bound
ERAP1 molecule. We also considered the pathway in which ERAP1 binds to empty
MHC. However, this did not make an appreciable difference to simulation results,
so we did not include interactions between ERAP1 and empty MHC in the model.
54 Chapter 2. Theoretical models of trimming by ERAP1
Again assuming mass action kinetics, the chemical reactions (2.1a)-(2.1d) and
(2.9b) can be translated into ODEs:
[M]′ = gM +￿
j,i
u ji [MPji ]+uE[EM]−(dM +bp￿
j,i
[Pji ]+bE[E])[M] (2.10a)
[E]′ = gE +uE￿
j,i
[EMPji ]+￿
j,i
ki, jcat[EMPj]+uE[EM] (2.10b)
−(dE +bE￿
j,i
[MPji ]+bE[M])[E]
[EM]′ = bE[E][M]+￿
j,i
u ji [EMPji ]−(uE +bp￿
j,i
[Pji ])[EM] (2.10c)
[EMPji ]′ = bE[E][MPji ]+bp[EM][Pji ]−(uE +u ji +ki, jcat)[EMPji ] (2.10d)[Pji ]′ = g ji +u ji ([EMPji ]+ [MPji ])−(dp+bp([M]+ [EM]))[Pji ] (2.10e)[MPji ]′ = bp[M][Pji ]+uE[EMPji ]+ki, j+1cat [EMPj+1i ]−(u ji +e+bE[E])[MPji ]
(2.10f)
[MePji ]′ = e[MPji ]−u ji [MePi] (2.10g)[Me]′ =￿
j,i
u ji [MePi]−dMeMe (2.10h)
The ratchet trimming mechanism enables multiple trims to occur following
a single binding event between ERAP1 and p:MHC. The trimmed product is not
automatically released upon cleavage, but is ratcheted through the enzyme so that
the next amino acid bond may also be cleaved. The product is only released if
the enzyme-substrate complex unbinds with unbinding rate uE . Analagously to the
changes made for System H1, this amounts to the substitution of equations (2.10d)
and (2.10f) for the following ratchet mechanism equations
[EMPji ]′ = bE[E][MPji ]+bp[EM][Pji ]+ki, j+1cat [EMPj+1i ]−(uE +u ji +ki, jcat)[EMPji ]
(2.11a)
[MPji ]′ = bp[M][Pji ]+uE[EMPji ]−(u ji +e+bE[E])[MPji ] (2.11b)
We used a quasi-steady state approximation (QSSA), as detailed in Section
A.2.2, to reduce the dimension of the system. This enabled the substitution of
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three ODEs: free enzyme E and the complexes EM and EMPji (equations (2.10b) -
(2.10d)), for three steady state equations
[E]∗ = ET￿￿1+ 1KA￿bE[M]+∑ j,i u ji [MPji ]K jM2 ￿￿1+￿j,i [P
j
i ]
K jM3
￿+￿
j,i
[MPji ]
KM2 j
￿￿
(2.12a)
[EM]∗ = [ET ]
KA
￿bE[M]+￿
j,i
u ji [MPji ]
KM2
￿ (2.12b)
[EMPji ]∗ = [ET ][MPji ]K jM2 + [EM][P
j
i ]
K jM3
(2.12c)
KA = uE +bP￿
j,i
[Pji ]￿1− u ji
uE +u ji +kPjicat ￿ (2.12d)
K jM2 = (uE +u ji +kMP
j
i
cat )
bE
(2.12e)
K jM3 = (uE +u ji +kMP
j
i
cat )
bP
(2.12f)
As explained in Section 2.1.1, non-dimensionalisation has several benefits, in-
cluding reducing the number of model parameters, as well as providing dimension-
less and therefore directly comparable parameter rates and species concentrations.
As detailed in Section A.3.2, we obtained a dimensionless version of the system,
and in the process removed the parameter rates for peptide-MHC binding bP and
egression eg.
2.1.3 Tapasin
Tapasin is a chaperone molecule of the peptide loading complex that helps to opti-
mise the peptide cargo of MHC by increasing the rate of peptide selection. In the
absence of tapasin, peptide loading onto MHC is often inefficient even for highly
abundant peptides [80], and intermediate and low affinity peptides are more readily
presented [176]. We know that MHC molecules play a role, either active or pas-
sive, in peptide trimming by ERAP1. It is therefore of interest to consider how
tapasin affects the ERAP1 systems. The Dalchau peptide optimisation model as-
signs tapasin-dependent p:MHC on- and off- rates that are faster than their tapasin-
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independent counterparts [38]. The formation of a stable tapasin:p:MHC complex
may induce tapasin to unbind the MHC molecule. Tapasin thus dissociates from a
tapasin:p:MHC complex at an enhanced rate, vuT , relative to its dissociation rate,
uT , from a tapasin:MHC complex [38].
Tapasin may be incorporated in System H1 by direct addition of the extra
equations for the tapasin pathway, (2.13a)-(2.13b), to the chemical reactions that
describe the tapasin− System H1 (2.1a)-(2.1d) and (2.2). This is possible for Sys-
tem H1 because tapasin and ERAP1 act independently of each other: tapasin always
interacts with MHC, and ERAP1 only interacts with free peptide.
T+M bT￿￿￿￿⇀￿
uT
TM (2.13a)
TM+Pji b￿￿￿⇀￿
u ji
TMPi
uT v￿￿→T +MPi e￿￿→MePji u ji￿￿→Me dMe￿￿→￿ (2.13b)
The full tapasin+ System H1 is presented in Section A.4.1.
Adding tapasin to System H2 is more complex. We first tried the simplest
method of adding the tapasin pathway (2.13a)-(2.13b) independently to the system,
as described above for System H1. However, this closely resembled the tapasin
negative system, because within System H2, the product of ERAP1 is MHC-bound
peptide, and tapasin is only able to bind to empty MHC. Therefore, trimmed peptide
has to first unbind MHC in order for tapasin to bind MHC. The unbinding rate of
p:MHC complexes is the rate limiting step, which obscures the impact of tapasin on
the peptide sampling rate.
Therefore, tapasin only has an effect on System H2 if both ERAP1 and tapasin
can bind MHC at the same time. Accordingly, we added two new equations which
describe ERAP1 interaction with tapasin-bound p:MHC.
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E +TM bE￿￿￿￿⇀￿
uE
ETM (2.14a)
E +TMPj+1i bE￿￿￿￿⇀￿uE ETMPj+1i u j+1i￿￿￿￿⇀￿bP ETM+Pj+1i￿￿￿￿￿￿kMP
j+1
i
cat
E +TMPji (2.14b)
The full tapasin+ version of System 2, given in Section A.4.2, consists of the
tapasin− equations (2.1a)-(2.1d), (2.14a) and (2.14b), as well as the tapasin pep-
tide optimisation pathway (2.13b), and the ERAP1:tapasin:MHC system described
above (2.14).
2.2 Equilibrium analysis
Closed form solutions are not possible for this model, so we used equilbrium anal-
ysis to provide an overview of the key mechanisms at play when the models are at
steady state (SS). Equilibria provide a simpler view of a dynamic model, which can
be more informative and amenable to analysis. Previous equilibrium analyses have
been useful for interpreting the function of tapasin in models of peptide competi-
tion for MHC [38]. The following equilibrium analysis highlights some important,
experimentally testable distinctions between the ERAP1 trimming hypotheses.
There are many ways to write a given equilibrium condition; here we present
several versions of the equilbrium condition for cell surface p:MHC expression for
all model variants. Their full derivations are given in Section A.5.
2.2.1 System H1
First consider System H1, in which ERAP1 trims free peptide. By setting equations
(2.3e) and (2.3f) to zero, we can see that the cell surface concentration of p:MHC,
depends on the rate of egression of ER resident p:MHC and their dissociation rate,
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whilst the concentration of ER p:MHC, depends on its rates of egression, dissoci-
ation, association and on the concentrations of peptide and MHC, as well as the
unbinding rate of tapasin from tapasin:p:MHC complexes.
[MePji ]∗ = eu ji [MPji ]∗ (2.15)[MPji ]∗ = 1u ji +e￿bP[M]∗[Pji ]∗+uT v[TMPji ]∗￿ (2.16)
The SS concentration of tapasin:p:MHC complexes depends on the tapasin depen-
dent association rate, c, the enhanced peptide off-rate, qu ji and the tapasin unbinding
rate, uT v
[TMPji ]∗ = c[TM]∗[Pji ]∗qu ji +uT v (2.17)
By substituting equation (2.17) into equation (2.16), and the resulting expression
into equation (2.15), the equilibrium condition for cell surface p:MHC can be writ-
ten in the same format as the peptide filtering relation derived by Dalchau et al.
[38].
[MePji ]∗ = 1u ji￿￿￿
surface
e
u ji +e￿￿￿ ￿￿￿
ER
￿￿bP[M]∗+ uT vuT v+qu ji￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
tapasin
c[TM]∗￿￿[Pji ]∗ (2.18)
This equation shows that cell surface expression of p:MHC is dependent on the op-
timisation of peptides within the ER and at the cell surface. Peptides with relatively
slower dissociation rates from MHC molecules are more likely to egress from the
ER to the cell surface ( e
u ji +e ), and to remain bound to MHC when at the cell surface
( 1
u ji
). For tapasin to be effective, the off-rate enhancement factor, q, must be greater
than the peptide-induced dissociation rate of tapasin from the tapasin:p:MHC com-
plex, that is, x = uT vq must be low. For low x, tapasin enhances peptide optimisation
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by the inverse of the off-rate, 1
u ji
.
The Dalchau model [38] does not explicitly consider N-terminal extensions to
peptides. The models introduced in previous sections extend the work of Dalchau
et al. by modelling peptide length, as trimmed by ERAP1. All models are set up
so that only full length peptide, PNi , is supplied to the ER, whilst all other peptide
lengths, Pji , are the product of trimming by ERAP1. The steady state concentration
of free peptide, Pji , in the ER is thus determined by its rate of generation and de-
struction by ERAP1, its binding and unbinding to MHC, and its export rate to the
cytosol. Full length peptide, PNi , is supplied directly to the ER, rather than being
generated by ERAP1
[Pji ]∗ = 1
dP+bP[M]∗+ k jcatK jM [E]∗￿
k j+1cat
K j+1M [E]∗[Pj+1i ]∗+u ji [MPji ]∗￿ (2.19a)
[PNi ]∗ = 1
dP+bP[M]∗+ kNcatKNM [E]∗￿g
N
i +uNi [MPNi ]∗￿ (2.19b)
where Ki, jM = k jcat+uEbE .
Substitution of equations (2.19a) and (2.19b) into the tapasin independent part
of equation (2.16) yields slightly different quotients: 1
u ji +e−u2 ji and 1u ji +e respectively.
The quotient for trimmed peptides accounts for rebinding of peptides to MHC.
Shown is the expression for a trimmed p:MHC complex, where j ≠N.
[MPji ]∗ = 1￿u ji +e−u2 ji ￿￿dP+bP[M]∗+ k jcatK jM [E]∗￿￿bP[M]
∗ k j+1cat
K j+1M [E]∗[Pj+1i ]∗￿
(2.20)
where u2 ji = bP[M]∗u jidP+bP[M]∗+ kcatKNM [E]∗
Equation (2.20) shows the SS concentration of a p:MHC complex, MPji , in
terms of its generation by ERAP1 from the peptide, Pj+1i , that has a single aa exten-
sion. Substitution of (2.19a) over all j <N and then substitution of (2.19b) for j =N,
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and substitution of this expression into (2.18) produces a steady state expression for
cell surface expression of p:MHC in an ERAP1+ system that includes all possible
mechanistic steps in the model
[MePji ]∗ = B 1u ji￿￿￿
surface
e
u ji +e−u2 ji￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
ER
￿ N￿
n= j
1
dP+bP[M]∗+ k jcatK jM [E]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
loss
×￿
￿ gNi N￿
n= j+1
kncat
KnM
[E]∗
￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from peptides that have
not previously been bound to MHC
+ N￿
m= j+1
m￿
n= j+1
kncat
KM
[E]∗ umi
umi +ebP[M]∗[Pmi ]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from peptides that have
previously been bound to MHC
￿￿
(2.21)
where B = bP[M]∗.
Recall that full length peptide is supplied to the ER, whereupon it may either
bind MHC or ERAP1, or may be exported back to the cytosol. ERAP1’s role is
to bind peptide, remove a single amino acid, and release the shortened product.
The shortened peptide may then re-bind ERAP1 for a second cycle of trimming,
bind MHC, or be exported to the cytosol. The first term in the inner brackets of
equation (2.21) accounts for the case in which all extended peptide forms, Pni , where
n= j+1, ...,N, escape binding to MHC, so that the generation of peptide, Pji , is equal
to the product of the substrate specificity constants of ERAP1 towards each of the
precursor peptides, Pni , the supply rate of full length peptide, g
N
i , and the steady state
concentration of ERAP1, [E]∗. The second term in the inner brackets accounts for
the case in which a peptide binds MHC before it is fully trimmed. In this case
there is competition between egression and dissociation of the suboptimal p:MHC
complex, represented by the term u
j
i
u ji +e . If the peptide unbinds then it re-enters the
pool of free peptide substrate for trimming by ERAP1. Finally the third term in
the inner brackets adds that MPji may unbind, but this doesn’t prevent it from re-
binding and egressing to the cell surface. The loss term accounts for the fact that a
peptide of a given length may be removed from the pool of free peptide by either
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being exported to the cytosol, being trimmed by ERAP1 or binding to MHC. Note
that the product starts at n = j which accounts for overtrimming of peptide Pji by
ERAP1. The equilibrium expression also retains the key features of the peptide
optimisation condition for peptides of homogenous length, as in equation (2.18)
[38].
In a tapasin+ system, the majority of peptide loading is likely to take place
via the tapasin pathway, since tapasin accelerates peptide sampling by MHC
[80][176][38] and the concentration of tapasin:MHC is greater than the concentra-
tion of tapasin (TM∗ >>M∗) [38]. The equilibrium condition takes the same form as
equation (2.21), but peptides bind tapasin:MHC complexes rather than free MHC,
typically with faster binding and unbinding rates than within the tapasin− system
[MePji ]∗ =C 1u ji￿￿￿
surface
e
u ji +e￿￿￿ ￿￿￿
ER
qu ji
uT v+qu ji￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
tapasin
￿ N￿
n= j
1
dP+bP[M]∗+ k jcatK jM [E]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
loss
×￿
￿ gNi N￿
n= j+1
kncat
KnM
[E]∗
￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from peptides that have
not previously been bound to MHC
+ N￿
m= j+1
m￿
n= j+1
kncat
KM
[E]∗ qumi
qumi +uT vc[TM]∗[Pmi ]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from peptides that have
previously been bound to MHC
+qu ji [TMPji ]∗
￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
unbinding of Pji
￿￿ (2.22)
whereC = c[TM]∗.
The contribution of the final two terms in equation (2.22) is likely to exceed
the equivalent terms in equation (2.21), because tapasin increases the sampling rate
of peptides. This may reduce the efficiency of peptide catalysis by ERAP1 because
the competition for peptide is greater.
It is useful to see all possible interactions that may lead to cell surface presen-
tation of a peptide using equations (2.21) and (2.22). It is also useful to consider
the likely contributions of these processes in vivo and to obtain an approximate
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simplified steady state condition forMePji .
The total concentration of peptides in the model, PTOT , is equal to the summa-
tion of all free peptides and all peptide complexes: PTOT =∑i, j(Pji +EPji +MPji +
MePji +Pe ji ). Only free peptide is created and destroyed, the rest is simply moved
between different species and cellular compartments and is conserved. Thus the
rate of change of total peptide is equal to the the rate of change of free peptide
d[PTOT ]
dT
= gP+dP[Pji ] (2.23)
Peptides in the ER are short-lived [12][38]. Approximately 2× 104 peptides are
transported to the ER by TAP per minute [127] and once in the ER, they have a half
life of 1.5-4 minutes [100]. Using these quantities, and the approximation in (2.23),
the steady state concentration of total ER peptides is 6.3×104 peptides, whilst there
are only 1000-3000 MHC class I molecules in the ER at any time [184]. It can be
assumed that MHC interaction with peptide does not alter the steady state concen-
tration of free peptide [38] since peptide abundance exceeds MHC abundance by an
order of magnitude.
Equations (2.19a) and (2.19b) simplify to single quotients ((2.24a) and
(2.24b)), following the removal of the peptide-MHC interaction terms
[PNi ]∗ = gNi
dP+ kNcatKNM [E]∗ (2.24a)[Pji ]∗ = 1
dP+ k jcatK jM [E]∗￿
k j+1cat
K j+1M [E]∗[Pj+1i ]∗￿ (2.24b)
To obtain an expression that is dependent on only two SS variables, MHC concen-
tration, [M]∗, and ERAP1 concentration, [E]∗, we can substitute equations (2.24b)
and (2.24a) into the tapasin independent part of equation (2.18). The resulting
expression tracks a peptide, Pji , from its initial supply as full length peptide, P
N
i ,
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through subsequent binding and trimming events
[MePji ]∗ = B 1u ji￿￿￿
surface
e
u ji +e￿￿￿ ￿￿￿
ER
￿￿ gNi￿￿￿
supply
N￿
n= j+1
[E]∗kncat
KnM￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation
N￿
n= j
1
dP+ [E]∗kncatKnM￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
loss
￿￿ (2.25)
where B = b[M]∗.
The resulting equation (2.25) is similar to the first part of equation (2.21), but is
without the terms that account for the interaction of precursor peptides with MHC.
Similarly, the loss term of equation (2.25) does not include the loss of peptide to
binding with MHC.
The simplified equilibrium expression (2.25) is useful for interpreting the con-
tributions of extended peptides to the cell surface presentation of an optimal length
(nonameric) peptide. Equation (2.25) suggests that the extended forms, Pni , where
n = 10, ...,N, do not bind MHC and that full length peptide will be trimmed until
it is 9 residues long. At this point the peptide may bind MHC and egress to the
cell surface. This is a likely scenario in vivo because the kinetic rates of ERAP1
towards a good substrate are much faster than the p:MHC binding rate. Peptides of
nine residues or less are typically poor substrates for ERAP1 [27], and so ERAP1
presents less competition to MHC for the binding of nonamers.
In a tapasin+ system, the p:MHC binding term, B, in equation (2.25) is substi-
tuted for a tapasin:p:MHC affinity term: C qu
j
i
uT v+qu ji . This shows that tapasin does not
affect the generation of peptides by ERAP1, assuming that the interactions between
ERAP1 and peptide occur at faster rates than the interaction between peptide and
tapasin:MHC complexes. Tapasin only affects the overall optimisation of p:MHC
complexes, as in equation (2.18).
2.2.2 System H2
Now consider System H2, in which ERAP1 trims MHC-bound peptide. As is the
case for System H1, cell surface p:MHC expression depends on the unbinding and
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egression rates of the p:MHC complex
[MePji ]∗ = 1u ji eu ji +e[MPji ]∗ (2.26)
The ERAP1 trimming complex, EMPji , can form via two routes: ERAP1 can bind
p:MHC or ERAP1:MHC can bind peptide
[EMPji ]∗ = 1kcat +uE +u ji ￿bE[E]∗[MPji ]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
pathway 1
+bP[EM]∗[Pji ]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
pathway 2
￿ (2.27a)
[EMPji ]∗ = 1K jM2 [E]∗[MPji ]∗ (2.27b)
where K jM2 = bEkcat+uE+u ji
The first route is likely to be the dominant route, because within this system,
ERAP1 catalysis generates MHC-bound peptide, not free peptide. To access the
second route, a trimmed peptide must first unbind from MHC. ERAP1 kinetics are
faster than p:MHC kinetics, especially for high affinity peptides (that is, those with
low MHC off-rates, u ji ). Therefore, the second route is likely to be the preserve of
lower affinity peptides, which are less frequently presented at the cell surface, as
shown by equation (2.26). For this reason, we consider only the first pathway for
the formation of the trimming complex, EMPji .
The conventional Michaelis Menten constant, K jM, has been replaced by a new
constant, K jM2, in equation (2.27b). This constant takes account of peptide unbind-
ing from the MHC molecule in the trimming complex, EMPji , so that K
j
M2 < K jM.
This means that the trimming complex is less stable than its equivalent in Sys-
tem H1, assuming that ERAP1 has the same binding and unbinding rates towards
p:MHC as it does towards free peptide. However, the unbinding rate of peptide
from MHC is typically much slower than ERAP1 kinetics, so the affinity of pep-
tide for MHC is only likely to affect the trimming efficiency of peptides with very
low MHC affinities. Indeed, a peptide with very low affinity for MHC may not be
trimmed at all within System H2.
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A SS expression for the p:MHC complex,MPji , is obtained by setting the left-
hand-side of equation (2.10f) to zero and substituting for EMPji (equation (2.27b)).
The SS equation for p:MHC for full length peptide is similar, except there is no
generation of full length peptide from ERAP1 trimming
[MPji ]∗ = 1
u ji +e+ k jcatK jM2 [E]∗￿
k j+1cat
K j+1M [E]∗[MPj+1i ]∗+bP[M]∗[Pji ]∗￿ (2.28a)
[MPNi ]∗ = 1
uNi +e+ kNcatKNM2 [E]∗￿bP[M]
∗[PNi ]∗￿ (2.28b)
The steady state concentration of free peptide can be found by setting equation
(2.10e) to zero. All free peptide, Pji , except full length peptide, P
N
i , which is sup-
plied to directly to the ER, must unbind MHC. This is because ERAP1 trims and
therefore generates peptides that are in complex with MHC.
[Pji ]∗ = u ji [MPji ]∗dP+bP[M]∗ (2.29a)[PNi ]∗ = gNi +uNi [MPNi ]dP+bP[M]∗ (2.29b)
Substitution of equations (2.29) and (2.28) into (2.26) yields a steady state ex-
pression for cell surface presentation of p:MHC complexes in System H2, without
tapasin
[MePji ]∗ = B 1u ji￿￿￿
surface
e
u ji +e￿￿￿ ￿￿￿
ER
￿ 1
dP+bP[M]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
loss of free peptide
N￿
n= j
1
u ji +e+ [E]∗kncatKnM￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
loss of peptide:MHC
￿gNi N￿
n= j+1
k j+1cat
KM
[E]∗
￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from PNi+ N￿
m= j+1umi [MPmi ]∗ m￿n= j+1kncatKM [E]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from re-bound peptide
+ u ji [MPji ]∗
￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
unbinding of Pji
￿￿
(2.30)
Equation (2.30) is presented in the same format as equation (2.21) to aid compari-
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son; however, it is worth noting that this equation does not read in a linear order like
equation (2.21). In System H1, the peptide is generated first and then binds MHC
for egression to the cell surface, which means that the bracketed terms of equation
(2.21) occur first, and their sum is then multiplied by the exterior terms. However,
in System H2, peptide binding to MHC must occur before trimming by ERAP1,
which means that every term inside the brackets has already bound MHC (that is
they have been multiplied by the first term, B).
The first term in the inner brackets of equation (2.21) and equation (2.30) are
the same. The second term in the inner brackets of equation (2.30) accounts for
the fact that a p:MHC complex may unbind before the peptide is fully trimmed,
as shown by the term umi [MPmi ]∗. At this point there may be loss of free peptide,
Pmi , as shown by the ‘loss of free peptide’ term. The peptide will then re-bind
MHC, via the p:MHC binding term, B. Then the p:MHC complex can interact
with ERAP1 for trimming. The third term accounts for the fact that the p:MHC
complex may dissociate, and then rebind before egression to the cell surface. Note
that the concentration of all p:MHC complexes decreases as a result of peptide
unbinding, egression of the complex, and trimming by ERAP1, which is accounted
for by the ”loss of p:MHC” term. System H1 and System H2 also have different
Michaelis Menten constants, KM and KM2 respectively. The MM constant measures
the stability of the ERAP1 trimming complex. The ERAP1 trimming complex of
System H2 is less stable than System H1, because the peptide can unbind the MHC
molecule at rate u ji . If a peptide is a poor ERAP1 substrate and has a low affinity
for MHC, then it may unbind the trimming complex before it is trimmed.
Whilst equations (2.21) and (2.30) ostensibly appear similar, they highlight
key differences with respect to the parameters between the two systems. Recall
that the product of ERAP1 trimming is released following the cleavage of a sin-
gle amino acid. In System H1 the released product is free peptide, whereas in
System H2, the released product is p:MHC; these products then become ERAP1’s
substrate in the next round of trimming. During the stage in which ERAP1 is not
yet bound to its substrate, the substrate is subject to loss to other processes. In
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System H1, the substrate (free peptide) may be lost to export to the cytosol, bind-
ing to MHC, or trimming by ERAP1, whilst in System H2, the substrate (the pep-
tide:MHC complex) may be lost to egression to the cell surface, unbinding, or trim-
ming by ERAP1. These loss terms manifest as a product over all lengths of peptide,
Pni , where n = j, ..,N. Thus System H1 is likely to be more sensitive to the rate of
peptide export to the cytsol, dP, whereas System H2 is likely to be more sensitive
to the egression rate, e, and the unbinding rate of precursor peptides, uni , where
n = j+1, ...N.
It is useful to consider the most important contributions to the SS cell surface
expression of p:MHC complexes in equation (2.30). If a p:MHC complex unbinds,
then it is unlikely that it will re-bind and remain bound for long enough to bind
ERAP1 at rate bE and be trimmed at rate kcat . It can therefore be assumed that there
is no rebinding of peptide to MHC:
[MPji ]∗ = 1
u ji +e+ k jcatK jM2 [E]∗￿
k j+1cat
K j+1M [E]∗[MPj+1i ]∗￿ (2.31)
where K jM2 = k jcat+uE+u jibE
As previously discussed, peptide abundance exceeds MHC abundance by an
order of magnitude, so it can be assumed that peptide interaction with MHC does
not affect the SS concentration of free peptide in the ER (equation (2.24a)).
By substituting equations (2.31), (2.28b), and (2.24a) into equation (2.26), I
obtained an expression for the steady state concentration of cell surface p:MHC for
System H2 in the same format as equation (2.25) for System H1
[MePji ]∗ = B 1u ji￿￿￿
surface
e
u ji +e￿￿￿ ￿￿￿
ER
￿￿ gNidP￿￿￿
turnover of PNi
N￿
n= j+1
[E]∗kncat
KnM2￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation
N￿
n= j
1
u ji +e+ [E]∗kncatKnM￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
loss
￿￿ (2.32)
where B = bP[M]∗.
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2.2.3 Comparing equilibrium expressions between hypotheses
H1 and H2
Comparing the simplified equilibrium expressions for Systems H1 and H2 (equa-
tions (2.25) and (2.32)) it is clear that the important distinctions between the two
systems remain. Firstly, the ERAP1 trimming complex is less stable in System H2
than System H1, because the peptide can unbind the MHC molecule. This is likely
to only affect peptides with very low affinity for MHC, because typically ERAP1
kinetics are much faster than p:MHC off-rates. It may also affect peptides that are
poor substrates for ERAP1. If u ji >> k jcat +uE and u ji >> bE then the MM constant of
System H2, K jM2, amounts to an extra peptide optimisation step, so that low affinity
peptides for MHC do not get trimmed by ERAP1.
The other key difference between the two systems is shown by the loss term
for the ERAP1 substrates when they are not bound to ERAP1. Within System H2,
cell surface presentation of peptide, Pji , depends on the MHC affinity of all N-
terminally extended peptide forms: Pj+1i ,Pj+2i , ...,PNi , because the complexes must
remain bound for sufficient time to bind (and be trimmed) by ERAP1. In contrast,
the simplified SS equation for System H1 (equation (2.25)) is independent of the
off-rates of longer peptides. MHC affinity for a peptide of given sequence, i, is a
triangular function of its length, j, with peak affinity at 9 residues (Figures 2.1c and
2.1d) [45],[64],[116],[136].
The impact of this difference between the two systems will depend on the
relative rates of peptide unbinding fromMHC, u ji , egression, e, peptide degradation,
dP, and ERAP1 catalysis as measured by the substrate specificity constant,
k jcat
K jM
and
the concentration of ERAP1, E∗. If the egression rate and substrate specificity
constants are low (e+ [E]∗k jcat
K jM
<< u ji ), then the loss rate in System H2 amounts to a
further peptide optimisation stage. Taken in concert with the the new MM constant,
K jM2, trimming by ERAP1 within System H2 could enhance peptide optimisation at
the cell surface by up to the inverse of the square of the off-rate, 1(u j+1i )2 , relative to
trimming by ERAP1 within System H1.
However, if the egression rate is high, peptide expression at the cell surface
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may be less optimised within System H2 than within System H1. The p:MHC
complexes may egress to the cell surface before ERAP1 binds and trims the peptide
cargo, resulting in an overabundance of extended peptides at the cell surface.
It is important to note that if the rate of egression is slow, ERAP1 trimming
within the context of System H2 does not increase peptide optimisation absolutely
by 1
u j+1i when compared with an ERAP1 independent model such as the Dalchau et
al. model of peptides of homogenous length. In contrast to tapasin, which enhances
peptide optimisation at the cell surface by 1
u ji
for low egression and tapasin unbind-
ing rates, ERAP1 does not have a specific peptide optimisation role. This is because
the kinetic rates at which ERAP1 interacts with a given peptide, Pj+1i , as captured in
the specificity constant, k
j+1
cat
K j+1M in equation (2.32) tend to be much faster than the un-
binding rate of the peptide, Pj+1i , from MHC. Nevertheless, for low egression rates,
ERAP1 trimming within the context of System H2 does optimise peptide expres-
sion relative to ERAP1 trimming within System H1. Furthermore, peptides with
very low affinity for MHC will not be trimmed within System H2. Whereas within
System H1, all peptides can be trimmed by ERAP1, even if their affinity for MHC
is very low.
Consider now the ratchet model variant of System H1, in which the product
of ERAP1 trimming is not automatically released but remains bound to ERAP1 un-
til it unbinds via the unbinding rate, uE . I have chosen to include the simplified
case in which peptide interaction with MHC does not affect the steady state con-
centration of free peptide. Substitution for [EPji ]∗ into the ratchet ODE for free
peptide (equation (2.5b)) results in a SS equation for [Pji ]∗ that is also true for the
bind-trim-release model variant
[Pji ]∗ = 1dP￿k j+1cat [EPj+1i ]∗−k jcat[EPji ]∗￿ (2.33a)
[PNi ]∗ = 1
dP+ kNcatKNM [E]∗￿
gNi
dP
￿ (2.33b)
The SS equation for the trimming complex, EPji , is different to its equivalent for
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the bind-trim-release model variant because the product of ERAP1 catalysis is the
next trimming complex
[EPji ]∗ = 1uE +k jcat ￿bE[E]∗[Pji ]∗+k j+1cat [EPj+1i ]∗￿ (2.34)
Substitution of (2.34) into (2.33a) results in an equation for a SS peptide concen-
tration, Pji , that explains how the ratchet mechanism affects trimming by ERAP1 in
System H1
[Pji ]∗ = 1dP￿[E]∗￿ k j+1catK j+1M [Pj+1i ]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from Pj+1i
+ N−1￿
m= j+2
kmcat
KmM
[Pmi ]∗ m￿
n= j+1
kncat
uE +kncat￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from Pmi where m = j+2, ...,N
+ gNi
dP+ kNcatKNM [E]∗
kNcat
KNM
N￿
n= j+1
kncat
uE +kncat￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from PNi
￿￿1− k jcat
uE +k jcat￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿
overtrimming
￿￿ (2.35)
Within the ratchet mechanism, binding of ERAP1 to peptide only needs to occur
once to enable the trimming of multiple amino acids. Once the first amino acid has
been trimmed from peptide, Pmi , where m = j + 2, ...,N, according to kmcatKmM , (where
recall KmM = bEuE+kmcat ) the following amino acids will be trimmed according to their
catalytic rate versus their unbinding rate k
n
cat
uE+kncat where n = j+1, ...,m. Overtrimming
may occur, unless the catalytic rate is slower than the unbinding rate, k jcat < uE .
The trimming complex, EPmi , where m = j+1, ...,N −1, faces competition be-
tween dissociation, which occurs with unbinding rate, uE , and catalysis, with cat-
alytic rate, kmcat . Free trimmed peptide, Pmi , enters the system when the complex
dissociates. Since the model is deterministic, it is unlikely that a peptide that has
unbound the trimming complex will rebind and be trimmed by ERAP1. For this
reason, we assumed that all free trimmed peptide in the system has been generated
from the trimming of full length peptide. This simplifies equation (2.35) by remov-
ing the first two terms in the inner brackets. Substitution of this simplified equation
as well as equation (2.33b) into equation (2.18) yields an expression for the cell
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surface concentration of p:MHC complexes at steady state
[MePji ]∗ = B 1u ji￿￿￿
surface
e
u ji +e￿￿￿ ￿￿￿
ER
1
dP+ kNcatKNM [E]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
loss of PNi
1
dP￿￿￿
loss of Pji
×￿
￿[E]∗gNi kNcatKNM
m￿
n= j+1
kncat
uE +kncat￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from PNi
￿1− k jcat
uE +k jcat￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿
overtrimming
￿￿ (2.36)
Note that the loss of free peptide terms only apply to full length peptide, PNi , and
the peptide for presentation at the cell surface, Pji , because all other peptide lengths
are always bound to ERAP1. Full length peptide may be exported to the cytosol
according to the degradation rate, dP, before it binds ERAP1, and so may the pep-
tide, Pji , after it unbinds ERAP1 and before it binds MHC. This is different to the
bind-trim-release model variant in which all peptide lengths are free at somepoint,
and therefore are subject to loss to export to the cytosol or binding MHC or ERAP1.
This suggests that ratchet model variant may be more efficient than the bind-trim-
release variant, because there is less loss of free peptide substrate.
The effect of the ratchet mechanism on the simplified expression for [MePji ]∗
in System H2, is similar to the effect on System H1
[MePji ]∗ = B 1u ji￿￿￿
surface
e
u ji +e￿￿￿ ￿￿￿
ER
1
uNi +e+ kNcatKNM2 [E]∗￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
loss of MPNi
1
dP￿￿￿
degradation of PNi
×￿
￿[E]∗gNi kNcatKNM2
m￿
n= j+1
kncat
uE +kncat￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
generation from PNi
￿1− k jcat
uE +k jcat￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿
overtrimming
￿￿ (2.37)
The egression of immature peptide (that is Pmi wherem> j) in complex with MHC is
restricted to full length peptide (m =N), because all other lengths of peptide are pro-
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tected from egression by being bound to ERAP1 in the trimming complex, EMPmi .
This is in contrast to the bind-trim-release model variant, equation (2.32), which
is more sensitive to the unbinding and egression rate parameters because all com-
plexes,MPmi , where m = j, ...,N, may dissociate or egress in the intermediary period
between release from and successive rebinding to ERAP1.
For this reason, the expressions (2.36) and (2.37) are more similar to each other
than their bind-trim-release equivalents, (2.25) and (2.32).
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2.3 Simulation analysis
We simulated the models described in Section 2.1 for a single peptide species in
the ER. We assumed that this peptide represents 1500 of the different peptides in the
ER, and have divided the concentrations by 500 accordingly. This is the simplest
implementation of the models, and focuses on the dynamics of an individual pep-
tide undergoing ERAP1 trimming and MHC optimisation in the ER. However, in
reality there are thousands of different peptide species, each with different interac-
tion rates with ERAP1 and MHC. The current implementation assumes that peptide
competition for ERAP1 and MHC does not affect the length distribution of peptides
displayed at the cell surface.
The model is parameterised with data from a mixture of sources: the Dalchau
model of peptide optimisation in the ER [38], the literature, and unpublished data
from the Elliott group. Data in molar concentrations is converted to copy number
of molecules,CN , usingCN = c×NA×V , where Avogadro’s constant is NA = 6.022×
1023 molecules mole−1 and the estimated volume of the ER is VER = 2.5×10−13L.
Accordingly, for 1 nM, we have
CN = 1 nM×NA×VER= 10−9 moles L−1×6.022×1023 molecules mole−1×2.5×10−13L
≈ 150 molecules
That is, 1 nanomolar is approximately equal to 150 molecules in the ER. We hereby
use mol to denote ‘number of molecules’ or copy number.
Several groups have studied the effect of peptide length on the p:MHC un-
binding rate. We fitted these data to an exponential function (Figure 2.5) in order to
parameterise the length dependency of the unbinding rate. We chose the exponential
function because it is the simplest model with assymptote at zero. The C-terminal
extension data is presented separately to the N-terminal extension data because the
different termini have different relationships to the unbinding rate. We primarily
considered the N-terminal extension data, as this is more functionally relevant to
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ERAP1 trimming.
9 10 11 12 13 14 15 16
Length
10-6
10-4
10-2
100
Un
bin
din
g 
ra
te
X-FAPKNYPAL[6]
Fit[6]
FAPKNYPAL-X [6]
Fit[6]
X-FAPGNYPAL 37°C [3]
X-TYQRTRALV [4]
Fit [4]
TYQRTRALV-X [4]
Fit [4]
Y-X-SNENMDAM[1]
Fit N [1]
X-YSNENMDAM-X[1]
Fit C [1]
X-YSNENMDAM 37°C[1]
Figure 2.5: Length dependent p:MHC unbinding rate, u ji . Unbinding rates of three pep-
tide epitopes and their extended forms in complex with MHC [103]. Complexes
were incubated at 26 °C and 32 °C; the effect of temperature on the extended
peptides was minimal so the data have been combined.
The first set of data considers how the modification of peptide length, via 3
amino acid residue extensions at the N and C terminals, affects the unbinding rate
of a model peptide, FAPKNYPAL [63]. Complexes were incubated at 26 °C and
32 °C, but the effect of temperature on the extended peptides was minimal so the
data have been combined in Fig. 2.5. FAPKNYPAL was modified from the optimal
peptide FAPGNYPAL by substituting Lys for Glys (to attach a biotin for the isola-
tion of peptide complexes). The resulting peptide has suboptimal unbinding rates.
Therefore, we translated the function defined for X-FAPKNYPAL to the off-rate for
FAPGNYPAL at 37 °C [28], assuming that the relationship between length and the
unbinding rate is independent of temperature.
The next dataset measured by Cerundolo et al. [25], considers peptides with
the same N-terminals and 1 or 2 residues inserted to the interior of them. This
group also measured unbinding rates for C-terminally extended peptides. Extended
peptides were measured at 4 °C, so we translated the function defined at 4 °C for
Y-X-SNENMDAM to the off-rate for YSNENMDAM at 37 °C, again assuming that
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the relationship between length and the unbinding rate is independent of tempera-
ture. The curves obtained for the effect of N-terminal extensions on the unbinding
rates of the two optimal peptides (FAPGNYPAL and YSNENMDAM) at 37 °C, are
in close agreement.
Finally, Fahnestock et al. [53] considered extensions of 1 or 2 residues and
reported a more significant effect of length on the unbinding rate than the previous
two groups. It is possible that this effect would level off with increasing length, but
the fit for the data available from the Fahnestock group is different to the fits to the
other data.
Table 2.1 shows a set of parameter values used in model simulations. Param-
eter rates were obtained from from the Dalchau peptide optimisation model [38],
unless a better approximation was obtained from an extensive literature review. The
length dependent unbinding rates of peptide to MHC were obtained from the data
fitted in Figure 2.5 for the FAPGNYPAL peptide [28, 63]. The majority of com-
plete degradation of peptides takes place in the cytosol, not in the ER, so the pep-
tide degradation rate was obtained from the peptide half-life in the ER measured by
Koopman et al. [100], which is much slower than the peptide degradation rate used
in the Dalchau model. The ERAP1 parameters were obtained by fitting to data in
Hearn et al [72] and by making sure to satisfy the ERAP1 Michaelis Menten values
reported by several other groups [27, 52, 65]. Where possible the Dalchau model
parameter values were used because the model was calibrated to data for the H2-Kb
MHC molecule, which is the same MHC molecule used by Hearn et al. for the
primary datasets that we have attempted to reproduce. We have to be aware that
changing a model parameter may impact the values that the rest of the parameters
should be set at. We therefore decided to limit changing parameter values to these
limited cases in which we judged it to be necessary.
2.3.1 The effect of the enzymatic parameters on length distribu-
tion of cell surface p:MHC
The following results provide an overview of how ERAP1 determines the length
of peptides displayed at the cell surface, for different hydrolytic efficiencies. Each
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simulation assumes that ERAP1 has the same hydrolytic activity towards all pep-
tides in the system. Although peptide competition for ERAP1 has a role to play in
vivo we can interpret the systems’ results to be describing the way in which ERAP1
might respond to a particular substrate for which it has the associated parameters.
Recall that the Michaelis Menten constant describes the affinity of ERAP1 to its
substrate: Ki, jM = uE+ki, jcatbE . By varying each MM parameter independently, we gain
an understanding of the impact of that parameter rate on the cell surface length
distribution of p:MHC, within the context of varying KM values.
2.3.2 The rate of ERAP1 binding skews the cell surface length
distribution of p:MHC for all hypotheses
We simulated each hypothesis with binding rates between 10−9mol−1s−1 and
100mol−1s−1 for the model values of the of the catalytic and unbinding rates. The
higher the binding rate, bE , the more quickly peptides are sampled for trimming and
the better the peptide trimming optimisation, for all hypotheses.
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Figure 2.6: Length distribution of cell surface p:MHC for increasing rates of ERAP1
binding. Full length (14-mer) peptide was supplied to the ER whereupon it
may be trimmed by ERAP1 and bind to MHC. Bars represent the total cell sur-
face abundance of MePji for 8 ≤ j ≤ 14 at the final timepoint, after 12 hours.
The length dependent trimming for the molecular ruler hypothesis (System
H1, 2nd panel) and the MHC as template hypothesis (System H2, bottom
panel) is encoded by preventing the catalysis of nonameric peptides, that is
kcat = 0 for j ≤ 9. For comparison, the top panel shows the length distribution
obtained for indiscriminate, length independent, trimming of free peptide (Sys-
tem H1).
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2.3.3 The catalytic rate affects the cell surface length distribu-
tion of p:MHC complexes similarly for all hypotheses
The catalytic rate has a similar effect on all model variants: the proportion of non-
amers expressed at the cell surface is low for relatively slow rates of catalysis and
high for fast rates. We present the catalytic rate-dependent cell surface p:MHC
length distributions for both fast and slow ERAP1 binding rates to cover a range of
biologically plausible cases. For a low ERAP1 binding rate (bE = 10−4mols−1) the
catalytic rate has a similar effect on the length distribution of cell surface p:MHC,
MePji , for all hypotheses, though this effect is least pronounced for the indiscrimi-
nate trimming hypothesis. In all cases, if catalysis is too slow (kcat = 10−3s−1) only
the full length product is presented. As the rate of catalysis increases (kcat = 1s−1)
the shortened forms of the peptide are presented, but in descending order, indicat-
ing that catalysis is too slow for trimming optimisation. For faster rates of cataly-
sis, (kcat = 10s−1) nonamers dominate at the cell surface for all hypotheses. When
kcat = 100s−1, nonamer domination is more pronounced for the template and ruler
hypothesis, and the absolute presentation of nonamers is significantly increased for
all hypotheses.
For a high ERAP1 binding rate, (bE = 5x10−2s−1) the catalytic rate has a greater
impact on the promototion of nonamers at the cell surface. For the template hypoth-
esis, the absolute domination of nonamers is seen at relatively slow rates of cataly-
sis (∀kcat > 1s−1). Nonameric domination is also seen for slower rates of catalysis
within the ruler hypothesis (∀kcat > 1s−1), and trimming optimisation starts to occur
in general at slower catalytic rates. For the indiscriminate trimming hypothesis, op-
timisation also starts to occur for lower rates of catalysis, relative to those required
for optimisation at low ERAP1 binding rates. However, the effect is much less pro-
nounced for indiscriminate trimming than for the other trimming hypotheses, and
indiscriminate trimming is less sensitive to the catalytic rate. This is partly because
nonamers may also be destroyed by ERAP1, under the indiscriminate trimming
hypothesis, whereas trimming ceases at nonamers under the template and ruler hy-
potheses. Thus an increase in the catalytic rate increases both the rate of generation
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(b) High ERAP1 binding rate, bE = 5x10−2mols−1
Figure 2.7: Length distribution of cell surface peptidome for increasing rates of
ERAP1 catalysis, kcat . Full length (14-mer) peptide was supplied to the ER
whereupon it may be trimmed by ERAP1 and bind to MHC. Bars represent the
total cell surface abundance of MePji for ≥ 8 j ≤ 14 at the final timepoint, after
12 hours. The length dependent trimming for the molecular ruler hypothesis
(System H1, 2nd panel) and the MHC as template hypothesis (System H2, bot-
tom panel) is encoded by preventing the catalysis of nonameric peptides, that
is kcat = 0s−1 for j ≤ 9. For comparison, the top panel shows the length distribu-
tion obtained for indiscriminate, length independent, trimming of free peptide
(System H1).
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and destruction of nonamers under the indiscriminate trimming hypothesis, making
this model less sensitive to the parameter.
2.3.4 A compromise in ERAP1 unbinding is required for effi-
cient nonamer presentation within the ruler and template
model variants
Indiscriminate trimming is insensitive to the unbinding rate, uE . If the unbinding
rate is too low, ERAP1 can trim and release all peptides instead of unbinding them.
However, within the ruler and template model variants, trimming of nonamers is
forbidden. For this reason, if the unbinding rate is too low, there will be an accumu-
lation of nonamers bound to ERAP1, thereby depleting the system of free ERAP1.
To see this, we simulated each hypothesis with unbinding rates between 10−9s−1
and 500s−1. As we previously saw a strong dependency on the ERAP1 binding
rate, we also distinguished between low binding rates (bE = 10−4 mol−1 s−1; Figure
2.8a) and high binding rates (bE = 10−4 mol−1 s−1; Figure 2.8b). When the binding
rate is low, a high unbinding rate (uE = 500 s−1) prevents peptide trimming optimi-
sation for all hypotheses because the affinity of ERAP1 for its peptide substrate is
too low for efficient trimming. However, a high unbinding rate (uE = 500 s−1) does
not result in poor trimming optimisation if the binding rate is high (bE = 5×10−2)
because ERAP1 can quickly rebind a new substrate. When ERAP1 trims MHC-
bound peptide (System H2), the absolute presentation of cell surface p:MHC is
2-fold higher for high ERAP1 binding rates than low ERAP1 binding rates, for low
ERAP1 unbinding rates (uE < 0.1s−1). When ERAP1 trims free peptide (System
H1), presentation of cell surface p:MHC is invariant to the ERAP1 binding rate, for
low ERAP1 unbinding rates (uE < 0.1s−1).
2.3.5 Effectiveness of ERAP1
To provide a more general overview of each of the systems’ capabilities, we con-
sidered the effectiveness of ERAP1 within each system with respect to the three
enzymatic parameters. The effectiveness of ERAP1 is measured by the proportion
of total cell surface MHC containing nonameric peptides, where high proportions
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Figure 2.8: Length distribution of cell surface peptidome for increasing rates of
ERAP1 unbinding, uE . Full length (14-mer) peptide was supplied to the ER
whereupon it may be trimmed by ERAP1 and bind to MHC. Bars represent the
total cell surface abundance of MePji for ≥ 8 j ≤ 14 at the final timepoint, after
12 hours. The length dependent trimming for the molecular ruler hypothesis
(system 1, 2nd panel) and the MHC as template hypothesis (system 2, bot-
tom panel) is encoded by preventing the catalysis of nonameric peptides, that
is kcat = 0 for j ≤ 9. For comparison, the top panel shows the length distribu-
tion obtained for indiscriminate, length independent, trimming of free peptide
(system 1).
suggest an effective trimming mechanism. Total cell surface MHC includes empty
MHC, which has dissociated from its peptide cargo. This is more likely to occur
for extended peptides which form less stable p:MHC complexes than nonameric
peptides. The shaded regions in Figure 2.9 show the parameter values that keep the
Michaelis Menten constant, KM, within experimentally defined ranges [52, 65].
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In general, the molecular ruler and MHC as a template mechanisms outper-
form the indiscriminate trimming mechanism, except for at very low unbinding
rates, during which ERAP1 remains bound to 8 and 9mers that can’t be released via
trimming.
The MHC as template mechanism requires a higher ERAP1 binding rate to
become effective, possibly because it requires two binding stages - binding to MHC
and peptide binding to MHC. Theoretically, it is more effective than the other two
mechanisms for high binding rates, but not within experimentally defined KM values
for ERAP1 [52, 65].
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Figure 2.9: Effectiveness of ERAP1. Proportion of nonamers in cell surface peptidome
as a function of Michaelis Menten parameter values. Full length (14-mer)
peptide was supplied to the ER whereupon it may be trimmed by ERAP1 and
bind to MHC. After 12 hours, the proportion of total cell surface MHC contain-
ing nonamers was calculated. Shaded regions show the parameter values that
keep the Michaelis Menten constant, KM, within experimentally defined ranges
[52],[65].
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2.4 Sensitivity analysis
The candidate simulations provide an overview of ERAP1 catalysis within the ER
for a subset of parameter values. As Table 2.1 demonstrates, there are broad ranges
for all parameter values which means there are infinite possible combinations of
parameter values that cannot all be tested for with model simulations. It is therefore
very useful to see the effect of each parameter value on the total cell surface expres-
sion of nonameric p:MHC complexes. This provides an indication of the impact
of each parameter relative to the rest of the parameters. It also demonstrates the
different ways each system depends on a parameter value, confirming some of the
findings of the equilibrium analysis.
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Figure 2.10: Sensitivity of total cell surface nonamer presentation to all model pa-
rameters for all hypotheses.The sensitivities were tested for the basic set
of model parameters given in Table 1.
Importantly, Figure 2.10 shows that System H1 and H2 have opposite depen-
dencies on the unbinding rate of extended peptides longer than 10 amino acids in
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length. This is in agreement with the equilibrium analysis in Section 2.2, in which
it was found that the unbinding rate of extended peptides may reduce cell surface
expression of p:MHC within System H2 in comparison to System H1 by as much as
the product of the squared inverses of the unbinding rates of all extended peptides:
N￿
m= j+1 1(umi )2 . The sensitivity analysis shows that for the standard parameter set tested,
as shown in Table 2.1, an increase in the unbinding rate of extended peptides has a
negative impact on cell surface presentation in System H2, whereas it has a positive
impact in System H1. This represents a testable hypothesis which could be used
to help distinguish whether ERAP1 predominantly trims free peptides, or peptides
bound to MHC in vivo.
2.5 Discussion
The theoretical and numerical analyses in this chapter point towards an important
testable distinction between how the two system hypotheses respond to changes
in the dissociation rate of the p:MHC complex. The equilibrium analysis shows
that the unbinding rate of extended peptides from MHC may negatively scale cell
surface expression of p:MHC within System H2 by as much as the product of the
squared inverses of the unbinding rates of all extended peptides:
N￿
m= j+1 1(umi )2 . This
is because within System H2 the peptide must be bound to MHC in order to be
trimmed by ERAP1. It has two opportunities to unbind MHC and escape trimming
by ERAP1: during trimming by ERAP1 and before binding to ERAP1.
In order for the dissociation rate, u ji , to significantly reduce the rate of hydrol-
ysis by ERAP1, it must exceed the enzymatic rate parameters, u ji > uE ,ki, jcat ,bE . This
is only likely to happen for peptides with very low affinity for MHC, because in
general the dynamics between ERAP1 and peptide are much faster than between
MHC and peptide. Nevertheless, it is important to note that peptides whose ex-
tended forms have low affinity for MHC are unlikely to be presented under System
H2.
The other opportunity for peptide dissociation from MHC, is before ERAP1
binding. If the p:MHC unbinding rate is faster than the egression rate, and faster
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than the rate of binding and processing by ERAP1 (u ji >> e, [E]∗k jcatK jM ), then the p:MHC
complex will dissociate. Both of these opportunities for p:MHC dissociation may
reduce the efficiency of peptide trimming by ERAP1 within System H2, relative to
System H1.
These theoretical differences between the two systems have been confirmed
for a set of biologically plausible parameter values. Sensitivity analysis shows that
the systems have different dependencies on the p:MHC unbinding rates of the 11-
14mers. An increase in the p:MHC unbinding rates of the 11-14mers within System
H1, leads to an increase in the total concentration of nonamers displayed at the cell
surface, and to a decrease in the total concentration of cell surface nonamers within
System H2. Intuitively, this makes sense because within System H1, a high unbind-
ing rate of 11-14mers increases the total concentration of substrate for ERAP1 (free
peptide). Whereas within System H2, a high p:MHC dissociation rate of 11-14mers
depletes ERAP1’s substrate.
Our findings suggest that ERAP1 could have a peptide optimisation role if it
trims MHC-bound peptides. This is a hypothesis worth investigating in itself, and
will increase our understanding of the antigen processing and presentation pathway.
Furthermore, if it is found that ERAP1 does have a peptide optimisation role then
this suggests that it trims according to Hypothesis 2. Howarth et al conducted an
experiment to demonstrate the optimisation role of tapasin in vivo. The same ap-
proach may be used to determine if ERAP1 has an optimisation role. Peptides that
bind stably to MHC usually have a hydrophobic amino acid at the C terminus (Leu,
Met, Ile, or Val) and an aromatic anchor residue (Tyr or Phe) at the fifth position
within the epitope. Sub-optimal amino acid substitutions at these residues within
an immunogenic eptiope generates a set of epitopes with similar sequences but dif-
ferent binding affinities for MHC. Howarth et al. generated a set of sub-optimal
SIINFEKL variants and measured the cell surface presentation of the variants in
the presence and absence of tapasin [80]. Tapasin was found to enhance the cell
surface p:MHC expression in line with the half-life of the p:MHC complex. The
SIINFEKL variants used by Howarth et al could be assigned N-terminal extensions
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consisting of a defined amino acid sequence for an ERAP1 assay. We would assume
that the N-terminally extended precursors have p:MHC unbinding rates that are a
linear function of their epitope, as shown in Figure 2.5, so the low affinity epitopes
have low affinity precursor peptides and the high affinity epitopes have relatively
high affinity precursor peptides. If, like tapasin, ERAP1 enhances the presentation
of peptides with low p:MHC dissociation rates, then firstly we will have found out
that ERAP1 has a peptide optimisation role, and secondly it would suggest that
ERAP1 trims those peptide sequences when they are bound to MHC, rather than
when they are free.
The rate of dissociation of the p:MHC complex from the PLC is greater for
high affinity peptides than low affinity peptides. However, the rate of egression of
fully assembled p:MHC is independent of peptide affinity [114, 155]. The egression
rate of p:MHC from the ER to the Golgi can be measured using an endoglycosi-
dase H assay. An endoglycosidase H assay has previously been used to measure the
egression rate of newly synthesised MHC to the Golgi [114]. This assay could be re-
peated for p:MHC complexes to measure the rate of egression. An accurate measure
of egression would be highly informative to these models in general. Furthermore,
trimming by ERAP1 amounts to a further optimisation step if the unbinding rate
exceeds the egression rate and the rate of hydrolysis by ERAP1 (u ji >> e, [E]∗k jcatK jM ).
The egression rate is the missing parameter value to determine if this condition
holds for a variety of peptides. If the condition holds then trimming under Hypoth-
esis 2 should generate a cell surface peptidome that is scaled by the inverse of the
unbinding rate of all extended precursors in comparison to Hypothesis 1.
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Table 2.1: ERAP1 model parameter values. Parameter values obtained from a com-
prehensive literature search and from the Dalchau peptide optimisation model
[38, 39]
Description Parameter Value Units Source
Production of MHC gM 0.25 mols−1 [39]
Production of ERAP gE 0 mols−1 -
Supply of protein gi j
700 if j =N
0 otherwise mols
−1 [184]
Degradation of empty MHCn the ER dM 1.9×10−4 s−1 [95, 147]
Degradation of ERAP dE 0 s−1 -
Degradation of peptide in the ER dP 5.29×10−3 s−1 [100]
Degradation of cell surface empty MHC dN 1×10−4 s−1 [39, 80]
Binding of peptide to MHC bP 9×10−6 mol−1s−1 [156]a
ERAP1 binding to (free or MHC-bound)
peptide
bE 1×10−4 mol−1s−1
Catalytic rate kcat 12 s−1 [52, 65]
Unbinding of peptide to MHC
ui,8
ui,9
ui,10
ui,11
ui,12
ui,13
ui,14
4×10−4
1×10−4
2×10−4
1×10−4
1.3×10−3
3.7×10−3
1.08×10−2
s−1 [28, 63] a
ERAP1 unbinding from (free or MHC
bound) peptide
uE 25 s−1 b
Egression p:MHC to cell surface e 0.01 s−1 [39]
Total ERAP concentration ET 400 mol b
a Values for model peptide FAPGNYPAL
b Levels chosen to satisfy KM values in [27, 52, 65] according to our chosen catalytic
rate.
Chapter 3
Modelling the N-terminal amino acid
specificity of ERAP1
In the previous chapter we compared a series of hypotheses for how endoplasmic
reticulum aminopeptidase 1 (ERAP1) trims N-terminally extended peptides prior
to presentation at the cell surface on major histocompatability I (MHC). In this
chapter, we seek to distinguish between the hypotheses formulated in Chapter 2 by
comparing our mathematical models with experimental observations.
Specifically, we have modelled the cell surface presentation of SIINFEKL (S-
L), following the trimming of N-terminally extended precursors in the ER. S-L is an
antigen that has received considerable attention in studies concerning MHC class I
and ERAP1. This is because it is an immunodominant epitope, with high affinity
for MHC [32], and ERAP1 is essential for its efficient generation from precursor
peptides in the ER [146, 185].
Various studies have summarised the substrate specific Michaelis Menten
(MM) kinetics of ERAP1 with respect to several different peptide sequences [27,
65, 129]. One dataset of particular interest links the in vitro hydrolytic activity of
ERAP1 towards N-terminally extended S-L precursors with the cell surface abun-
dance of S-L, following the degradation of each precursor in the ER [185].
In vitro and in vivo datasets are complementary for the purposes of mathemati-
cal modelling. In vitro experiments enable the study of distinct processes that occur
between a set of chosen species, under a set of chosen conditons. The species in-
88 Chapter 3. Modelling the N-terminal amino acid specificity of ERAP1
volved, as well as their initial concentrations, are known, which affords accurate
modelling. The limitation of in vitro studies is that the dynamics of the simplified
system may not be representative of the dynamics within a cell, where other species
and interactions come in to play, which is why in vivo studies are important.
We have used in vitro data to explore the mechanistic details of the trimming of
a single amino acid from a sequence of amino acids by ERAP1, and derived the cor-
responding kinetic parameter rates. Then we applied our findings to a larger model
of peptide trimming and optimisation in the ER. We have used in vivo data to test
the model predictions under various hypotheses concerning the mechanism of trim-
ming by ERAP1, and have found the most consistent hypothesis to be that ERAP1
trims free peptide substrate (Hypothesis 1). By comparing the model output to in
vivo observations we have also tested the current level of quantitative understanding
of the key processes involved in antigen presentation that occur in and downstream
of the ER, and have suggested areas that would benefit from further research.
3.1 Materials and methods
We use published data [72] to parameterise the models developed in Chapter 2.
3.1.1 Experimental datasets from the literature
In vitro degradation dataset
Hearn et al. [72] measured the N-terminus dependent hydrolytic activity of ERAP1
towards amino acid sequences XS-L, where X is one of the 20 different standard
amino acids. Each peptide precursor (100 µM) was incubated with ERAP1 (3.5
µg￿ml) for 180 minutes. Reversed-phase HPLC was used at various time intervals
to quantify the total remaining precursor. Results for four of the possible 20 precur-
sors were excluded due to inaccuracies. The degradation of the non-extended form,
S-L, was also measured in this way.
In vivo cell surface presentation dataset
Hearn et al. [72] measured the cell surface presentation of S-L following the degra-
dation of each XS-L precursor in the ER. Hela cells were transfected with H-2Kb,
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Figure 3.1: Degradation of XS-L and S-L in vitro. The hydrolytic activity varies dis-
tinctly as a function of the amino acid at the N-terminus, and the mature epi-
tope S-L is a poor substrate for ERAP1. Unfavoured substrates, such as S-L
and DS-L are depleted by less than 20% after 180 minutes, whereas favoured
substrates such as Y-SL and M-SL are fully depleted within 90 minutes.
siRNA for ERAP1, and the TAP blocker ICP47. Blocking TAP reduces export of
peptides out of the ER. Hela-Kb-ICP47 were transfected with 1 µg of peptide plas-
mid and incubated for 24-48 hours. The peptide plasmid encoded the X- or XXS-L
sequence, fused at the N-terminus to the adenoviral E3/19K protein. This ensured
that the precursors were targeted to the ER. Further, an alanine was fused between
the two sequences to ensure that all N-terminally extended S-L precurors were liber-
ated at the same rate from the adenoviral protein. Empty MHC had been denatured
by heating the cells to 40°C for 1 hour. The antibody 25.D1.16 was used to detect
S-L-Kb complexes on the cell surface.
3.1.2 Derivation of enzymatic parameter rates from in vitro
degradation rates
An established methodology from the literature
The Michaelis Menten enzyme processing reaction consists of the reversible bind-
ing, bE , and unbinding, uE , of substrate, S, and enzyme, E, and the irreversible
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Figure 3.2: Degradation of XS-L and S-L in vivo.The N-terminal dependent trimming
rate of XS-L, for each aa, X , observed in vitro (b) corresponds to the distinct
hierarchy of cell surface presentation observed in vivo following incubation of
XXS-L (a).
catalytic processing, kcat , of substrate into product, P.
S+E bE￿⇀￿
uE
ES kcat￿￿→ P+E (3.1)
Typically, in the study of enzymes that conform to Michaelis Menten kinetics, the
catalytic rate will be derived from the maximum degradation rate using the fol-
lowing mathematical assumption. The Michaelis Menten equation states that the
substrate degradation rate, V , is a function of the enzymatic parameters, the total
enzyme concentration, ET , and the free substrate concentration, S:
V = kcatET [S]
KM + [S] (3.2)
where
KM = kcat +uEbE (3.3)
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is the substrate concentration at which the reaction rate, V , is half of the maximum
rate of degradation Vmax . If the concentration of substrate is much greater than the
KM value, then it is assumed that all enzyme is bound to substrate and degradation
is at its maximal rate, limited only by the catalytic rate.
Vmax = kcatET (3.4)
From equation (3.4) it is possible to derive the catalytic rate if the total concentration
of ERAP1 is known.
We were not able to use (3.4) to infer the catalytic rates from the in vitro dataset
(Figure 3.1), because it is not clear if the degradation rate is at its maximum value.
Accordingly, an increase in the substrate concentration could yield an increase in
the concentration of enzyme bound to substrate. The assays contained 100 µM
of peptide, an order of magnitude less than some KM values for ERAP1 [65]. It
is therefore not possible to assume that S￿ KM to make the simplification as in
(3.4). This means it is possible that the parameter responsible for the amino acid
dependent hierarchy of degradation is the catalytic rate, the binding rate, or the
unbinding rate.
In order to elucidate the amino acid specific effects of binding and catalysis in
the future, the same experiment may be repeated with increasing concentrations of
substrate until the reaction rate is at equilibrium, VX∗ =VXmax, where X is the amino
acid extension. The substrate concentration required to achieve this may be different
for each precursor. This would imply that the binding rate is amino acid dependent.
If the same amino-acid specific trimming hierarchy persists then it is likely that
the dominant amino acid dependent parameter is the catalytic rate. Whereas, if the
degradation rates of each precursor become more similar, then it is likely that the
binding rate is the dominant amino acid dependent parameter.
A methodology based on time-series model fitting
Since the established methodology of the previous section could not be reliably ap-
plied, we decided instead to fit to the dynamics observable in Figure 3.1 directly
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with an ODE model. Specifically, we modelled the degradation of XS-L by ERAP1
using three coupled Michaelis Menten ODEs describing the concentrations of en-
zyme, E, peptide, P, and the enzyme-peptide complex, EP. The ODEs are a sub-
module of the larger model for Hypothesis 1 described in equations (2.3) of Chapter
2.
dPj
dt
= uE[EPj]+k j+1cat [EPj+1]−bE[E][Pj] (3.5a)
dEPj
dt
= bE[E][Pj]−(kcat +uE)[EPj] (3.5b)
dE
dt
=￿
j
(uE +kcat)[EP]−bE[E][Pj] (3.5c)
The model assumes that ERAP1 trims free peptide of length j+1 under a bind-trim-
release mechanism (as described in Chapter 2) to a peptide of length j.
As mentioned in the previous section, the amino acid variation in peptide pro-
cessing by ERAP1 could result from differences in ERAP1:peptide binding, bE , or
directly from differences in the rate of catalysis, kcat . Therefore, we set the reaction
rates for either unbinding, uE , and binding, bE , and optimised for an amino acid
specific catalytic rate, kcat , or we fixed uE and kcat and optimised for an amino acid
specific binding rate, bE . We initialised the species concentrations at the same lev-
els as those used in the in vitro assays described in Section 3.1.1. This equated to a
concentration of 100 µM for the peptide precursor and 33 nM for ERAP1.
The measured data corresponds to the percentage of the total remaining con-
centration of peptide precursor within the system, at up to 5 different timepoints.
Therefore, we can define the simulated model output as
sk = 100￿P(tk)+EP(tk)P0 ￿ (3.6)
where the tk (k = 1,2, . . . ,nd) are the time-points corresponding to the experimental
measurements.
We used a cost function, C, that is the sum of the squares of the residuals,
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between the target data, yk, and the model simulated output, sk.
C = nd￿
k=1(yk− sk)2 (3.7)
We provided an initial estimates for the parameter rate, and tried multiple different
initial conditions if a good fit was not obtained. We used the Matlab algorithms
fminsearch or fmincon to search for the parameter values that minimised the
cost function. The added functionality of fmincon is that the fit may be con-
strained. In this case, we constrained the fit by the range of values found in the
literature for KM, that is 2 µM <KM < 3100 µM [52, 65].
Incorporating MHC class I binding into the model of ERAP1 trim-
ming in vitro
To assess the impact of MHC binding on the dynamics of peptide trimming, we
added p:MHC interactions to the system described by equations (3.5a)-(3.5c) .
MHC may bind and unbind peptide according to rates bP and u j respectively.
dE
dt
=￿
j
(uE +kcat)[EP]−bE[E][Pj] (3.8a)
dM
dt
= −bP[M]￿[Pj]+￿u j[MPj] (3.8b)
dEPj
dt
= bE[E][Pj]−(kcat +uE)[EPj] (3.8c)
dPj
dt
= uE[EPj]+k j+1cat [EPj+1]+u j[MPj]−(bE[E]+bP[M])[Pj] (3.8d)
dMPj
dt
= bP[M][Pj]−u j[MPj] (3.8e)
3.1.3 Performance metrics
Normalised root mean square error
To measure the goodness of a fit to data, we used the normalised root mean square
error (NRMSE), which is defined as
NE = 1− ￿￿yk− so￿￿￿￿so− s¯o￿￿ (3.9)
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The root mean square error (RMSE) is typically used to measure the differences
between the observed values and model predicted values [148]. Normalisation of
the RMSE removes the inherent scale in the data, and so enables a more convenient
comparison between datasets.
Lin’s concordance correlation
To measure the goodness of fit of the in vivo model predictions to the observations
we used Lin’s concordance correlation [109].
rc = 2sXYsXX +sYY +(µX −µY )2 (3.10)
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3.2 Results 1: Modelling ERAP1 trimming in vitro
We derived in vitro kinetic parameter rates of ERAP1 towards XS-L by modelling
the data described in Section 3.1.1, using the methodology described in Section
3.1.2. First we optimised for the amino acid specific trimming rate (kcat or bE) of
the 8mer, S-L, that is we set j = 8 in the model equations (3.5a) - (3.5c). Then
using this rate for the peptide species P8, we ran the optimisation independently for
each of the 16 XS-L precursors to find their aa specific trimming rate, that is we set
j = [8,9] in the model equations. The degradation dynamics of IINFEKL (I-L) were
not measured, so we make the simplifying assumption that the 7mer is not trimmed.
This assumption is fair because the degradation rate of S-L is already very low, and
ERAP1 has a distinct length preference; in general the rate of N-terminus removal
for 7mers is very slow and is undetectable for peptides of 5 amino acids or less [27].
3.2.1 Amino acid specific trimming of XS-L can be quantified
by peptide binding or by enzyme catalysis
Within the bind-trim-release mechanism, the data can be explained by either an
amino acid specific catalytic rate kcat or an amino acid specific peptide binding
rate bE (Figure 3.3a,b). The average fit over all precursors, as measured by the
normalised mean square root (NRMSE), is 0.9 and 0.94, respectively. Note that a
perfect fit would achieve a score of 1 using this metric.
The key difference between the two fits is that when kcat is the amino acid spe-
cific parameter, a more efficiently trimmed peptide has a higher kcat which results
in a higher KM value. Whereas, when bE is the amino acid specific parameter, the
more efficiently trimmed a peptide is, the higher the bE value, and the lower its
KM value. It is usually assumed that more efficiently trimmed peptides have lower
KM values. This is because efficient trimming requires a low KM, as otherwise the
catalytic step will happen infrequently.
The fit obtained for the catalytic rate within the ratchet mechanim did the least
well, with a NRMSE value of 0.75 (Figure 3.3c). Under this model, the product
remains bound to enzyme after being trimmed. We assumed that all parameters
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(a) Optimisation of the catalytic
rate parameter, kcat , within the
bind-trim-release mechanism.
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(c) Optimisation of the catalytic rate
parameter, kcat , within the ratchet
mechanism. NRMSE = 0.7488
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binding rate parameter, bE ,
within the ratchet mechanism.
NMRSE = 0.9402
Figure 3.3: Optimisation of the ERAP1 catalytic rate, kcat , and binding rate, bE , pa-
rameters. Peptide precursors (100 µM) were incubated with ERAP1 (33 µM)
for 180 minutes. Reversed-phase HPLC was used to measure the total remain-
ing precursor at 5 timepoints (datapoints). We modeled this system using the
ODE equations given in Section 3.1.2 and optimised the sytem for the amino
acid specific trimming rate, either kcat (a) or bE (b) using the methodology
described in Section 3.1.2. The NRMSE was averaged over all N-termimal
extensions.
remained equal, except for the catalytic rate. The catalytic rate that was inferred for
S-L is very slow. This means that the majority of ERAP1 in the system was bound
to S-L. This could be resolved by increasing the unbinding rate of S-L. The ratchet
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model could have a length dependent unbinding rate such that substrates that are
too short to be efficiently trimmed by ERAP1 would have a high rate of unbinding.
3.2.2 Trimming of single amino acid extensions is independent
of physiological levels of MHC
To determine how MHC class I binding impacts the dynamics of S-L production
in vitro, we added p:MHC class I binding and unbinding to the model of precursor
trimming by ERAP1 (see Section 3.1.2). Within Hypothesis 1, in which ERAP1
trims free peptide, it is thought that MHC may protect peptides of optimal length
for cell-surface presentation from further degradation by ERAP1 by binding to them
and thereby removing them from the pool of substrate [90]. In order for MHC to
significantly impact the total concentration of S-L, the flux of peptide that is saved
from degradation by MHC must be comparable to the flux of peptide that is de-
stroyed by ERAP1 when there is no MHC.
The flux of P8 which is lost to enzymatic degradation is equal to the catalysis
of the ERAP-P8 complex.
V = kcat[EP8] (3.11)
We consider the enzyme-substrate complex to be at steady state, which allows us to
write V in terms of P8.
[EP8]∗ = bE
uE +kcat [E][P8] = [E][P8]KM V = kcatKM [E][P8] (3.12)
The flux of P8 that binds to MHC is a function of the concentrations of peptide and
MHC, and the binding rate of peptide to MHC.
FlM = −bP[M][P8] (3.13)
We can therefore derive a condition under which MHC is ineffective at protect-
ing peptides from further degradation. Note that the concentration of MHC in the
ER is approximately 5-fold greater than that of ERAP1 accross different cell lines
[59], however, a greater proportion of ERAP1 may be free than MHC. We do not
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see an effect of MHC on the accumulation of a given peptide in vitro if
kcat
KM
[E]￿ bP[M] (3.14)
If, however, the binding rate is comparable to the rate of degradation, then a
further condition is required in order for MHC to reduce peptide degradation; the
p:MHC affinity must be sufficiently high, that is, the peptide unbinding rate ui must
be sufficiently slow.
We found that, under current assumptions, MHC has no effect on the in vitro
system (Figure 3.4). We set peptide concentrations to values corresponding to the
range of ER supply rates found for individual peptides [21]. Shown in Figure 3.4 are
the dynamics for a peptide that has a lower supply rate. We present these dynamics
because the effect of degradation of S-L can be seen in its declining concentration
levels, as the supply of XS-L is depleted. The ineffectiveness of MHC is the same
if the supply level of XS-L is relatively high.
It is clear that the presence of MHC (blue line) has no effect on the dynamics
of either peptide. Free XS-L is trimmed and depleted, whilst its product accumu-
lates. The concentration of free S-L eventually starts to decrease as it too undergoes
trimming by ERAP1. Comparing the top row with the third row, it is clear that
the majority of peptides exist in the free form. The concentration of MHC-bound
peptide represents a small proportion of total peptide, which is why the presence of
MHC has little effect on the concentration of peptide within the system.
It can be seen that the concentration of free S-L, which increases according to
equation (3.12) is far greater than the concentration of MHC-bound S-L which in-
creases according to equation (3.13). This means that the presence of MHC doesn’t
have a significant impact on P8, so the flux of S-L that is degraded by ERAP1
(equation (3.12)) doesn’t significantly fall.
This is an important observation because S-L is an immunodominant epitope,
with high affinity for MHC. Further, it is relatively poorly trimmed by ERAP1.
That is, it has a relatively low kcatKM rate and a relatively high p:MHC binding rate,
bP. Despite this, condition (3.14) holds, which means that MHC is ineffective at
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Figure 3.4: Degradation of XS-L in vitro in the presence and absence of MHC. Simu-
lation of ERAP1 (33CN) incubated with physiologically relevant levels of pep-
tide (300 CN) and MHC (165 CN). Blue line shows the dynamics of a system
with no MHC. Simulation of model equations (3.5b)-(3.5c) and (3.8b)-(3.8d).
preventing further degradation.
kcat
KM
= 1.26×10−7￿ bP = 1.1×10−9 (3.15)
where our value for bP is taken from Ref. [76].
In order for MHC to have a significant protective role, one of two things is
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required. One option would be for the peptides to be very poor ERAP1 substrates.
However, in vivo, they are likely to be out-competed by better ERAP1 substrates,
so would not be trimmed whether MHC was present or not. The alternative is that
the p:MHC binding rate must be higher. This may be possible if ERAP1 functions
in close association with MHC; trimmed peptides would have a better chance of
being loaded on to MHC rather than rebinding enzyme and being destroyed. This
suggests that MHC may have a protective role to play if ERAP1 is part of the PLC,
but otherwise does not perform this function in the ERAP1 pathway. This is because
the enzyme kinetics are far faster than the p:MHC kinetics.
3.3. Results 2: Modelling ERAP1 trimming in vivo 101
3.3 Results 2: Modelling ERAP1 trimming in vivo
We simulated the in vivo cell surface presentation of SIINFEKL derived from
ERAP1 trimming of N-terminally extended precursor peptides using models of
Chapter 2: System H1 and System H2.
3.3.1 Predicting how the amino acid extension determines cell
surface presentation
We used the Dalchau model of MHC class I peptide optimisation which incorpo-
rates tapasin expression [38], and extended it to incorporate trimming by ERAP1,
according to the models developed in Chapter 2. The optimisation model was cal-
ibrated to data from human cell lines [179] and able to reproduce observtions in
mice [80], so we used the inferred parameter rates, alongside the enzymatic param-
eter rates that we fitted in Section 3.1.2.
It is considered that a biologically plausible range for the rate of egression
(10−4 s−1 < e < 10−1 s−1) [38]. We have found that for fast egression rates within
this range (10−2 s−1 < e < 10−1 s−1) cell surface presentation of S-L-H-2Kb distinctly
depends on the rate of N-terminus removal from XS-L, for all hypotheses tested. In
general, all systems output a similar hierarchy of presentation (Figure 3.5), that is
similar to in vivo observations (Figure 3.2). However, there are some important
differences between the model output distributions and the observed distributions.
Firstly, the hierarchy of the N-terminal amino acid specificity of ERAP1 in vitro
is not entirely conserved at the cell surface in vivo. For example, the S-L epitope
derived from the Tyrosine-extended precursor is the most presented peptide in vivo
but is the fourth most efficiently trimmed by ERAP1 in vitro. On the other hand,
the Lysine precursor was the most efficiently trimmed precursor in vitro but was the
third most presented in vivo. The model hierarchy is exactly the same as the in vitro
trimming efficiency hierarchy, because there are no other processes in the model
with N-terminal specificity. In addition to this, the shape of the model output dis-
tributions are somewhat different to the shape of the observed distribution. Under
System H1, the model outputs at least 2-fold more S-L derived from the most effi-
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ciently trimmed precursor than the second most efficiently trimmed precursor. The
three most well presented precursor peptides are also 2-fold more than the fourth
most presented precursor in vivo. Thus System H1 begins to represent the in vivo
observations, but the Lysine-extended precursor should not be the only highly pre-
sented epitope. System H1 generally reproduces the long tail of the distribution,
with many precursor peptides being presented at relatively low levels. The shape
of the output distribution of System H2, is in general too linear, when compared to
the exponential shape of the observed distribution. There is not enough difference
between the most presented precursors and the rest of the precursors. Neverthe-
less, the ratchet model in which kcat is the amino acid specific parameter, achieves
a similar output distribution to the observed distribution in vivo.
For low egression rates (10−4 s−1 < e < 10−3 s−1), cell surface presentation of
S-L-H-2Kb distinctly depends on the rate of N-terminus removal from XS-L within
System H1, but not within System H2. Within System H1, presentation of S-L
is a distinct function of the amino acid at the N-terminus, X , of XXS-L for all
hypotheses tested. Whereas within System H2, the level of cell surface presentation
of S-L is similar across all XXS-L precursors for all hypotheses tested, that is the
variance of the N-terminal dependent trimming rates observed in vitro (Figure 3.2)
is significantly reduced at the cell surface, Figure 3.6. When catalysis is the amino
acid dependent parameter within the ratchet mechanism, there is more variance in
the distribution of cell surface presentation. However, the parameter set inferred for
this mechanism achieved the least accurate fit to in vitro data (NRMSE = 0.7488,
Figure 3.3c).
3.3.2 Slow egression rates lead to overtrimming in System H2
We have shown that within System H2, cell surface presentation appears to be in-
dependent of the amino acid dependent trimming rate of the N-terminus, for slow
egression rates (e < 10−3s−1). This is as a result of overtrimming of the more effi-
ciently trimmed precursors; the longer a mature epitope remains in the ER, the more
likely it is to be destroyed by overtrimming. In the model, this is represented by the
generation of the I-L peptide, P7. For this reason the variance in cell surface pre-
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Figure 3.5: Effect of N-terminus specificity of ERAP1 on cell surface presentation of
S-L when the rate of egression, e, is high. Cell surface presentation of S-L-
H-2Kb after 48 hours, following the independent supply and trimming of each
XXS-L precursor, for a relatively high (10−2 s-1) rate of egression. Plots (a)-(f)
show the effect of N-terminus specificity of ERAP1 operating under a bind-
trim-release mechanism and plots (e)-(h) under a ratchet mechanism. Plots
(a),(b),(e),(f) use the model equations (2.3) of System H1 and (c),(d),(g),(h)
use the model equations (2.10) of System H2. All simulations use the param-
eter values specified in Table 2.1 and run in MATLAB using the differential
equation solvers.
sentation of S-L derived from each XS-L decreases as the egression rate decreases
(second panel in Figure 3.6, subplot (3,3) in Figure 3.7 and Figure 3.9).
Within System H2, the substrate for ERAP1 is MHC-bound peptide. This
means that the egression rate is competing with the turnover rate of ERAP1, as
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Figure 3.6: Effect of N-terminus specificity of ERAP1 on cell surface presentation of
S-L when the rate of egression, e, is low. Cell surface presentation of S-L-
H-2Kb after 48 hours, following the independent supply and trimming of each
XXS-L precursor, for a relatively low (10−4 s−1) rate of egression. Plots (a)-(f)
show the effect of N-terminus specificity of ERAP1 operating under a bind-
trim-release mechanism and plots (e)-(h) under a ratchet mechanism. Plots
(a),(b),(e),(f) use the model equations (2.3) of System H1 and (c),(d),(g),(h)
use the model equations (2.10) of System H2. All simulations use the param-
eter values specified in Table 2.1 and run in MATLAB using the differential
equation solvers.
defined in equation (3.4). If egression is very slow, then even peptides with low
turnover rates, for example S-L itself (P8), will be degraded. It can be seen from
subplots (3,3) and (4,3) in Figure 3.7 that S-L is frequently destroyed, and presenta-
tion of I-L far exceeds presentation of S-L. It is also clear from Figure 3.7, that the
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generation of the 8- and 7mers is independent of the amino acid at the N-terminus.
This is because, as explained in Section 3.2.2, the enzyme-peptide dynamics are
much faster than the MHC-peptide dynamics. For a slow egression rate, the com-
plexes remain in the ER for a relatively long time. All complexes undergo ERAP1
trimming and the rate limiting step is the binding rate of peptide to MHC.
3.3.3 MHC has a protective role in System H1
We have shown that within System H1, cell surface presentation is a distinct func-
tion of the amino acid at the N-terminus, for all biologically plausible rates of
egression. This shows that the N terminal trimming rate is the limiting factor of
peptide generation, and overtrimming is not, suggesting that there is a mechanism
that prevents overtrimming. Indeed, MHC functions to protect peptide from further
degradation from ERAP1, since within SystemH1 ERAP1 cannot trimMHC-bound
peptide. It can be seen in Figure 3.8, that the majority of peptides of length j within
the system are bound to MHC, either within the ER or on the cell surface, and that
free peptide represents a very small proportion of total peptide with the system.
Since S-L has a strong affinity for MHC, it is protected from overtrimming even
for very slow egression rates. It can be seen from subplots (3,3) and (4,3) in Figure
(3.8) that presentation of S-L far exceeds presentation of I-L. This is because MHC
protects the peptide from further trimming, until the p:MHC complex egresses to
the cell surface.
3.3.4 System H1, in contrast to System H2, is robust to changes
in the egression rate
We used summary statistics to quantify the difference between the output distribu-
tions and the observed distributions [72] of each hypothesis over a range of egres-
sion rates. The concordance correlation coefficient evaluates the reproducibility of
the data by the model by measuring the agreement between the model output distri-
bution and the observed distribution. The concordance correlation coefficient rc is
given as [110]:
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Figure 3.7: Degradation of XXS-L in vivo when the rate of egression, e, is low Trim-
ming and presentation of each XXS-L precursor and their products in System
H2 when the egression rate is low (10−4 s−1). Initial concentrations (except
ERAP1) were set to zero, and the species’ dynamics were simulated for 48
hours so that concentrations could reach the model’s predicted SS levels (not
shown). After 48 hours XXS-L precursors were added at a constant supply
rate. Plots show the dynamics of peptide and MHC concentrations over the
subsequent 48 hours.
rc = 2rsxsyr2x +rxy +(µx−µy)2 (3.16)
where µ is mean and s is standard deviation.
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Figure 3.8: Degradation of XXS-L in vivo when the rate of egression, e, is high. Trim-
ming and presentation of each XXS-L precursor and their products in System
H1 when the egression rate is high (10−2 s−1). Initial concentrations (except
ERAP1) were set to zero, and the species’ dynamics were simulated for 48
hours so that concentrations could reach the model’s predicted SS levels (not
shown). After 48 hours XXS-L precursors were added at a constant supply
rate. Plots show the dynamics of peptide and MHC concentrations over the
subsequent 48 hours.
It is also useful to look at how similar the variance and skewness of the H1 and
H2 output distributions are to the variance and skewness of the observed distribu-
tion. Variance, s2 is the second central moment of a distribution and measures the
spread of the data about the mean. Skewness, g , is the third central moment and
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measures the asymetry of the distribution about the mean. They are given by the
following formulae:
s2 = E[(X −µ)2] = E[X2]−E[X]2 (3.17)
g = E￿￿X −µ
s
￿3￿ = E[X3]−3µs2−µ3
s3
(3.18)
The concordance, variance, and skewness of the output of System H2 varies as a
function of the rate of egression, whilst System H1 is relatively insensitive to the
rate of egression in terms of the three measures. The agreement between System
H2 and the data in Figure (3.9) (concordance correlation; panel one) peaks at a
threshold rate of egression, above or below which the agreement declines. There is
no agreement between the data and the output of System H2, at low egression rates.
The effect of the eggression rate on the variance of the systems’ outputs (sec-
ond panel) is similar to its effect on the concordance correlation. The variance of
both systems’ output is much lower than the observed variance in vivo. The skew-
ness (panel three) of the output of System H1 is in almost perfect agreement with
the skewness of the data, and is independent of the rate of egression. The skewness
of the output of System H2 monotonically increases as a function of the egression
rate for the range of egression rates tested.
3.3.5 Tapasin doesn’t change the shape of the output, but does
change the absolute presentation
To determine the combined impact of tapasin and ERAP1 in shaping cell surface
presentation, we compared simulations of tapasin-competent and tapasin-negative
cells. Tapasin-negative cells were simulated by setting the rate of generation of
tapasin to zero. We found that Tapasin did not change the shape of the distribu-
tion, but did enhance absolute presentation (Figures 3.5 and 3.6). Furthermore, the
concordance correlation coefficient, calculated on the data scaled to relative per-
centages, is the same for the system with and without tapasin for all values of the
egression rate (data not shown).
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Figure 3.9: Sensitivity of model performance with respect to the rate of egression, e
The systems’ performances over a physiologically plausible range of egression
rates [38]. The first panel shows the agreement between the systems’ output dis-
tributions and the observed distributions in vivo, as measured by concordance
correlation. All distributions are scaled by the cell surface presentation of S-
L following the trimming of the LL-S-L precursor, because this is the amino
acid that had the highest trimming rate. That is the unit of S-L presentation is
percentage, with S-L presentation from LL-S-L set to 100%. In general, the
concordance correlation coefficient, rc, (equation (3.10)) satisfies −1 ≤ rc ≤ 1.
A value of rc = −1 corresponds to perfect negative agreement, a value of rc = 0
corresponds to no agreement, and a value of rc = 1 corresponds to perfect agree-
ment. Panels two and three show the variance and skewness, respectively, of
the ordered distribution of the output of cell surface presentation of S-L from
each precursor XXS-L. A skewness of zero corresponds to an even distribution
around the mean value. A negative skew corresponds to more points to the left
of the mean, and a positive skew corresponds to more points to the right of the
mean.
3.4 Discussion
We have shown that for a set of biologically plausible parameter rates, all hypothe-
ses are able to predict the same qualitative distribution of XS-L derived cell surface
presentation of S-L (where X is one of 17 different amino acids) as is observed in
vivo. Overall, System H1 is more plausible than System H2 because it is insen-
sitive to the rate of egression for the entire range of biologically plausible values,
whereas System H2 requires an intermediate rate of egression, as both high and
low values can lead to behaviours that are incompatible with experimental observa-
tions (Figure 3.9). Unfortunately, the rate of egression of p:MHC from the ER has
not been measured directly, though it has been suggested that approximately 150
molecules leave the ER per second [184]. However, without knowing the number
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of peptide molecules and MHC within the ER, it is not possible to calculate the
rate. Without knowing the rate of egression, it is not possible to say whether Sys-
tem H2 predicts the cell surface abundance levels in accordance with experimental
observations. However, we can say that System H1 does predict cell surface levels
in accordance with experimental observations, as the behaviour of System H1 is
relatively insensitive to rate of egression.
Quantitative comparison is not directly possible, because the data is measured
by the mean fluorescence intensity. Fluorescence intensity, can be used to mea-
sure molecular concentrations because the intensity is linearly proportional to the
fluorescent molecule. However, if the constant of proportionality is unknown then
fluorescence intensity is not quantitatively useful.
The results detailed in 3.2 could be improved with further data. The fits were
constrained by the range of KM values in the literature. It would be beneficial to
have a KM value for each XS-L, and by extension we could obtain the catalytic rate,
using the methodology detailed in Section 3.1.2. This would improve the accuracy
of the in vivo model’s predictions.
The in vitro and in vivo experimental data are not entirely consistent with each
other. The order of cell surface abundance of S-L-H-2-Kb is not entirely consistent
with the order of in vitro trimming rates. This suggests that there are other amino
acid dependent mechanisms within the ER. For example, the XS-L affinity for MHC
may be dependent on X. We could answer this hypothesis with further data. If there
are still significant discrepancies between the in vitro and in vivo data then this
would suggest that there is another important amino acid dependent mechanism
within the ER. The output of the network is y in [0,1] which may be interpreted
as the posterior probability of cleavage. The network predicts that the sequence
window contains a cleavage site if y > t for some threshold t, or does not contain
a cleavage site if y < t. The models we have developed in this and the previous
chapter are dynamic, and dynamic models require dynamic data. The in vitro data is
dynamic, which is unusual as a lot of enzyme activity data is measured with respect
to substrate concentration levels, or at equilibrium, and it is often summarised by
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the MM rate constants. However, the in vivo data is taken at equilibrium, after 48
hours. It would be useful to have dynamic in vivo data, so that the dynamics, as
well as the final output can be compared.
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Figure 3.10: Effect of tapasin on the degradation of XXS-L in vivo under the ratchet
mechanism when the rate of egression, e, is high. Cell surface presentation
of S-L-H-2Kb after 48 hours, following the independent supply and trimming
of each XXS-L precursor, for a relatively high (10−2 s−1 s-1) rate of egression.
Plots (a)-(f) and (e)-(h) show the effect of N-terminus specificity of ERAP1
operating under a molecular ruler mechanism in a TPN+ and TPN− environ-
ment, using the model equations (2.3) and (A.25) of System H1, respectively.
Plots (i)-(l) and (m)-(n) show the effect of N-terminus specificity of ERAP1
trimming MHC-bound peptides in a TPN+ and TPN− environment, using the
model equations (2.10) and (A.26) of System H2, respectively. All simula-
tions use the parameter values specified in Table 2.1 and run in MATLAB
using the differential equation solvers.
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Figure 3.11: Effect of tapasin on the degradation under the ratchet mechanism of
XXS-L in vivo when the rate of egression, e, is high. Cell surface pre-
sentation of S-L-H-2Kb after 48 hours, following the independent supply and
trimming of each XXS-L precursor, for a relatively high (10−2 s−1 s-1) rate of
egression. Plots (a)-(f) and (e)-(h) show the effect of N-terminus specificity of
ERAP1 operating under a molecular ruler mechanism in a TPN+ and TPN−
environment, using the model equations (2.3) and (A.25) of System H1, re-
spectively. Plots (i)-(l) and (m)-(n) show the effect of N-terminus specificity
of ERAP1 trimming MHC-bound peptides in a TPN+ and TPN− environment,
using the model equations (2.10) and (A.26) of System H2, respectively. All
simulations use the parameter values specified in Table 2.1 and run in MAT-
LAB using the differential equation solvers.
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Figure 3.12: Effect of tapasin on the degradation of XXS-L in vivo under a bind-trim-
release mechanism when the rate of egression, e, is low. Cell surface pre-
sentation of S-L-H-2Kb after 48 hours, following the independent supply and
trimming of each XXS-L precursor, for a relatively low (10−4 s−1 ) rate of
egression. Plots (a),(b),(e),(f) and (c),(d),(g),(h) show the effect of N-terminus
specificity of ERAP1 operating under a molecular ruler mechanism in a TPN+
and TPN− environment, using the model equations (2.3) and (A.25) of Sys-
tem H1, respectively. Plots (i)-(l) and (m)-(n) show the effect of N-terminus
specificity of ERAP1 trimming MHC-bound peptides in a TPN+ and TPN−
environment, using the model equations (2.10) and (A.26) of System H2, re-
spectively. All simulations use the parameter values specified in Table 2.1 and
run in MATLAB using the differential equation solvers.
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Figure 3.13: Effect of tapasin on the degradation of XXS-L in vivo under a ratchet
mechanism when the rate of egression, e, is low. Cell surface presentation
of S-L-H-2Kb after 48 hours, following the independent supply and trimming
of each XXS-L precursor, for a relatively low (10−4 s−1 ) rate of egression.
Plots (a),(b),(e),(f) and (c),(d),(g),(h) show the effect of N-terminus specificity
of ERAP1 operating under a molecular ruler mechanism in a TPN+ and TPN−
environment, using the model equations (2.3) and (A.25) of System H1, re-
spectively. Plots (i)-(l) and (m)-(n) show the effect of N-terminus specificity
of ERAP1 trimming MHC-bound peptides in a TPN+ and TPN− environment,
using the model equations (2.10) and (A.26) of System H2, respectively. All
simulations use the parameter values specified in Table 2.1 and run in MAT-
LAB using the differential equation solvers.

Chapter 4
Neural network predictions of
proteasomal cleavage
Predictive algorithms have been used extensively in the field of MHC class I pro-
cessing: to determine the sequence dependent specificities of the proteasome [94,
130, 132, 175], TAP[18, 43, 187], and MHC class I [22, 113, 119]. Neural networks
have consistently been deemed the most useful algorithm for these purposes [130,
136].
PAProC was the first publicly available algorithm for the prediction of protein
cleavage by the proteasome. It was trained on specially collected in vitro data of
the degradation of yeast enoloase-1 by the constitutive proteasome. Although the
data was of good quality, the low quantity of data limited its predictive capacity
for unseen random polypeptide sequences. Furthermore, PAProC is of limited rel-
evance to immunology, due to its focus on the constitutive proteasome and not the
immuno-proteasome. The immunoproteasome which is stimulated by IFN-g upon
cell infection, has different catalytic subunits to the constitutive proteasome and is
thought to be responsible for the generation of most immunodominant epitopes.
Netchop, which was first developed in 2002 [94] and updated in 2005 with new
data and new methods [130], is a multilayered neural network that was trained on
publicly available immune epitope data. The availability of more than a decade’s
worth of new epitope data calls for a renewed attempt to predict cleavage by the
proteasome, with the aim of improving prediction accuracy. In this chapter we
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determine whether similar methods could be reused, against a larger database of
eptitopes to improve performance.
Peptide vaccines are under development for the treatment of autoimmune dis-
eases and cancer and for the prevention of viral infections. At present, the majority
of autoimmune therapies are non-specific and immunosuppresive, putting patients
at increased risk of infection. Peptide vaccines can be used in autoimmune disease
treatment to induce a specific set of T regulatory cells for the suppression of spe-
cific autoreactivities. Tumor antigen peptide vaccines are being researched for the
treatment of cancer. Many tumor epitopes are now known and are currently being
used in peptide vaccines that are being developed for the treatment of cancer. They
induce highly immunogenic T cell responses in blood, but have a clinical response
rate of only 3-5%. Different combinations of tumor epitopes may improve clinical
response. Therapeutic vaccines are being developed as potential functional cures
for HIV [79]. The vaccines induce T cell immunity to conserved, immunogenic,
HIV-1 epitopes that bind common HLA alleles. An accurate predictive algorithm
of proteasomal cleavage, and of the C terminus of epitopes enables the discovery
of novel peptides that may be suitable for inclusion in peptide vaccines. Such a
predictive algorithm also identifies peptides that are unsuitable for inclusion, and in
doing so reduces the experimental costs to test potential epitopes.
4.1 Materials and Methods
We trained neural networks to predict C terminal cleavage by the proteasome. The
networks consider peptide sequences, like the one displayed in Figure 4.5, and pre-
dict whether the C terminal residue is a cleavage site or not. Figure 4.5 shows a
positive datum, because SIINFEKL is an MHC epitope. The network also receives
negative data, in which the amino acid at the position of the C terminus is a non-
cleavage site.
4.1.1 Neural network architecture
A single input to the network is a ‘sequence window’ of 1-29 amino acids (Figure
4.5 shows a sequence window of 29 amino acids). Sequence windows are rep-
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resented by bit vectors, P of length R, to the neural network displayed in Figure
1.1. Each of the 20 human amino acids is encoded by 20 bits, for example Ala-
nine is encoded by A = 10000000000000000000, and Cystine is encoded by C =
01000000000000000000. The output of the network is y in [0,1] which may be
interpreted as the posterior probability of cleavage. The network predicts that the
sequence window contains a cleavage site if y > t for some threshold t, or does not
contain a cleavage site if y < t.
The network has a single hidden layer of neurons because the universal ap-
proximator theorem states that one hidden layer is sufficient for the approximation
of any continuous function by a nerual network [78]. There is no single best method
to determine the appropriate number of neurons in the hidden layer or the opti-
mal weight values, since this is dependent on the number of training examples, the
amount of noise in the data and the complexity of the function to be modelled [135].
The structure of the neural networks for the classification of a single input
datum is shown in Figure 1.1. Every neuron in the hidden layer is connected to
every bit of the input datum by a weight. Each neuron’s output is determined by its
transfer function and the argument of the transfer function, which is the dot product
of the input data and their associated weights plus a scalar bias (p ⋅W + b). The
transfer function is a tan-sigmoid and outputs a value between -1 and 1. The output
of all neurons in the hidden layer, y1s , becomes the input to the single neuron in
the hidden layer. The neuron has an activation function whose argument is again
the dot product of its input data and their associated weights plus a scalar bias(y1 ⋅W +b). The output function is a smooth, monotonic squashing function (log-
sigmoid) which constrains the output, y2, to be within its bounds of 0 and 1. The
model is repeated and optimised over i training examples. The scaled conjugate
gradient backpropogation algorithm is used to find the solution W that minimises
the mean square error between the targets and the outputs MSE = 1n∑ni=1(ti − yi)
[123, 152] .
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PDEVSGLEQLESIINFEKLTEWTSSNVME
Upstream	
flanking	region
N	terminus C terminus;	
cleavage	site
Downstream
flanking	region
Epitope
Figure 4.1: Example input datum to neural network. The input data was compiled so
that there are 10 flanking residues downstream of the C terminus and the full
polypeptide length is 29 residues. If the polypeptide sequence within the par-
ent protein did not meet these criteria the data was excluded. When shorter
sequence window lengths were used, they were extracted from the 29 residue
long polypeptide data.
4.1.2 Data
The training data was downloaded from two databases of MHC class I epitopes:
SYFPEITHI (http://www.syfpeithi.de/) and MHCPEP [19]. Epitopes were included
if they met each of the following requirements
i. they are between 7 and 11 amino acids in length
ii. they bind human leukocyte antigen (HLA) class I alleles
iii. their flanking regions could be reconstructed uniquely
iv. they do not originate from HIV
2197 peptides from the SYFPEITHI database and 1339 peptides from the MHCPEP
database met these requirements; of these a total of 3464 were unique.
HIV epitopes were removed from the training set because they constitute the
independent test set. The test set was downloaded from the HIV molecular im-
munology database (https://www.hiv.lanl.gov/content/immunology/index.html) and
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had to meet requirements (i)-(iii). A total of 279 HIV peptides met these require-
ments.
The epitopes were searched for within their parent proteins, in order to recon-
struct the flanking regions. The full length amino acid sequence extracted from the
parent proteins consisted of 29 residues, with epitopes aligned by their C terminus
at position 19. MHCPEP does not include the amino acid sequence of the parent
protein, but it includes its unique SWISS-PROT ID. We used the SWISS-PROT
IDs to retrieve the parent proteins from the FASTA database, which contains the
sequences of all known proteins.
Non-cleavage sites are more difficult to determine. Nevertheless by definition,
it can be assumed that the interior sites of an intact epitope are at most minor cleav-
age sites. Labelling all interior residues (excluding both termini) of peptides as
non-cleavage sites generates 5-9 times more negative than positive data. It is well
known that neural networks perform less well under class imbalance [137]. For this
reason we used positive resampling to balance the size of two classes. The data is
divided into training, test and validation subsets in the ratio 70:15:15. The positive
data was independently resampled in each subset, so that each subset contains only
unique sequences.
4.2 Results
The Kullback and Liebler information content (IC), plotted in Figures 4.2a and 4.2b,
provides a visual representation of the data. It measures the distance between the
cleavage, p, and non-cleavage, q, probability distributions
I(i) = 20￿
L=1 pLi log2(pLi ￿qLi ) (4.1)
The non-cleavage distribution can be thought of as the background distribution,
since it constitutes a more random set of polypeptide sequences. The amino acid,
L, at position, i, has a large positive information content if it occurs frequently at
position, i, relative to the background distribution, a large negative information con-
tent if it occurs infrequently, and a small information content if it occurs similarly
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Figure 4.2: Kullback and Liebler Information Content for epitope-containing
polypeptides. Polypeptides of 29 amino acids were compiled, with the C ter-
mini of all epitopes aligned at position 19. Further information about the com-
pilation of data is detailed in Section 4.1.1. Each coloured bar represents the
information content of an amino acid at a particular position in the polypep-
tide sequence. Negative information content means the amino acid at the given
location is under-represented. The data displayed in panel (a) comprises 3005
cleavage C terminal sites downloaded from SYFPEITHI and MHCPEP and
23207 non-cleavage C terminal sites assigend as described in Section 4.1.1.
The data displayed in panel (b) comprises 279 cleavage sites downloaded from
HIV LANL and 783 non-cleavage terminal sites assigned as described in Sec-
tion 4.1.1.
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to background levels.
Each peptide is aligned so that the C-terminus is at position 19. It is clear
from Figures 4.2a and 4.2b that this position has the greatest information content.
The next seven residues of the MHC dataset epitopes, displayed in panel (a) have
a higher IC that the rest of the sequence window. Recall, that the epitope lengths
range from 8-11 amino acids. The N-terminus of epitopes of length 8 has the second
highest IC within the sequence window. However, for all other epitope lengths, the
N-terminus has a much lower IC, similar to that of other flanking residues. This
suggests that the residue at position 8 is typically an anchor residue, and that the
amino acid at the N-terminus is of lower importance and is not conserved. The low
information content of the N-terminus suggests that a neural network is not a useful
tool to predict N-terminal cleavage.
The IC of the HIV dataset, displayed in panel b, shows no clear distinction
between the interior amino acids of the HIV peptide and the flanking residues. This
low information content fits with the paradigm of the high escape rate of HIV epi-
topes. [44]. Furthermore, the training set has a much greater information content
than the HIV dataset, note the different y-axis scales on Figures 4.2a and 4.2b.
The amino acid with the highest information content within both the MHC
dataset and the HIV dataset, is Lysine (L) at the C terminus. This is the amino acid
that Toes et al. found to be the most preferred cleavage site by both the constitu-
tive and immuno- proteasomes, with 10.3% and 9.4% of total cleavages occuring
at this site [165]. The cysteine residue (C), has negative information content at the
C terminus in both datasets, which is consistent with another finding by Toes et al.,
that neither type of proteasome produced any cleavages at this residue. However,
the Toes group also found that the most cleaved site by both proteasomes was ala-
nine (A), representing 10.5% and 11.4% of total cleavages. Analine has negative
information content at the C terminus in both datasets, suggesting that this residue
is actively disfavoured as a cleavage site. This is also the case for the older dataset
used in the work by Kesmir et. al [94]. It is likely that processes downstream of pro-
teasomal hydrolysis, such as peptide-MHC binding, disfavour peptides with alanine
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at the C terminus.
4.2.1 Balanced datasets improve neural network performance
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Figure 4.3: Neural network performance as a function of hidden layer size. Neural
network performance is measured by the Matthews’ Correlation Coefficient
(MCC) between the target and the output data. 100 different network sizes
were tested, ranging from 1 to 100 neurons in the hidden layer. Curves show
the mean MCC value and points show the maximum MCC value of 500 neural
networks, each initialised with different weight values, for each network size.
These figures summarise the average and best output of 50 000 different neural
networks. We ran the code on the UCL cluster, Legion. Panels (a) and (b)
display the training, validation and test set performances of the imbalanced,
and balancedMHC datasets respectively. Panels (c) and (d) display the HIV test
set performances for neural networks trained on the imbalanced and balanced
MHC dataset respectively. Performance was the same for the imbalanced and
balanced HIV datasest, as shown in panel (c).
When training a neural network on highly variable data, there is a trade off be-
tween obtaining a high degree of accuracy on the training dataset and the network’s
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generalisation to new datasets. Overfitting occurs when an increase in performance
on the training dataset results in a decrease in performance on unseen datasets [106].
One method to avoid overfitting a model is to implement early stopping during
the training stage if a given condition is violated. Training was terminated if the
performance on the validation dataset decreased for six successive iterations. The
MHC dataset is divided into training, testing, and validation sets in the ratio of
75:15:15, respectively. Early stopping occured in most cases, and the performance
was found to have the same relationship to hidden layer size across the different
sets as shown in Figures 4.4a and 4.4b. The performance on the training set was
the best, followed by the validation set and the performance was the worst on the
unseen test set.
First, neural networks were trained on the unbalanced MHC dataset, Figure
4.4a. The mean performance, as measured by mean MCC, increased as a function
of the number of neurons in the hidden layer, until about 8-10 neurons. For hidden
layers larger than 10 neurons, increasing size did not affect performance. Perfor-
mance on the HIV test set performance was inversely proportional to performance
on the unbalanced MHC dataset, Figure 4.4c despite the early stopping criterion.
This suggests that the networks were overtrained. These networks were also tested
on the balanced HIV test set for which the performance was the same as for the
unbalanced HIV test set. Next, the neural networks were trained on the balanced
MHC dataset, Figure 4.4b. The relationship between hidden layer size and perfor-
mance was similar to the unbalanced MHC dataset. However, the performance was
significantly improved, note the y axis scales of Figures 4.4a and 4.4b. The per-
formance on the HIV test set was also significantly improved, particularly for the
balanced HIV test set, Figure 4.4d. The mean MCC values obtained for the HIV
test sets are independent of hidden layer size. However, the maximum MCC values
for the HIV test sets still seem to be inversely proportional to the MCC values of
the MHC datasets. It may be a result of the difference between the HIV and MHC
datasets, that the better trained and more complex function that is derived for the
MHC dataset, the worse the neural network will perform on the HIV dataset.
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4.2.2 The MHC and HIV datasets have opposite dependencies
on the sequence window length
A single input to the model is a sequence window that consists of the cleavage
or non-cleavage site as well as some flanking residues. Flanking residues contain
variable amounts of information about whether the given residue is a cleavage or
non-cleavage site. The dimension of the input space is equal to the number of
bits encoding each residue to the power of the size of the sequence window: D =
20N where D is dimension and N is the size of the sequence window. The larger
the input space, the more training data is required. Thus the optimal size of the
sequence window reflects a balance between maximising the information content,
and mimimising the size of the input space.
To determine the optimal length for the sequence window, we trained 500 neu-
ral networks each with different initial conditions and with 10 neurons in the hidden
layer. we tested windows of length, L, L = r+ l+1 where r is the number of residues
up-stream, or to the left, of the C terminus and l is the number of residues down-
stream, or to the right, of the N-terminus.
The results demonstrate key differences in sequence window length dependen-
cies, between the different data sets and between the training and testing stages.
During training, neural network performance increases as a function of sequence
window length, Figure 4.5. The more information that is provided to the network,
the better the network is able to approximate the nonlinear function that governs
proteasomal cleavage specificity. This is also the case during the validation stage,
however, there is more noise in the relationship. The network is not specifically
trained to the validation data, however, training will stop if the error between the
output and target validation dataset increases in 6 recurrent iterations. From this
it can be understood that neural network performance on the validation dataset in-
creases as a function of sequence window length, but imperfectly. The MHC test
set, which is unseen by the neural network, appears to have an optimum window
size, above and below which performance is worse. Longer sequence windows in-
crease the complexity of the function to be learned and so require more training
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examples to achieve the same performance on an unseen test set.
Remarkably, the performance on the HIV test dataset decreases as a function of
sequence window length, which is opposite to the dependency of the MHC dataset
on sequence window length.
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Figure 4.4: Effect of sequence window length and alignment on neural network per-
formance. The input data to neural networks ranged from sequence windows
of 1 residue (top left bar in plots) to sequence windows of 29 residues (bot-
tom left bar in plots). In total 209 different sequence window alignments were
tested. Neural network performance is measured by the Matthews’ Correlation
Coefficient (MCC) between the target and the output data. The MCC value
for each sequence window alignment is shown by the colour scale, and is the
mean value for 500 networks, each inititialised with different weight values.
All networks have 10 neurons in the hidden layer. The sequence window de-
pendent average MCC values are presented for (a) the MHC training, (b) the
MHC validation, (c) the MHC test, and (d) the HIV test datasets.
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4.2.3 The learnt weights correspond to the information content
of the data
The weight values of each neuron in the hidden layer reflect the information the
neuron has learned. Figure 4.5 shows the average weight values learned by 500 dif-
ferent neural networks with four neurons in the hidden layer for sequence window
inputs of 12 amino acids. Three of the neurons learn that the data has a distribution
similar to that of the MHC dataset (Figure 4.2a). The fourth neuron (Figure 4.5d)
is mostly inhibitory for most amino acids at most locations within the sequence
window. The fourth neuron also promotes the hydrophobic amino acids Tyrosine
(Y), Tryptophan (W), Leucine, and Valine (V) at the C terminus. Its inhibitory ef-
fect for other amino acids positions may also be interpreted as further promoting
the prevalence of Y, W, L, and V at the C terminus. These amino acids are also
promoted at the C terminus by the weights of the neurons displayed in Figure 4.5b
and 4.5c. These are amino acids that are predominant at the C terminal of epi-
topes (Figure 4.2a). The weights of the neuron displayed in Figure 4.5a have in
general learnt the opposite amino acid specific information to the data and to the
other neurons. Nevertheless, it maintains the distribution shape of the information.
The neuron may have learnt this information to enable amino acids that are rare at
a given position to occur there when within a specific peptide sequence. All neuron
weights also learn that after the C terminus, the N terminus contains the most infor-
mation in the sequence windows. This is consistent with the information content of
the MHC dataset (Figure 4.2a) but inconsistent with the information content of the
HIV dataset (Figure 4.2b). It is clear that the hidden layer weights are optimised
for the MHC dataset, on which they were trained, and that performance on the HIV
dataset is likely to suffer as a result of the different structure of the data.
4.2.4 The neural network outperforms other models in terms of
correlation
Standard measures are used to evaluate network performance. The Mathews’ cor-
relation coefficient, MCC, is the overall measure of performance and is used in-
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Figure 4.5: Average learnt weight values for 500 neural networks with four neurons
in the hidden layer. 500 neural networks with four hidden layer weights
were trained for different initial weight values and for sequence windows of 12
amino acids. Each neuron has a weight value for each bit of input data. Thus
each neuron has a weight value for each amino acid at each location within the
sequence window. Each amino acid is assigned a different colour.
terchangably with performance in this report. Sensitivity and specificity show the
percentage of correctly predicted cleavage and non-cleavage sites respectively, and
the positive and negative prediction values, PPV and NPV, indicate the reliability of
the cleavage and non-cleavage predictions respectively.
MCC = PxNx−NfxPf x￿(Nx+Nf x)(Nx+Px)(Px+Nf x)(Px+Pf x) (4.2)
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Sensitivity = Px(Px+Nfx) ,Speci f icity = Nx(Nx+Pfx) ,
PPV = Px(Px+Pfx) ,NPV = Nx(Nx+Nfx) ,
(4.3)
Table 4.1: Best neural network performances. Best predictive performance of neural net-
works, as determined by highest correlation coefficient, for networks tested on
100 000 different initial conditions (combination of weights and hidden neurons)
The highest value between NetChop’s scores and ours is shown in bold.
Trained on Tested on Sensitivity Specificity PPV NPV MCC
Netchop: MHC + 20S MHC set 72 92 53 96 0.56
Netchop: MHC MHC set 80 88 44 97 53
Us: MHC set MHC set 82 79 80 81 0.61
Netchop: Enlarged MHC set HIV set 66 74 50 85 0.37
Us: Enlarged MHC set HIV set 63 59 60 62 0.23
Our neural networks more accurately distinguish cleavage sites from non-cleavage
sites, when tested on an unseen dataset of MHC epitopes. The best MCC value ob-
tained by the networks presented in this chapter is 0.61, which is an improvement
on the best published MCC value of 0.56 for a proteasomal cleavage neural net-
work. The published MCC value of 0.56 was obtained for a neural network trained
on old data and on experimentally measured 20S proteasome data. The MCC value
of the published neural networks trained only on the old data, and not on the exper-
imentally obtained data was 0.53. A comparison of Netchop trained on the MHC
set, and our neural networks trained on the MHC set most clearly demonstrates the
performance improvements acquired by updating the dataset. Updating the dataset
improved the MCC value by 8%. In addition the PPV values, which indicate the
prediction accuracy of cleavage site classification obtained by Netchop were just
0.44 and 0.53. The networks erroneously classified a lot of non-cleavage sites as
cleavage sites. This is not reflected in their specificity scores because the Netchop
datasets were unbalanced: N >> P. The neural networks developed in this chapter
therefore also offer a more well-rounded prediction algorithm that is able to ac-
curately predict cleavage sites without the need to erroneously classify a similar
4.3. Discussion 131
number of non-cleavage sites as cleavage sites.
On the other hand, Netchop performed significantly better on the HIV test
set than our networks did. The HIV dataset is very different to the MHC dataset
as shown in Figures 4.4 and 4.5. This difference manifested itself in an inverse
relationship between performance on the MHC test set and on the HIV test set, as
shown in Figures 4.4 and 4.5. Netchop learnt the MHC data less well than our
networks and performed less well on the MHC test set, which may in part explain
its better performance on the HIV test set. There may also be differences between
the two HIV test sets that we are unaware of, as the HIV test set and its information
content was not published by Kesmir et al.
4.3 Discussion
Updating the training dataset with newly available epitope data offers a moderate
improvement to the predictive capacity of neural network models of proteasomal
cleavage specificity. However, the new networks performed less well on an inde-
pendent test set of HIV epitopes than previously published networks [94]. Never-
theless, we found that in many instances, the prediction accuracy on the HIV test
set was inversely proportional to the prediction accuracy on the unseen MHC epi-
tope test set (Figures 4.4 and 4.5). Furthermore, the HIV dataset is very different
to the MHC epitope dataset and only the C terminus of the HIV epitopes have an
information content greater than the flanking residues.
The data inclusion criteria listed in Section 4.1.1, and the data compilation
methods may have contributed to the differences between the HIV epitope data and
the MHC epitope data. An epitope was only included in the datasets if its flanking
regions could be reconstructed such that the full length polypeptide sequence was 29
residues and the downstream flanking region consisted of 10 residues. HIV proteins
are typically shorter than other cellular proteins. 929 epitopes were lost because the
flanking regions couldn’t be reconstructed.
A further 367 epitopes were lost because they contained mutations, and thus
were not retreived from the parent protein. Mutated proteins were retrieved from
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the dataset by finding sequences that had similarity ratios > 0.5, as defined by
SequenceMatcher in Python. This result hints at a potential explanation as to
why the HIV epitopes are so different from other epitopes, and why the neural net-
works are unable to classify them correctly, despite being able to accurately classify
another set of unseen epitopes to a high degree of accuracy. HIV has the highest rate
of mutation known for any biological entity [37]. It is likely that the HIV proteins
have mutated out their MHC anchor residues and are atypical proteins. If this is the
case then further research should be carried out to see if certain amino acid substi-
tutions at the anchor residues may enhance the immunogenecity of HIV epitopes.
This could enhance HIV peptide vaccine design [79].
In this chapter, we used the same methods as existing models because exist-
ing models already achieve good results and it allows us to measure the importance
of keeping model training data up to date. The neural networks approximate the
non-linear function that maps the input data to the target data. This is known as
supervised learning because the networks learn from labeled data. In unsupervised
learning, the data is unlabeled allowing the algorithm to learn intrinsic patterns
within the data. Supervised learning algorithms can often be improved by the ad-
dition of an unsupervised learning component, particularly in a pre-training phase
[50]. Deep neural networks, which have gained popularity in recent years, consists
of many hidden layers and enable unsupervised learning. An unsupervised autoen-
coder can be used to learn a lower dimensional representation, or encoding of the
training data. Deep neural networks may comprise multiple stacks of autoencoders
of decreasing sizes. Each autoencoder provides a lower dimensional, non-linear
representation of the layer above it. The output of the final autoencoder becomes
the input to a supervised layer, which attempts to predict the target data from the
encoded data.
The unsupervised layer weights may provide useful information about our
dataset. We created the non-cleavage dataset by assigning all interior epitope
residues to it. The interior residues clearly escape cleavage regularly enough for
the epitope to be presented at the cell surface. However, it is possible that some
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interior sites are regularly cleaved. Unsupervised learning removes bias and hu-
man error, and the layer weights may provide important insights to the data such as
elucidating sites that may have been misclassified as non-cleavage sites by us.
It is possible to reproduce the training data very accurately using stacked au-
toencoders. However, it is important that the network does not learn the data too
well in order to avoid overfitting. A form of regularisation known as dropout can be
used to reduce overfitting [157]. This involves dropping random neurons out so that
the network is forced to learn multiple independent represenations of the training
data, thus improving generalisability. A well trained deep neural network may offer
further improvements to the predictive accuracy of models of proteasomal cleavage
specificity.

Chapter 5
Discussion
The aim of this thesis was to develop models of the key stages of peptide process-
ing within the antigen presentation pathway, to test hypotheses proposed from prior
experimental work, to improve the predictive capacity of current models, and to in-
crease functional understanding at a systems level. The aminopeptidase ERAP1 is
responsible for the generation of mature peptide antigens of 8-9 residues in length
for presentation on MHC molecules. Experimental work has determined two trim-
ming mechanisms utilised by ERAP1 in vitro to generate such peptides: ERAP1
trims free peptide substrates using an internal molecular ruler and also trims MHC-
bound peptide substrates using the MHC peptide binding groove as a template for
trimming. Extending the Dalchau peptide optimisation model [38] to incorporate
trimming by ERAP1 allowed for a thorough analysis of the parameter conditions
under which each trimming mechanism may be dominant in vivo (Chapter 2). A
comparison of the equilibrium expressions for cell surface p:MHC under the two
hypotheses, suggests that the mechanisms have opposite dependencies on the dis-
sociation rate of peptides from MHC. This finding was supported by a sensitivity
analysis of the simulated output of cell surface nonamers under physiologically re-
alistic conditions and kinetic rates. The models developed in Chapter 1 were fitted
to in vitro ERAP1 N-terminal specificity data in Chapter 2, and the simulated re-
sults were measured against in vivo data of cell surface p:MHC expression. Both
hypotheses were able to reproduce similar ERAP1 dependent distributions of cell
surface p:MHC. Hypothesis 1, the molecular ruler mechanism, was more robust to
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changes in parameter values than Hypothesis 2, which was unable to reproduce a
qualitatively similar cell surface p:MHC distribution to the in vivo data under some
physiologically plausible parameter rates. In Chapter 4, we trained neural networks
to predict C terminal cleavage by the proteasome to a greater degree of accuracy
than previously published neural networks. We showed that HIV epitopes have a
less distinct internal structure, relative to their flanking regions, than other epitopes.
The neural networks that best predicted HIV cleavage sites were trained on data
consisting only of the cleavage site, and no flanking residues, whilst these networks
had the worst performance on the MHC dataset. Furthermore, neural network pre-
diction performance was four-fold better on the unseen MHC test set than on the
HIV test set. We propose that the highly mutated proteins of HIV have mutated out
the conserved anchor residues of regular epitopes.
5.1 Future developments to the ERAP1 models
The ERAP1 models developed in this thesis, are able to approximate in vivo data
(Chapter 2) reasonably, but failed to reproduce specific amino acid distribution dif-
ferences between the in vitro and in vivo data. For this reason, the models should
be extended to include N terminal specificities of other molecules such as TAP and
MHC I. This may enable the models to explain why a particular precursor whose
N terminus is less favoured by ERAP1 is expressed at higher levels in vivo than a
precursor whose N terminus is favoured by ERAP1.
Tapasin stabilises the MHC peptide binding groove in an open, peptide-
receptive conformation. This increases the sampling rate as well as the ratio of
highly stable peptides relative to unstable peptides. As a result of this, tapasin is
known to alter the hierarchy of peptides displayed at the cell surface. The in vivo
models of Chapter 2 demonstrated that tapasin upregulates the overall cell surface
expression of peptides, but did not demonstrate that tapasin alters the hierarchy of
peptides. The peptide unbinding rate used in the models is length dependent but
not sequence dependent. In order to see the effect of tapasin on the hierarchy of
peptides displayed at the cell surface in the simulations of Chapter 2, we should
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incorporate N-terminal specificity of the MHC binding groove.
ERAP2 is the other ER resident aminopeptidase that is responsible for N ter-
minal trimming of peptides for display on MHC I. ERAP2 is less well characterised
than ERAP1 because mice do not express ERAP2. Nevertheless ERAP2 is asso-
ciated with Chron’s disease [57] and further research is required to determine its
contribution to the generation of mature epitopes as well as its association with
other diseases. Eventually the ERAP1 models should be developed to incorporate
ERAP2. Recently, it has been shown that ERAP1/2 heterodimers trim MHC bound
peptides to their correct and final lengths. The study measured the rate of ERAP1/2
trimming of peptide substrates, both in their free state and when bound to MHC
[29]. At the time of completing the work for Chapter 2, there was no available data
pertaining to the rate of trimming of MHC-bound peptides. We fitted the Michaelis
Menten parameter values to data from digests of ERAP1 and free peptide, and used
the same parameter values for MHC-bound peptides. However, the recent findings
of Chen et al. sugggest that ERAP1 trims free peptides and MHC-bound peptides
at different rates and to different lengths in vitro. When incubated with free peptide
substrates ERAP1/2 generated fragments as short as 4 residues in length. Whereas,
ERAP1/2 stopped trimming peptides bound to MHC when they were the correct
length of 8-9 residues. Nevertheless, the rate of trimming was much slower for
MHC bound peptide and took up to 10 hours for the final epitope to become the
dominant peptide length. It is not known whether ERAP1 exhibits the same kinet-
ics when not part of the ERAP1/2 heterodimer. It would be of particular interest
to measure the ERAP1 trimming rate of XS−L (where X is any amino acid) when
bound to MHC. The in vivo model could then be correctly paramaterised for both
trimming hypotheses. If the kinetics and behaviours of the two mechanisms for the
trimming of XS-L are as divergent as those for the peptides considered by Chen et
al. then the newly parameterised in vivo models are likely to finally elucidate the
dominant mechanism used by ERAP1 to trim X-SL in vivo. More generally, the
models could be used to test the new hypothesis, that ERAP1 trimming kinetics are
much slower for peptides bound to MHC than for free peptides, but free peptides
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are more frequently overtrimmed.
5.2 ERAP1 mutations
The in vitro degradation rate of HLA-B27 peptide epitopes by four ankylosing
spondylitis (AS)-associated ERAP1 variants has recently been measured [117].
Some variants appeared to exhibit substrate inhibition dynamics. It would be inter-
esting to use the time-series model fitting techniques as described and used in Sec-
tion 3.1.2 to compare the fits obtained to a conventional Michaelis Menten model
and to a competitive inhibition Michaelis Menten model. This may help to elucidate
the differences between wild-type ERAP1 and the AS-associated ERAP1 variants.
The authors have also characterised the in vivo length distribution of the HLA-B27
peptidome under various ERAP1 contexts [62]. The modelling work of Chapter 2
could be repeated for these new datasets to gain insights into how AS-associated
ERAP1 mutations affect the repetoire of peptides as well as the quantities of empty
MHC displayed at the cell surface. As discussed in Section 1.4.3, the altered pep-
tidome and increased levels of cell surface empty MHC expression are both hy-
potheses for ERAP1’s involvement in the pathogenesis of AS.
5.3 The neural network dataset
The neural networks of Chapter 4 were developed because the most accurate pro-
teasomal cleavage prediction algorithm is trained on a dataset that is >10 years old.
Updating the dataset improved the predictive accuracy, as measured by the MCC, of
the neural networks on the MHC test set by 5%. Nevertheless, there remain inherent
issues with the dataset. The data comprises epitopes that bind to MHC. However,
MHC present only 150 peptides for every 2 million peptides generated [184]. Pro-
teasomal cleavage products that do not bind MHC are lost from the dataset. The
dataset contains information about the specificities of other molecules involved in
the antigen processing and presentation pathway, such as TAP andMHC. This limits
the use of the algorithm to proteasomal degradation within the antigen processing
pathway.
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5.4 Poor prediction performance on a dataset of HIV
epitopes
A model that is unable to reproduce the expected output can still be considerably
informative. First of all, this unsuccessful model reveals that there is some unknown
information. Hypotheses can be suggested and tested either using new models or
experimentally. The analysis of Chapter 4 throws light on the differences between
HIV epitopes and other MHC epitopes. It appears that HIV epitopes do not have
conserved anchor residues like those in regular epitopes. A comprehensive study of
the binding affinities of HIV-derived immunodominant epitopes may determine if
these epitopes are sufficient in number and of sufficient stability to induce immuno-
genic CD8+ T cell responses. Single amino acid substitutions in HIV epitopes could
enhance their stability, providing better candidates for HIV vaccine design.
5.5 Model combination
Future work might seek to connect the two models, to obtain a model of the gener-
ation and presentation of mature antigenic peptides from full length proteins. The
cleavage probabilities obtained from the neural network algorithm could be used
to parameterise an existing dynamic ODE model of proteasomal cleavage [120].
The ODE proteasome model generates peptide fragments of varied lengths, using
length dependent cleavage and export rates. The output of the neural network-
parameterised ODE model, could be directly connected to the ERAP1 models. As
discussed in the previous section, the proteasomal cleavage algorithm favours pep-
tides that are transported by TAP. At the initial stages of building the connected
model, it would be reasonable to give all proteasomal cleavage products the same
supply rate to the ER. In later stages of the model development, it may be beneficial
to incorporate peptide specific TAP transport efficiency using available TAP predic-
tion algorithms [10, 187]. The connected model could be used to simulate peptide
generation from the entire cellular proteome, providing insights into how the key
enzymatic processes shape the entire immunopeptidome.
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5.6 Conclusions
This thesis contributes towards our understanding of the dynamics and specificity
of the key enzymatic stages of the antigen processing pathway. Dynamical mod-
els have provided testable predictions for the mechanism of trimming by ERAP1.
Machine learning approaches have provided an accurate prediction algorithm of C
terminal cleavage by the proteasome. These protease activities have important con-
sequences at the cellular and organismal levels. This thesis shows how mathemati-
cal modelling techniques and biochemical experimental research can work together
to further functional understanding of immunological systems.
Appendices
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Appendix
A.1 Nomenclature
The nomenclature used for the ERAP1 models of Chapters 2 and 3 is given in the
following table.
Species Description
M MHC I
E ERAP1
P ji Peptide of sequence i and length j
Pext Extended peptide
T Tapasin
Me Cell surface empty MHC I
MP ji p:MHC I complex where peptide has sequence i and length j
EP ji ERAP1:peptide complex where peptide has sequence i and length j
EPext ERAP:peptide complex where peptide is in extended form
EM ERAP1:MHCI complex
EMP ji ERAP1:p:MHCI complex where peptide has sequence i and length
j
EMPext ERAP1:p:MHCI complex where peptide is in extended form
TM Tapasin:MHCI complex
TMP ji Tapasin:p:MHCI complex where peptide has sequence i and length
j
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TMPext Tapasin:p:MHCI complex where peptide is in extended form
ETM ERAP1:tapasin:MHCI complex
ETMP ji ERAP1:tapasin:p:MHCI complex where peptide has sequence i and
length j
ETMPext ERAP1:tapasin:p:MHCI complex where peptide is in extended
form
MeP ji Cell surface p:MHCI where peptide has sequence i and length j
MePext Cell surface p:MHCI where peptide is in extended form
Parameters Description
gM Production of MHC I
gE Production of ERAP1
g ji Production of peptide of sequence i and length j
gT Production of tapasin
dM Degradation of empty MHC I in the ER
dE Degradation of ERAP1
dP Degradation of peptide in the ER
dN Degradation of empty MHC I at the cell surface
dT Degradation of tapasin
bP Binding of peptide to MHC I
bE Binding of ERAP1 to peptide, MHC I, or p:MHCI
c Binding of peptide to tapasin-bound MHC i
kcat Catalysis of ERAP1 trimming
u ji Unbinding of peptide sequence i and of length j from MHC I
uE Unbinding of ERAP1 from peptide, MHC I, or p:MHC I
uT Unbinding of tapasin
q Effect of tapasin on unbinding of p:MHC I
v Effect of peptide on unbinding of tapasin:MHC I
eg Egression
ET Total ERAP1 concentration
KM Michaelis Menten constant
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KM2 Derived Michaelis Menten constant for System H2
Peptide
variables
Description
i Peptide sequence type
j Peptide sequence length
j+1 Peptide sequence length with single amino acid extension
N Full length of peptide sequence
ext Extended peptide length
Mathematical
notations
Description
′ Denotes rate of change∗ Specifies that species is at equilibrium concentration
A.2 Simplification using quasi-steady state approxi-
mation
ERAP1 kinetics are relatively fast in comparison to the kinetics of all other pro-
cesses within the models. ERAP1 concentrations therefore reach equilibrium more
quickly than other molecular species. This enables the use of quasi steady state
approximations (QSSA) of free ERAP1 and ERAP1 complexes.
A.2.1 System H1
We may assume that enzyme binds peptide relatively quickly, which implies that
the complex EPji reaches steady state relatively quickly allowing us to make a quasi
steady state approximation.
[EPji ]∗ = 1KM [Ef ][Pji ] (A.1a)
KM = uE +kcatbE (A.1b)
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We also make the assumption that enzyme is conserved in this system (A.1c).
ET = Ef +Eb (A.1c)
Eb =￿
j
￿
i
[EPji ] =￿
j
￿
i
[Ef ][Pji ]
KM
(A.1d)
Equation (A.1d) is important, because it shows that at QSS, bound enzyme is pro-
portional to free enzyme by a factor
Pji
KM
. This allows us to write Ef and by exten-
sion EPji as functions of total enzyme, ET , which remains constant over time. Upon
substitution of (A.1d), into (A.1c) and (A.1a) we obtain
ET = Ef￿1+￿
j
￿
i
[Pji ]
KM
￿ (A.1e)
Ef = ET￿1+∑ j∑i [Pji ]KM ￿
(A.1f)
[EPji ]∗ = [ET ][Pji ]
KM￿1+∑ j∑i [Pji ]KM ￿
(A.1g)
This simplification allows us to remove ODE expressions (2.3b) and (2.3c) and
instead use expressions to directly describe E and EPji , (A.1f) and (A.1g).
A.2.2 System H2
We assume that enzyme is conserved according to equation A.1c. We also assume
that enzyme binds MHC and p-MHC rapidly, as it does peptide in System H1, to
obtain QSSAs for [EM] and [EMP] concentrations. To derive an expression for
conserved enzyme we must sum over [EMP]∗ and [EM]∗.
Using the equations for [EM] and [EMPji ], we can simply rearrange to obtain
the QSSA:
[EMPji ] = bE[E][MPji ]+bp[EM][Pji ]
uE +u ji +kPjicat (A.2a)
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[EM] = bE[E][M]+￿j,i u
j
i [EMPji ]
uE +bp￿
j,i
[Pji ] (A.2b)
Using (A.2a) we may write an expression for￿
j,i
u ji [EMPji ].
￿
j,i
u ji [EMPji ]∗ = bE[E]￿
j,i
u ji [MPji ]
uE +u ji +kPjicat +bp[EM]￿j,i
u ji [Pji ]
uE +u ji +kPjicat (A.3)
And substitute into (A.2b). Upon rearrangement we obtain a new QSSA for [EM]
that is independent of [EMPji ]∗.
[EM]∗ = 1￿uE +bP￿
j,i
[Pji ]−bp￿
j,i
u ji [Pji ]
uE +u ji +kPjicat ￿
￿bE[E][M]+bE[E]￿
j,i
u ji [MPji ]
uE +u ji +kPjicat ￿
(A.4)
Now, by using the conservation of mas on ERAP1, we can enforce
ET = Eb+Ef = [E]+ [EM]+￿
j,i
[EMPji ] (A.5)
where Eb = [EM]+￿
j,i
[EMPji ] and Ef = [E].
Substituting (A.2a) and (A.4) and rearranging we obtain
Eb = [Ef ]￿￿ 1KM2￿bE[M]+bE￿j,i u
j
i [MPji ]
KM3
￿￿1+bp￿
j,i
[Pji ]
KM3
￿+bE￿
j,i
[MPji ]
KM3
￿￿ (A.6)
where,
KM2 = ￿uE +bP￿
j,i
[Pji ]−bp￿
j,i
u ji [Pji ]
uE +u ji +kPjicat ￿ (A.7)
= ￿uE +bP￿
j,i
[Pji ](1− u ji
uE +u ji +kPjicat )￿ (A.8)
KM3 = uE +u ji +kPjicat (A.9)
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Upon substitution of (A.6) into (A.5) we derive an expression for [E]∗ in terms of
the constant, ET .
ET = Ef￿￿1+ bEKM2￿[M]+￿j,i u
j
i [MPji ]
KM3
￿￿1+bp￿
j,i
[Pji ]
KM3
￿+bE￿
j,i
[MPji ]
KM3
￿￿ (A.10)
[E]∗ = ET￿￿1+ bEKM2￿[M]+∑ j,i u
j
i [MPji ]
KM3
￿￿1+bp￿
j,i
[Pji ]
KM3
￿+bE￿
j,i
[MPji ]
KM3
￿￿
(A.11)
By extension, [EM]∗ and [EMPji ]∗ are now functions of total enzyme concentra-
tion, ET .
The original system of 9 ODEs is reduced to a system of 6 ODEs with 3 QS-
SAs.
[Mu]′ = gmu−(dMu+m)[Mu] (A.12a)[M]′ =m[Mu]+￿
j
￿
i
u ji [MPji ]+uE[EM]∗−(dM +bp￿
j
￿
i
[Pji ]+bE[E]∗)[M]
(A.12b)
[Pji ]′ = g ji +u ji ([EMPji ]∗+ [MPji ])−(dp+bp([M]+ [EM]∗))[Pji ] (A.12c)[MPji ]′ = bp[M][Pji ]+uE[EMPji ]∗+kMPj+1icat [EMPj+1i ]∗−(u ji +e+bE[E]∗)[MPji ]
(A.12d)
[MePji ]′ = e[MPji ]−u ji [MePi] (A.12e)[Me]′ =￿
j
￿
i
u ji [MePi]−dMeMe (A.12f)
where,
[E]∗ = ET￿￿1+ 1KM2￿bE[M]+bE∑ j,i u
j
i [MPji ]
KM3
￿￿1+bp￿
j,i
[Pji ]
KM3
￿+bE￿
j,i
[MPji ]
KM3
￿￿
(A.13a)
[EM]∗ = 1
KM2
￿bE[E][M]+bE[E]￿
j,i
u ji [MPji ]
KM3
￿ (A.13b)
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[EMPji ]∗ = bE[E][MPji ]+bp[EM][Pji ]KM3 (A.13c)
A.3 Non-dimensionalisation
We re-scale the systems so that all species concentrations are unitless.
A.3.1 System H1
Consider an equation for immature MHC, Mu, which has dimension mol. We can
assign a new, dimensionless variable for immature MHC, mu by rescaling by a quo-
tient of the parameters that has dimension mass, mol. We also introduce a dimen-
sionless time, by rescaling by a parameter that has dimension time, s. In this context
we use the variable tm to denote transport of MHC, in place of the usual parameter
e because e is the non-dimensional variable for ERAP1 within these systems.
dMu
dt
= gMu−dMu[Mu]− tMu[Mu] (A.14)
Let
[mu] = bP[Mu]
tM
, t = ttM, (A.15)
then
d[Mu]
d[mu] d[mu]dt dtdt = t2MbP d[mu]dt = gMu−(dMu+ tMu) tMbP [mu] (A.16)
d[mu]
dt
= gˆMu−(tˆMu+ dˆMu)[mu] (A.17)
where
tˆMu = tMutM , dˆMu = dMutM (A.18)
In the same way me may non-dimensionalize the rest of the system, using the
following non-dimensional variables.
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[m] = bP[M]
tM
, [p ji ] = bP[Pji ]tM , [mpji ] = bP[MP
j
i ]
tM
, [np ji ] = bP[MePji ]tM
[n ji ] = bP[Me]eg , [e]∗ = bP[E]∗eg , [ep ji ]∗ = bP[EP
j
i ]∗
tM
, [eT ] = bP[ET ]eg
(A.19)
We obtain the following non-dimensional system, with time scaled by eg, t =
teg.
d[mu]
dt
= tˆMu−(tˆMu+ dˆMu)[mu] (A.20a)
d[m]
dt
= gˆMu[mu]+￿
j
￿
i
uˆ ji [mpji ]−(dˆM +￿
j
￿
i
[p ji ])[m] (A.20b)
d[p ji ]
dt
= gˆ ji + uˆ ji [mp]+ kˆ j+1cat [ep j+1i ]−(dˆP+ [m])[p ji ] (A.20c)
d[mpji ]
dt
= [m][p ji ]−(uˆ ji +1)[mpji ] (A.20d)
d[np ji ]
dt
= [mpji ]− uˆ ji [np ji ] (A.20e)
d[n ji ]
dt
=￿
j
￿
i
uˆ ji [np ji ]− dˆN[n ji ] (A.20f)
[e]∗ = EˆT −￿
j
￿
i
[p ji ] (A.20g)
[ep ji ]∗ = EˆT [p ji ]KˆM(1+∑ j∑i[p ji ]) (A.20h)
gˆMu = gMubpt2M uˆ ji = u
j
i
tM
dˆM = dMtM gˆE = gEbEtM kˆ jcat = k jcattM
dˆE = dEtM gˆ ji = g
j
i bp
t2M
dˆP = dPtM dˆN = dNtM kˆM = KMbPtM
(A.21)
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The entire system may now be described by 6 dimensionless ODEs and two
steady state equations.
A.3.2 System H2
We may apply the same non-dimensionalisation process to System H2. We intro-
duce non-dimensional variables, scaled by the parameters of the system
[m] = bP[M]
tM
[p ji ] = bP[Pji ]tM [mpji ] = bP[MP
j
i ]
tM
[np ji ] = bP[MePji ]tM (A.22)
[n ji ] = bP[Me]tM [em] = bE[EM]tM [e]∗ = bP[E]∗tM [ep ji ]∗ = bP[EP
j
i ]∗
tM
d[mu]
dt
= gˆMu−(tˆMu+ dˆMu)[mu] (A.23a)
d[m]
dt
= tˆMu[mu]+￿
j
￿
i
uˆ ji [mpji ]−(dˆM +￿
j
￿
i
[p ji ])[m] (A.23b)
d[p ji ]
dt
= gˆ ji + uˆ ji ([emp ji ]∗+ [mpji ])−(dˆP+ [em]∗+ [m])[p ji ] (A.23c)
d[mpji ]
dt
= [m][p ji ]+ kˆ j+1cat [empj+1i ]−(uˆ ji + tˆM)[mpji ] (A.23d)
d[np ji ]
dt
= tˆM[mpji ]− uˆ ji [np ji ] (A.23e)
d[n ji ]
dt
=￿
j
￿
i
uˆ ji [np ji ]− dˆN[n ji ] (A.23f)
[e]∗ = EˆT￿￿1+ bˆEKˆM2￿[m]+￿j,i uˆk[mpji ]￿￿1+￿j,i KˆM3[p ji ]￿+ bˆE￿j,i KˆM3[mpji ]￿￿
(A.23g)
[em]∗ = KˆM2bˆE[e]([m]+￿
j,i
uˆk[mpji ]) (A.23h)
[emp ji ]∗ = KˆM3(bˆE[e][mpji ]+ [em][p ji ]) (A.23i)
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gˆMu = gMubpt2M uˆ ji = u
j
i
tM
dˆM = dMtM gˆE = gEbEtM kˆ jcat = k jcattM
dˆE = dEtM gˆ ji = g
j
i bp
t2M
dˆP = dPtM KˆM3 = tMKM3 dˆN = dNtM
EˆT = ETbptM uˆk = u
j
i
KM3
bˆE = bEbP KˆM2 = tMKM2 (A.24)
A.4 Tapasin
The ODEs for the tapasin+ ERAP1 models are presented in this section.
A.4.1 System H1
The addition of tapasin to System H1 requires three new ODEs to describe the
tapasin associated species: tapasin, T , tapasin:MHC, TM, and tapasin:p:MHC,
TMPji
[M]′ = gM +￿
j,i
u ji [MPji ]+uT [TM]−(dM +bT [T ]+bP￿
j,i
[Pji ])[M] (A.25a)
[T ]′ = gT +uT [TM]+uT v￿
j,i
[TMPji ]−(bT [M]+dT )[T ] (A.25b)
[TM]′ = bT [T ][M]+q￿
j,i
u ji [TMPji ]−(uT +c￿
j,i
[Pji ])[TM] (A.25c)
[E]′ = gE +￿
j,i
[EPji ](uE +kPjicat)−(dE +bE￿
j,i
[Pji ])[E] (A.25d)
[EPji ]′ = bE[E][Pji ]−(uE +kPjicat)[EPji ] (A.25e)[TMPji ]′ = b[TM][Pji ]−(u ji q+uT v)[TMPji ] (A.25f)[Pji ]′ = g ji +u ji [MPji ]+u ji q[TMPji ]+uE[EPji ]+kPj+1icat [EPj+1i ]−(dP+bP[M]+c[TM]+bE[E])[Pji ] (A.25g)[MPji ]′ = bP[M][Pji ]+uT v[TMPji ]−(u ji +e)[MPji ] (A.25h)[MePji ]′ = e[MPji ]−u ji [MePji ] (A.25i)
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A.4.2 System H2
The addition of tapasin to System H2 requires four new ODEs to describe the
tapasin associated species: tapasin, T , tapasin:MHC, TM, ERAP1:tapasin:MHC,
ETM, tapasin:p:MHC, TMP, and ERAP1:tapasin:peptide:MHC, ETMP
[M]′ = gM +￿
j,i
u ji [MPji ]+uE[EM]+uT [TM]
−(dM +bp￿
j,i
[Pji ]+bE[E]+bT [T ])[M] (A.26a)
[E]′ = gE +uE([EM]+ [ETM]+￿
j,i
[EMPji ]+￿
j,i
[ETMPji ])+￿
j,i
kMP
j
cat ([EMPji ]
+ [ETMPji ])−(dE +bE([M]+ [TM]+￿
j,i
([MPji ]+ [TMPji ])))[E]
(A.26b)
[EM]′ = bE[E][M]+￿
j,i
u ji [EMPji ]+uT [ETM]−(uE +bT [T ]+bp￿
j,i
[Pji ])[EM]
(A.26c)
[EMPji ]′ = bE[E][MPji ]+bp[EM][Pji ]+uT v[ETMPji ]−(uE +u ji +kPjicat)[EMPji ]
(A.26d)
[T ]′ = gT +uT ([TM]+ [ETM])+uT v￿
j,i
([TMPji ]+ [ETMPji ])
−(bT ([M]+ [EM])+dT )[T ] (A.26e)[ETM]′ = bE[E][TM]+bT [T ][EM]+q￿
j,i
u ji [ETMPji ]
−(uE +uT +c￿
j,i
[Pji ])[ETM] (A.26f)
[ETMPji ]′ = bE[E][TMP]+c[ETM][Pji ]−(uE +uT v+qu ji +k jcat)[ETMPji ] (A.26g)[Pji ]′ = g ji +u ji ([EMPji ]+ [MPji ])+qu ji ([ETMPji ]+TMPji ])−(dp+bp([M]+ [EM])+c([TM]+ [ETM]))[Pji ] (A.26h)[TMPji ] = c[TM][Pji ]+k j+1cat [ETMPj+1i ]+uE[ETMPji ]−(bE[E]+qu ji +uT v)[TMPji ] (A.26i)[MPji ]′ = bp[M][Pji ]+uE[EMPji ]+uT v[TMPji ]+kMPj+1icat [EMPj+1i ]
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−(u ji +e+bE[E])[MPji ] (A.26j)[MePji ]′ = e[MPji ]−u ji [MePi] (A.26k)[Me]′ =￿
j,i
u ji [MePi]−dMeMe (A.26l)
A.5 Equilibrium analysis
A.5.1 System H1
By equating each of the equations in (2.3) to zero, we can derive a set of relation-
ships between the variables of interest.
[MePji ]∗ = eu ji [MPji ]∗[MPji ]∗ = 1(u ji +e)(bp[M]∗[Pji ]∗)
bp[M]∗[Pji ]∗ = g ji +u ji [MPji ]∗+uE[EPji ]∗+kPji +1cat [EPj+1i ]∗−(dP+bE[E]∗)[Pji ]∗[MPji ]∗ = 1e(g ji +ue[EPji ]∗+kPj+1icat [EPj+1i ]∗−(dp+bE[E]∗)[Pji ]∗)
MePji = 1u ji eu ji +e￿ bP[M]dP+bP[M]￿g ji +u ji [MPji ]+k j+1cat EP j+1i −k jcat[EPji ]￿+uT v[TMPji ]￿
(A.27)
After some substitution and rearrangement, we can arrive at an expression that
quantifies cell surface presentation in terms of the abundance of peptide i, ERAP1
and MHC.
[MePji ]∗ = 1u ji ￿￿g ji + [E]∗￿￿kP
j+1
i
cat
bE
uE +kPji +1cat [Pj+1i ]∗−k
Pji
cat
bE
uE +kPjicat [Pji ]∗
￿￿−dp[Pji ]∗￿￿
(A.28)
[MePji ]∗ = 1u ji ￿￿g ji +V
j+1
max [Pj+1i ]∗
K j+1M −V
j
max[Pji ]∗
K jM
−dp[Pji ]∗￿￿ (A.29)
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where g ji = 0 if j ≠N
A.5.2 System H2
By equating each of the equations in (2.10) to zero, we can derive a set of relation-
ships between the variables of interest.
[MePji ]∗ = eu ji [MPji ]∗[MPji ]∗ = 1(u ji +e)(bP[M]∗[Pji ]∗+uE[EMPji ]∗+kMP
j+1
i
cat [EMPj+1i ]∗−bE[E]∗[MPji ]∗)
The interactions between peptide and enzyme occur at faster rates than between
peptide and MHC, so I removed the peptide:MHC binding and unbinding terms. All
shorterned forms of peptide are generated via trimming by ERAP1, which means
that they will be in complex with MHC (MP is the product of EMP) unless they
are poor binders. If they are poor binders then they are unlikely to contribute much
towards EMP. So bE[E][MP] > bP[EM][P] so we ignore bP[EM][P] in this substi-
tution step. Similarly I have removed the peptide unbinding term from the equation
for [EMPji ]∗, as this occurs at a much slower rate than the other processes. I sub-
stituted for [EMPji ]
[MPji ]∗ = 1(u ji +e)￿kMP
j+1
i
cat [EMPj+1i ]∗−kMPjicat [EMPji ]∗￿ (A.30)
(A.31)
[MePji ]∗ = 1u ji eu ji +e￿￿￿ k
j+1
cat
K j+1M [E]∗[MPj+1i ]∗+ k
j+1
cat
K j+1M2 [EM]∗[Pj+1]∗￿
−￿k jcat
K jM
[E]∗[MPji ]∗+ k jcatK jM2 [EM]∗[Pji ]∗￿￿￿ (A.32)
where KM2 = uE +kcatbP
Equations (A.28) and (A.32) have some differences. In System H2 (equation
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A.32) ERAP1 trims MHC-bound peptides, as can be seen in the second and third
terms. In System H1 peptide can only be liberated from enzyme if the enzyme
unbinds (or if it is catalysed), whereas in System H2 either enzyme or peptide may
unbind from the enzyme:MHC complex, which is reflected in the higher scale factor
in the second term. The final term represents the loss of peptides of the correct
length for binding MHC to binding with E:MHC complexes (see equation A.30).
As shown in equation (A.32) this requires total free MHC at timepoint t coming in
to contact and binding enzyme, and is scaled by its unbinding rate and its binding
rate to peptide.
Under System H2, in which enzyme trims MHC-bound peptide, the relation-
ship is more complex. For large egression rates e,
e
u ji (e+bEE) becomes 1u ji as per
System H1. However, for small e,
e
u ji (e+bEE) ≈ eu ji bEE . If ebEE < 1, then System
H2 generates higherMePji concentrations than System H1. This may be interpreted
as System H2 will outperfom System H1 if the peptide-MHC complex is more
likely to escape the ER than bind to free enzyme. The opposite holds true unless
u ji [EMPji ]∗ is sufficiently high, which is unlikely because a peptide of the correct
length for MHC binding has a very low off-rate, u ji .
A.5.3 System H1 with Tapasin
By equating each of the equations in (A.25) to zero, we can derive a set of relation-
ships between the variables of interest.
[MePji ]∗ = eu ji [MPji ]∗[MPji ]∗ = 1(u ji +e)(bp[M]∗[Pji ]∗+uT v[TMPji ]∗)
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We can derive the following expression to show the impact of tapasin on the cell
surface levels of peptide-MHC complexes
[MPji ]∗ = 1(u ji +e)(bp[M]∗+ uT vu ji +uT vb[TM]∗)[Pji ]∗ (A.34)
If we derive the equilibrium condition using the same steps as we used for other
systems, then tapasin is not present in the equilibrium condition. This is because the
conditions are given in terms of the generation and loss of peptide, Pji and tapasin
does not effect trimming by ERAP1.
uT v[TMPji ]∗ = b[TM]∗[Pji ]∗−u ji [TMPji ]∗
bP[M]∗[Pji ]∗+b[TM]∗[Pji ]∗−u ji [TMPji ]∗ = g ji +u ji [MPji ]∗+uE[EPji ]∗+kPji +1cat [EPj+1i ]∗−(dP+bE[E]∗)[Pji ]∗[MPji ]∗ = 1e(g ji +ue[EPji ]∗+kPj+1icat [EPj+1i ]∗−(dp+bE[E]∗)[Pji ]∗
After some substitution and rearrangement, we can arrive at an expression that
quantifies cell surface presentation in terms of the abundance of peptide i, ERAP1
and MHC.
[MePji ]∗ = 1u ji ￿￿g ji + [E]∗￿￿kP
j+1
i
cat
bE
uE +kPji +1cat [Pj+1i ]∗−k
Pji
cat
bE
uE +kPjicat [Pji ]∗
￿￿−dp[Pji ]∗￿￿
(A.36)
[MePji ]∗ = 1u ji ￿￿g ji +V
j+1
max [Pj+1i ]∗
K j+1M −V
j
max[Pji ]∗
K jM
−dp[Pji ]∗￿￿ (A.37)
where g ji = 0 if j ≠N
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A.5.4 System H2 with tapasin
By equating each of the equations in (A.26) to zero, we can derive a set of relation-
ships between the variables of interest.
[MePji ]∗ = eu ji [MPji ]∗[MPji ]∗ = 1(u ji +e)(bP[M]∗[Pji ]∗+uE[EMPji ]∗+uT v[TMPji ]+kEMPj+1icat [EMPj+1i ]∗−bE[E]∗[MPji ]∗)
If the tapasin pathway dominates, then
[MPji ]∗ = 1u ji +e(uT v[TMPji ])
TMP = 1
qu ji +uT vk j+1cat [ETMPj+1i ]+uE[ETMPji ]−(bE[E]+qu ji +uT v)[TMPji ]
TMP = 1
qu ji +uT vk j+1cat [ETMPj+1i ]−k jcat[ETMPji ]−(uT v+qu ji )[ETMPji ]
A.5.5 System H1 with ratchet
By equating each of the equations in (2.3) and (2.11) to zero, we can derive a set of
relationships between the variables of interest.
[MePji ]∗ = eu ji [MPji ]∗[MPji ]∗ = 1(u ji +e)(bp[M]∗[Pji ]∗)
bp[M]∗[Pji ]∗ = g ji +u ji [MPji ]∗+uE[EPji ]∗+kPji +1cat [EPj+1i ]∗−(dP+bE[E]∗)[Pji ]∗[MPji ]∗ = 1e(g ji +uE[EPji ]∗−(dp+bE[E]∗)[Pji ]∗)
[MPji ]∗ = 1e(g ji +uE￿￿bE[E]∗[Pji ]∗uE +k jcat + k
j+1
cat [EPj+1i ]∗
uE +k jcat ￿￿−(dp+bE[E]∗)[Pji ]∗)
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[MPji ]∗ = 1e(g ji − k jcatbE[E]∗[Pji ]∗uE +k jcat
+ uE
uE +kcat ￿￿ N￿n=1 k
j+n
cat bE[E]∗[Pj+ni ]∗
uE +k j+ncat ￿￿−dp[Pji ]∗)
After some substitution and rearrangement, we can arrive at an expression that
quantifies cell surface presentation in terms of the abundance of peptide i, ERAP1
and MHC.
[MePji ]∗ = 1u ji ￿￿g ji + uEuE +kcat ￿￿
N￿
n=1
V j+nmax [Pj+ni ]∗
K j+nM
￿￿−V jmaxP jiK jM −dp[Pji ]∗￿￿ (A.39)
where g ji = 0 if j ≠N
A.5.6 Examples of MATLAB code
This section contains examples of basic MATLAB files that can be used to simulate
the model equations for System H1.
A.5.6.1 Basic ODE function file for System 1
To use the MATLAB ODE solvers, a function file should be created containing the
model equations. The following code is the function file used to simulate System
H1, for the full ODE model (rather than the simplified or non-dimensional model).
function dxdt = MHC_Kb(t,x,p)
% assign parameters --------------
u_t = p.u_t;
b_t = p.b_t;
b = p.b;
d_m = p.d_m;
g_t = p.g_t;
v_t = p.v_t;
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d_t = p.d_t;
e = p.e;
q = p.q;
c = p.c;
d_p = p.d_p;
d_me = p.d_me;
E_T = p.E_T;
g_m = p.g_m;
u = p.u;
g_p = p.g_p;
u_E = p.u_E;
b_E = p.b_E;
k_catP = p.k_catP;
K_M = (u_E+k_catP)./b_E;
N = p.N;
TT = p.TT;
MM = p.MM;
k_catPjp1 = circshift(k_catP,[0,N-1]);
k_catPjp1(:,N) = 0;
% end parameters --------------
% assign variables --------------
M = zeros(1,1,MM);
MP = zeros(TT,N,MM);
P = zeros(TT,N);
TMP = zeros(TT,N,MM);
MeP = zeros(TT,N,MM);
Mee = zeros(1,1,MM);
TM = zeros(1,1,MM);
EP = zeros(TT,N,1);
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T = x(1);
M = x(2);
E = x(3);
EP= x(4:4+(TT*N)-1);
TM = x(4+(TT*N));
P = x(5+(TT*N):5+(2*TT*N)-1);
MP = x(5+(2*TT*N):5+(TT*N*(MM+2))-1);
TMP = x(5+(TT*N*(MM+2)):5+(TT*N*(2*MM+2))-1);
MeP = x(5+(TT*N*(2*MM+2)):5+(TT*N*(3*MM+2))-1);
Mee = x(5+(TT*N*(3*MM+2)));
TM = reshape(TM, [1,1,MM]);
MP = reshape(MP, [TT,N,MM]);
M = reshape(M, [1,1,MM]);
TMP = reshape(TMP, [TT,N,MM]);
P = reshape(P, [TT,N]);
EP = reshape(EP,[TT,N]);
MeP = reshape(MeP, [TT,N,MM]);
Mee= reshape(Mee, [1,1,MM]);
Tmat = repmat(T, 1,1, MM);
Mmat = repmat(M, TT, N);
Pmat = repmat(P, 1,1, MM);
TMmat = repmat(TM, TT, N);
EPjp1 = circshift(EP,[0,N-1]);
EPjp1(:,N) = 0;
% end variables --------------
% ODEs --------------
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dT = u_t*sum(TM,3) + g_t + v_t*sum(sum(sum(TMP)))...
- (b_t*sum(M,3) + d_t)*T;
dM = g_m + u_t*TM + sum(sum(umat.*MP)) - (b*sum(sum(P))...
+ b_t*T + d_m).*M;
dE = sum(sum(EP.*(u_E+k_catP))) - ( sum(sum(b_E.*P)))*E;
dEP = b_E*E.*P - (u_E + k_catP).*EP;
dTM = b_t*M.*Tmat + q*sum(sum(umat.*TMP)) - (u_t ...
+ c*sum(sum(P)))*(TM);
dP = u.*sum(MP,3) + q*u.*sum(TMP,3) + g_p +k_catPjp1.*EPjp1 + u_E*EP...
- (b*sum(M,3) + c*sum(TM,3) + d_p+ b_E*E ).*P;
dMP = b*Mmat.*Pmat + v_t*TMP - (umat + e).*MP;
dTMP = c*TMmat.*Pmat - (umat*q + v_t).*TMP; %*TMmat.*Pmat
dMeP = e*MP - umat.*MeP;
dMee= sum(sum(umat.*MeP)) - d_me.*Mee;
% end ODEs --------------
dM = reshape(dM, [MM 1]);
dTM = reshape(dTM, [MM 1]);
dP = reshape(dP, [TT*N 1]);
dEP = reshape(dEP,[TT*N 1]);
dMP = reshape(dMP, [TT*N*MM 1]);
dTMP = reshape(dTMP, [TT*N*MM 1]);
dMeP = reshape(dMeP, [TT*N*MM 1]);
dMee= reshape(dMee, [MM 1]);
dxdt = [dT;dM;dE;dEP;dTM;dP;dMP;dTMP;dMeP;dMee];
return
A.5. Equilibrium analysis 163
A.5.6.2 Basic Masterfile for System 1
The function file containing the ODEs is then called using:
[t,y] = odesolver(@odefunctionfile, tspan, y0), where [t,y]
is the time and species’ concentrations output, tspan is the time the simulation is
to be run over and y0 is the initial values of the species concentrations. The call
may be contained in a separate script file, commonly referred to as a masterfile.
The following code is an example masterfile script to simulate System H1 under
the amino acid dependent binding rate bE and the amino acid dependent catalytic
rate kcat .
% parameter values are stored in another function
% file called set_parameters.m, where for e.g. p.g_M = 150.5;
p = set_parameters;
FIT = {’kcat’;’bE’};
fnc1 = ’MHC_Kb’
% first simulation to be run over 48 hours
time1 = 0:500:48*60*60;
% second simulation to be run over 96 hours
time2 = 48*60*60:500:48*60*60*2;
% initial conditions
x0 = zeros(5+TT*N*(3*MM+2),1);
x0(3,1) = 600000;
for fit = 1:2
% R is each amino acid N terminus extension
for R = 1:p.allR
switch(fit)
case ’kcat’
% p.k_catPall contains the 17 different N terminus
% dependent catalytic rates
p.k_catP(1,3:N) = p.k_catPall(1);
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p.k_catP(2,3:N) = p.k_catPall(5);
p.k_catP(3,3:N) = p.k_catPall(R);
% : = all three peptides
% 1 = SIINFEKL (or the other 2 8-mers)
p.k_catP(:,2) = p.k_catPall(17);
p.k_catP(:,1) = 0;
p.b_E(:,2:N) = p.b_Eset;
case ’bE’
p.k_catP(:,:) = p.k_catset;
% where p.b_Eall contains the 17 different N terminus
% dependent binding rates
p.b_E(1,3:N) = p.b_Eall(1);
p.b_E(1,3:N) = p.b_Eall(5);
p.b_E(3,3:N) = p.b_Eall(R);
p.b_E(:,2) = p.b_Eall(17);
p.b_E(:,1) = 0;
end
%first simulate for background peptides only
p.g_p(3,:) = 0;
% Note if running for fit = 1:2 then results of fit = 1
% (fit = ’kcat’) will be overwritten. In the files used in this
% thesis, plotting happens within the for loop so that the results
% don’t need to be saved - the data files would be very large
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% if saved for all iterations of the model
[˜,Y1(:,:,R)] = ode23tb(str2func(fnc1),time1,x0,options,p);
% x0 contains initial conditions for the next simulation
x0 = Y1(end,:,R);
% Add in the extended peptide and simulate again
p.g_p(3,N) = 100;
% Note if running for fit = 1:2 then results of fit = 1
% (fit = ’kcat’) will be overwritten.
[˜,Y(:,:,R)] = ode23tb(str2func(fnc1),time,x0,options,p);
end
end
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